10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

___________________________________

FORM 10-Q

___________________________________

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2022

OR

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                to                

Commission File Number: 001-39427

___________________________________

Oak Street Health, Inc.

(Exact Name of Registrant as Specified in its Charter)

___________________________________

Delaware	84-3446686
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
30 W. Monroe Street Suite 1200 Chicago, Illinois 60603	60603
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (844) 871-5650

___________________________________

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	OSH	NYSE

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No ☒

As of November 2, 2022, the registrant had 242,915,915 shares of common stock, $0.001 par value per share, outstanding.

PART I.	FINANCIAL INFORMATION	6
Item 1.	Financial Statements	6
	Consolidated Balance Sheets as of September 30, 2022 (unaudited) and December 31, 2021	6
	Consolidated Statements of Operations for the Three and Nine-Months Ended September 30, 2022 and 2021 (unaudited)	7
	Consolidated Statements of Comprehensive Loss for the Three and Nine-Months Ended September 30, 2022 and 2021 (unaudited)	8
	Consolidated Statements of Changes in Stockholders’ Equity/(Deficit) for the Three and Nine-Months Ended September 30, 2022 and 2021 (unaudited)	9
	Consolidated Statements of Cash Flows for the Nine-Months Ended September 30, 2022 and 2021 (unaudited)	13
	Notes to Consolidated Financial Statements	14
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	28
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	42
Item 4.	Controls and Procedures	42
PART II.	OTHER INFORMATION	43
Item 1.	Legal Proceedings	43
Item 1A.	Risk Factors	43
Item 2.	Unregistered Sale of Equity Securities and Use of Proceeds	43
Item 3.	Defaults upon Senior Securities	43
Item 4.	Mine Safety Disclosures	43
Item 5.	Other Information	43
Item 6.	Exhibits	43

FORWARD-LOOKING STATEMENTS

Throughout this Quarterly Report on Form 10-Q, we make “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements describe future expectations, plans, results or strategies and can often be identified by the use of terminology such as “may,” “will,” “estimate,” “intend,” “plan,” “continue,” “believe,” “expect,” “anticipate,” “target,” “should,” “could,” “potential,” “opportunity,” “goal” or similar terminology. The forward-looking statements contained in this Quarterly Report on Form 10-Q are generally set forth under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” but may be found in other sections as well. These statements are based upon management’s current expectations, assumptions and estimates and are not guarantees of timing, future results or performance. Therefore, you should not rely on any of these forward-looking statements as predictions of future events. Actual results may differ materially from those contemplated in these statements due to a variety of risks and uncertainties and other factors, including, among other things:

•our history of net losses and our ability to achieve or maintain profitability in an environment of increasing expenses;

•the impact of the Coronavirus disease 2019 (“COVID-19”) pandemic or any other pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide on our business, financial condition and results of operations;

•the effect of our relatively limited operating history on investors’ ability to evaluate our current business and future prospects;

•the viability of our growth strategy and our ability to realize expected results;

•our ability to manage our growth effectively, execute our business plan, maintain high levels of service and patient satisfaction and adequately address competitive challenges;

•our ability to attract new patients;

•the dependence of our revenues and operations on a limited number of key payors;

•the potential adverse impact of legal proceedings and litigation;

•the risk of termination or non-renewal of the Medicare Advantage contracts held by the health plans with which we contract, or the termination or non-renewal of our contracts with those plans;

•the impact on our business from changes in the payor mix of our patients and potential decreases in our reimbursement rates;

•our ability to compete in the healthcare industry;

•our ability to timely enroll new physicians and other providers in governmental healthcare programs before we can receive reimbursement for their services;

•the impact on our business of reductions in Medicare reimbursement rates or changes in the rules governing the Medicare program;

•our dependence on reimbursements by third-party payors and payments by individuals;

•our assumption under most of our agreements with health plans of some or all of the risk that the cost of providing services will exceed our compensation;

•the impact on our business of renegotiation, non-renewal or termination of capitation agreements with health plans;

•risks associated with estimating the amount of revenues and refund liabilities that we recognize under our risk agreements with health plans;

•the impact on our business of security breaches, loss of data or other disruptions causing the compromise of sensitive information or preventing us from accessing critical information;

•the impact on our business of disruptions in our disaster recovery systems or management continuity planning;

•the impact of reductions in the quality ratings of the health plans we serve;

•the risk of our agreements with the physician equity holder of our practices being deemed invalid;

3

•our ability to maintain and enhance our reputation and brand recognition;

•our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems;

•our ability to obtain, maintain and enforce intellectual property protection for our technology;

•the potential adverse impact of claims by third parties that we are infringing on or otherwise violating their intellectual property rights;

•risks associated with existing securities class action litigation;

•our ability to protect the confidentiality of our trade secrets, know-how and other internally developed information;

•the impact of any restrictions on our use of or ability to license data or our failure to license data and integrate third-party technologies;

•risks associated with our use of “open-source” software;

•our dependence on our senior management team and other key employees;

•the concentration of our primary care centers in Illinois, Michigan, Pennsylvania, Ohio and Texas;

•the impact on our business of an economic downturn;

•our ability to attract and retain highly qualified personnel;

•our management team’s limited experience managing a public company;

•the impact on our business of the termination of our leases, increases in rent or inability to renew or extend leases;

•the impact of failures by our suppliers, material price increases on supplies, lack of reimbursement for drugs we purchase or limitations on our ability to access new technology or products;

•our ability to maintain our corporate culture;

•the impact of competition for physicians and nurses, shortages of qualified personnel and related increases in our labor costs;

•our ability to attract and retain the services of key primary care physicians;

•the risk that our submissions to health plans may contain inaccurate or unsupportable information regarding risk adjustment scores of members;

•our ability to accurately estimate incurred but not reported medical expense;

•the impact of negative publicity regarding the managed healthcare industry;

•the impact of state and federal efforts to reduce Medicaid spending;

•the impact on our centers of adverse weather conditions and other factors beyond our control;

•factors related to our indebtedness; and

•our ability to develop and maintain proper and effective internal control over financial reporting.

We derive many of our forward-looking statements from our operating budgets and forecasts, which are based on many detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and it is impossible for us to anticipate all factors that could affect our actual results. Important factors that could cause actual results to differ materially from our expectations, or cautionary statements, are disclosed under the sections entitled “Risk Factors” in our Form 10-K for the year-ended December 31, 2021 ("2021 Form 10-K") and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2021 Form 10-K and this Quarterly Report on Form 10-Q. All written and oral forward-looking statements attributable to us, or persons acting on our behalf, are expressly qualified in their entirety by these cautionary statements as well as other cautionary statements that are made from time to time in our other filings with the Securities and Exchange Commission ("SEC") and public communications. You should evaluate all forward-looking statements made in this Quarterly Report on Form 10-Q in the context of these risks and uncertainties.

4

We caution you that the important factors referenced above may not contain all of the factors that are important to you. In addition, we cannot assure you that we will realize the results or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our operations in the way we expect. The forward-looking statements included in this Quarterly Report on Form 10-Q are made only as of the date hereof. We undertake no obligation to update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.

5

PART I    FINANCIAL INFORMATION

Item 1.    FINANCIAL STATEMENTS

OAK STREET HEALTH, INC.

CONSOLIDATED FINANCIAL STATEMENTS

For the quarterly period ended September 30, 2022

OAK STREET HEALTH, INC.

CONSOLIDATED BALANCE SHEETS

($ in millions, except shares and per share data)

	September 30, 2022 (unaudited)		December 31, 2021
ASSETS
Current assets:
Cash and cash equivalents	$	204.3	$	104.7
Restricted cash	18.7		15.7
Other receivables, net (Humana comprised $0.2 as of December 31, 2021)	2.1		3.1
Capitated accounts receivable (Humana comprised $105.0 as of December 31, 2021)	833.9		559.4
Marketable debt securities	339.0		671.1
Prepaid expenses and other current assets	18.1		14.0
Total current assets	1,416.1		1,368.0
Property, plant and equipment, net	196.1		144.8
Goodwill	158.0		152.9
Intangible assets, net	9.6		10.8
Operating right-of-use assets (Humana comprised $70.9 as of December 31, 2021)	313.1		157.7
Other long-term assets	7.6		6.9
Total assets	$	2,100.5	$	1,841.1
LIABILITIES AND STOCKHOLDERS' EQUITY/(DEFICIT)
Current liabilities:
Accounts payable	$	25.9	$	22.1
Accrued compensation and benefits	47.1		41.7
Liability for unpaid claims (Humana comprised $99.1 as of December 31, 2021)	787.1		556.3
Other liabilities (Humana comprised $19.3 as of December 31, 2021)	46.4		44.0
Total current liabilities	906.5		664.1
Long-term debt	977.0		901.4
Long-term operating lease liabilities (Humana comprised $66.0 as of December 31, 2021)	341.8		164.2
Other long-term liabilities (Humana comprised $43.1 as of December 31, 2021)	30.8		55.4
Total liabilities	2,256.1		1,785.1
Commitments and contingencies (See Note 10)
STOCKHOLDERS' EQUITY/(DEFICIT)
Preferred stock, par value $0.001; 50,000,000 shares authorized as of September 30, 2022 and December 31, 2021; no shares issued and outstanding as of September 30, 2022 and December 31, 2021	—		—
Common stock, par value $0.001; 500,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 242,950,926 and 240,937,465 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively	0.2		0.2
Additional paid-in capital (Humana comprised $50.0 as of December 31, 2021)	1,185.0		1,017.9
Accumulated other comprehensive loss	(4.1)		(1.4)
Accumulated deficit	(1,341.5)		(965.3)
Total stockholders' equity/(deficit) allocated to Oak Street Health, Inc.	(160.4)		51.4
Non-controlling interests	4.8		4.6
Total stockholders' equity/(deficit)	(155.6)		56.0
Total liabilities and stockholders' equity/(deficit)	$	2,100.5	$	1,841.1

The accompanying notes are an integral part of these consolidated financial statements.

6

OAK STREET HEALTH, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

($ in millions, except shares and per share data)

	Three-Months Ended September 30,				Nine-Months Ended September 30,
	2022		2021		2022		2021
Revenues:
Capitated revenue (Humana comprised $130.7 for the three-months ended September 30, 2021 and $379.2 for the nine-months ended September 30, 2021)	$	537.9	$	376.7	$	1,560.1	$	1,014.6
Other revenue (Humana comprised $2.8 for the three-months ended September 30, 2021 and $4.5 for the nine-months ended September 30, 2021)	7.8		12.0		23.1		23.9
Total revenues	545.7		388.7		1,583.2		1,038.5
Operating expenses:
Medical claims expense (Humana comprised $99.1 for the three-months ended September 30, 2021 and $277.7 for the nine-months ended September 30, 2021)	427.4		309.8		1,198.4		790.9
Cost of care, excluding depreciation and amortization (Humana comprised $2.8 for the three-months ended September 30, 2021 and $7.1 for the nine-months ended September 30, 2021)	113.6		76.3		307.6		203.6
Sales and marketing	44.1		30.5		120.5		80.5
Corporate, general and administrative	81.7		77.0		265.3		224.3
Depreciation and amortization	9.1		4.5		25.3		11.7
Total operating expenses	675.9		498.1		1,917.1		1,311.0
Loss from operations	(130.2)		(109.4)		(333.9)		(272.5)
Other (expense):
Interest expense, net	—		(0.6)		(1.1)		(1.8)
Other	(0.2)		—		(40.3)		—
Total other (expense)	(0.2)		(0.6)		(41.4)		(1.8)
Net loss	(130.4)		(110.0)		(375.3)		(274.3)
Net income/(loss) attributable to non-controlling interests	0.3		(0.6)		0.9		(3.5)
Net loss attributable to Oak Street Health, Inc.	$	(130.7)	$	(109.4)	$	(376.2)	$	(270.8)
Weighted average common shares outstanding - basic and diluted	231,919,421		223,435,698		228,042,160		221,932,624
Net loss per share – basic and diluted	$	(0.56)	$	(0.49)	$	(1.65)	$	(1.22)

The accompanying notes are an integral part of these consolidated financial statements.

7

OAK STREET HEALTH, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(Unaudited)

($ in millions, except shares and per share data)

	Three-Months Ended September 30,				Nine-Months Ended September 30,
	2022		2021		2022		2021
Net loss	$	(130.4)	$	(110.0)	$	(375.3)	$	(274.3)
Other comprehensive loss:
Net unrealized gain/(loss) on marketable debt securities, net of tax	0.7		0.1		(2.7)		(0.2)
Comprehensive loss	(129.7)		(109.9)		(378.0)		(274.5)
Less: Comprehensive income/(loss) attributable to non-controlling interests	0.3		(0.6)		0.9		(3.5)
Comprehensive loss attributable to Oak Street Health, Inc.	$	(130.0)	$	(109.3)	$	(378.9)	$	(271.0)

The accompanying notes are an integral part of these consolidated financial statements.

8

OAK STREET HEALTH, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY/(DEFICIT)

(Unaudited)

($ in millions, except shares and per share data)

	Three-Months Ended
	Common Stock			Additional Paid-In Capital	Accumulated Deficit		Accumulated Other Comprehensive Loss	Non-controlling Interest		Total Equity/(Deficit)
	Shares Issued	Amount
Balances June 30, 2021	240,785,554	$	0.2	935.0	$	(717.2)	(0.3)	$	3.1	$	220.8
Issuance of common stock upon vesting of restricted stock units	33,542	—		—	—		—	—		$	—
Issuance of common stock upon exercise of options	47,389	—		0.9	—		—	—		$	0.9
Shares withheld related to net settlement of stock based awards	(782)	—		—	—		—	—		$	—
Issuance of common stock under the employee purchase plan	62,575	—		3.0	—		—	—		$	3.0
Forfeitures	(8,322)	—		(0.1)	—		—	—		$	(0.1)
Stock-based compensation expense		—		38.8	—		—	—		$	38.8
Payments to non-controlling interests		—		—	—		—	(0.4)		$	(0.4)
Net unrealized gain on marketable debt securities		—		—	—		0.1	—		$	0.1
Net loss		—		—	(109.4)		—	(0.6)		$	(110.0)
Balances September 30, 2021	240,919,956	0.2		977.6	(826.6)		(0.2)	2.1		$	153.1

The accompanying notes are an integral part of these consolidated financial statements.

9

OAK STREET HEALTH, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY/(DEFICIT)

(Unaudited)

($ in millions, except shares and per share data)

	Three-Months Ended
	Common Stock			Additional Paid-In Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Non-controlling Interests		Total Equity/(Deficit)
	Shares Issued	Amount
Balances June 30, 2022	241,084,244	$	0.2	$	1,108.5	$	(1,210.8)	$	(4.8)	$	5.0	$	(101.9)
Issuance of common stock upon vesting of restricted stock units	70,849	—		—		—		—		—		—
Issuance of common stock upon exercise of options	543,082	—		11.1		—		—		—		11.1
Shares withheld related to net settlement of stock based awards	(9,478)	—		(0.2)		—		—		—		(0.2)
Issuance of common stock under the employee purchase plan	161,189	—		2.3		—		—		—		2.3
Issuance of common stock pursuant to RubiconMD Holdings, Inc. earn-out	1,225,122	—		32.5		—		—		—		32.5
Forfeitures	(124,082)	—		(2.9)		—		—		—		(2.9)
Stock-based compensation expense	—	—		33.7		—		—		—		33.7
Payments to non-controlling interests	—	—		—		—		—		(0.5)		(0.5)
Net unrealized gain on marketable debt securities	—	—		—		—		0.7		—		0.7
Net loss	—	—		—		(130.7)		—		0.3		(130.4)
Balances September 30, 2022	242,950,926	$	0.2	$	1,185.0	$	(1,341.5)	$	(4.1)	$	4.8	$	(155.6)

The accompanying notes are an integral part of these consolidated financial statements.

10

OAK STREET HEALTH, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY/(DEFICIT)

(Unaudited)

($ in millions, except shares and per share data)

	Nine-Months Ended
	Common Stock			Additional Paid-In Capital	Accumulated Deficit		Accumulated Other Comprehensive Income (Loss)	Non-controlling Interest		Total Equity/(Deficit)
	Shares Issued	Amount
Balances December 31, 2020	240,756,714	$	0.2	971.8	$	(555.8)	—	$	7.0	$	423.2
Purchase of capped calls	—	—		(123.6)	—		—	—		$	(123.6)
Issuance of common stock upon vesting of restricted stock units	55,781	—		—	—		—	—		$	—
Issuance of common stock upon exercise of options	222,203	—		4.5	—		—	—		$	4.5
Shares withheld related to net settlement of stock based awards	(1,412)	—		—	—		—	—		$	—
Issuance of common stock under the employee purchase plan	62,575	—		3.0	—		—	—		$	3.0
Forfeitures	(175,905)	—		(0.9)	—		—	—		$	(0.9)
Stock-based compensation expense	—	—		122.8	—		—	—		$	122.8
Payments from non-controlling interests	—	—		—	—		—	0.1		$	0.1
Payments to non-controlling interests	—	—		—	—		—	(1.5)		$	(1.5)
Net unrealized loss on marketable debt securities	—	—		—	—		(0.2)	—		$	(0.2)
Net loss	—	—		—	(270.8)		—	(3.5)		$	(274.3)
Balances September 30, 2021	240,919,956	0.2		977.6	(826.6)		(0.2)	2.1		153.1

The accompanying notes are an integral part of these consolidated financial statements.

11

OAK STREET HEALTH, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY/(DEFICIT)

(Unaudited)

($ in millions, except shares and per share data)

	Nine-Months Ended
	Common Stock			Additional Paid-In Capital		Accumulated Deficit		Accumulated Other Comprehensive Income (Loss)		Non-controlling Interest		Total Equity/(Deficit)
	Shares Issued	Amount
Balances December 31, 2021	240,937,465	$	0.2	$	1,017.9	$	(965.3)	$	(1.4)	$	4.6	$	56.0
Issuance of common stock upon vesting of restricted stock units	149,850	—		—		—		—		—		—
Issuance of common stock upon exercise of options	662,034	—		13.4		—		—		—		13.4
Shares withheld related to net settlement of stock based awards	(15,995)	—		(0.2)		—		—		—		(0.2)
Issuance of common stock under the employee purchase plan	224,473	—		4.1		—		—		—		4.1
Issuance of common stock pursuant to RubiconMD Holdings, Inc. earn-out	1,225,122	—		32.5		—		—		—		32.5
Forfeitures	(232,023)	—		(4.3)		—		—		—		(4.3)
Stock-based compensation expense	—	—		124.3		—		—		—		124.3
Payments to non-controlling interest	—	—		—		—		—		(1.3)		(1.3)
Purchase of joint venture minority interest	—	—		(2.7)		—		—		0.6		(2.1)
Net unrealized loss on marketable debt securities	—	—		—		—		(2.7)		—		(2.7)
Net loss	—	—		—		(376.2)		—		0.9		(375.3)
Balances September 30, 2022	242,950,926	$	0.2	$	1,185.0	$	(1,341.5)	$	(4.1)	$	4.8	$	(155.6)

The accompanying notes are an integral part of these consolidated financial statements.

12

OAK STREET HEALTH, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

($ in millions)

(Unaudited)

	Nine-Months Ended September 30,
	2022		2021
Cash flows from operating activities:
Net loss	$	(375.3)	$	(274.3)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of discount on debt and related issuance costs	3.3		2.4
Accretion of discounts and amortization of premiums on short-term marketable securities, net	4.9		2.4
Fair value adjustment to contingent consideration	38.3		—
Depreciation and amortization	25.3		11.7
Non-cash operating lease costs	31.6		11.2
Stock-based compensation, net of forfeitures	120.0		121.9
Change in operating assets and liabilities, net of impact of acquisitions:
Accounts receivables	(273.4)		(208.0)
Other assets	(5.3)		(10.5)
Accounts payable and accrued compensation and benefits	7.4		23.1
Liability for unpaid claims	230.9		180.2
Operating lease liabilities	(15.6)		(9.9)
Other liabilities	(5.4)		23.9
Net cash used in operating activities	$	(213.3)	(125.9)
Cash flows from investing activities:
Proceeds from sales and maturities of marketable debt securities	$	716.6	43.7
Purchases of marketable debt securities	(392.2)		(817.6)
Purchase of business, net of cash acquired	(5.6)		(1.4)
Purchases of property and equipment	(67.6)		(40.6)
Net cash provided by (used by) investing activities	$	251.2	(815.9)
Cash flows from financing activities:
Proceeds from borrowings on term loan, net	$	72.3	$	—
Proceeds from borrowings on Convertible Senior Notes, net	—		897.9
Purchase of capped calls	—		(123.6)
Capital contributions from non-controlling interests	—		0.1
Settlement of contingent earnout liability	(21.7)		—
Capital distributions to non-controlling interests	(1.3)		(1.5)
Purchase of joint venture minority interest	(2.1)		—
Proceeds from exercise of options	13.4		4.5
Proceeds from issuance of common stock under the employee purchase plan	4.1		3.0
Net cash provided by financing activities	$	64.7	780.4
Net change in cash, cash equivalents and restricted cash	102.6		(161.4)
Cash, cash equivalents and restricted cash, beginning of period	120.4		419.7
Cash, cash equivalents and restricted cash, end of period	$	223.0	$	258.3
Supplemental disclosures
Additions to construction in process funded through accounts payable	7.0		4.7

The accompanying notes are an integral part of these consolidated financial statements.

13

OAK STREET HEALTH, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1. ORGANIZATION AND NATURE OF BUSINESS

Description of Business

Oak Street Health, Inc. (collectively with its consolidated subsidiaries is referred to as “Oak Street Health,” “OSH,” “we,” “us,” “our” or the “Company”) was formed as a Delaware corporation on October 22, 2019 for the purpose of completing a public offering and related reorganization transactions (collectively referred to as the “IPO”) in order to carry on the business of Oak Street Health, LLC (“OSH LLC”) and its affiliates. On August 10, 2020, the Company completed its IPO. As the managing member of OSH LLC, Oak Street Health, Inc. operates and controls all of the business affairs of OSH LLC and its affiliates.

The Company operates primary care centers serving Medicare beneficiaries. The Company, through its centers and management services organization, combines an innovative care model with superior patient experience. The Company invests resources into primary care to prevent unnecessary acute events and manage chronic illnesses. The Company engages Medicare eligible patients through the use of an innovative community outreach approach. Once patients are engaged, the Company integrates population health analytics, social support services and primary care into the care model to drive improved outcomes. The Company contracts with health plans to generate medical costs savings and realize a return on its investment in primary care. As of September 30, 2022, the Company operated 161 centers.

Basis of Presentation and Consolidation

The accompanying unaudited interim consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such regulations that would substantially duplicate the disclosures contained in the Company's annual audited consolidated financial statements. These financial statements have been prepared on a basis consistent with the accounting principles applied for the fiscal year ended December 31, 2021 in the Company’s 2021 Form 10-K filed with the SEC. In the opinion of management, all adjustments (consisting of all normal and recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and nine-months ended September 30, 2022, including the impact of COVID-19, are not necessarily indicative of the results that may be expected any other interim period for or for the year ending December 31, 2022.

The consolidated financial statements of the Company include the financial statements of all wholly owned subsidiaries and majority-owned or controlled companies, which include the variable interest entities (“VIE”) in which OSH has an interest and is the primary beneficiary. See Note 11, “Variable Interest Entities.” For those consolidated subsidiaries where our ownership is less than 100%, the portion of the net income or loss allocable to the non-controlling interests is reported as “Net loss (gain) attributable to non-controlling interests” in the consolidated statements of operations. Intercompany balances and transactions have been eliminated in consolidation.

In addition, Oak Street Health is the majority interest owner in two joint ventures: OSH-PCJ Joliet, LLC ("PCJ JV") and OSH-RI, LLC ("RI JV"), which are consolidated in the Company’s financial statements. In January 2022, the Company paid a former joint venture partner, Evangelical Services Corporation, $2.1 million to acquire its 49.9% ownership interest in OSH-ESC Joint Venture, LLC. As such, OSH owned 100% of this entity as of March 31, 2022, and the joint venture was effectively dissolved. During the quarters ended June and September 30, 2022, distributions were made from OSH-PCJ Joliet, LLC to Oak Street Health MSO, LLC, a subsidiary of the Company that holds 50.1% ownership interest in PCJ JV, and Primary Care Physicians of Joliet, an unaffiliated third party that holds 49.9% ownership interest in PCJ JV. Distributions made during the quarter ended June 30, 2022 totaled $0.8 million to each owner and in the quarter ended September 30, 2022 distributions totaled $0.5 million to each owner.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates on the information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of COVID-19. The areas

14

where significant estimates are used in the accompanying financial statements include revenue recognition, the liability for unpaid claims, stock-based compensation, valuation and related impairment recognition of long-lived assets, including intangibles and goodwill and the valuation of stock options. Actual results could differ from those estimates.

COVID-19

Even as the COVID-19 pandemic subsides, disruptions caused by the pandemic, including labor shortages and inflationary pressures, may continue and could, in turn, have a negative impact on the Company. Further, recurring COVID-19 outbreaks, including outbreaks caused by different virus variants, could have the potential to impact the Company and its future results of operations, cash flows and financial position.

On March 27, 2020, the United States President signed into law the Coronavirus Aid, Relief and Economic Securities Act (“CARES Act”) which provides economic assistance to a wide array of industries, including healthcare. This legislation did not have a material impact on our financial statements as of and for the nine-months ended September 30, 2022. Refer to our 2021 Form 10-K for details on the prior year impact of the legislation.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company described its significant accounting policies in Note 2 of the notes to consolidated financial statements for the year ended December 31, 2021 included in its 2021 Form 10-K. During the nine-months ended September 30, 2022, there were no significant changes to those accounting policies, other than those noted below and those policies impacted by the new accounting pronouncements adopted during the period and further described below.

Stock-based compensation expense

The Company accounts for stock-based compensation as an expense in the statements of operations based on the awards' fair values at their respective grant dates. The Company estimates the fair value of options with service conditions granted using the Black-Scholes option pricing model. Stock options that include service and performance conditions are valued at their grant date using the Black-Scholes model and estimates regarding the probability of achieving the performance metrics. The Black-Scholes option pricing model requires inputs based on certain assumptions, including (a) the fair value per share of the Company's common stock, (b) the expected stock price volatility, (c) the expected term of the award, (d) the risk-free interest rate and (e) expected dividends.

The fair value of stock-based awards is recognized as compensation expense, net of actual forfeitures, over the requisite service period, which is generally the vesting period, with the exception of the fair value of stock-based payments for awards that include service and performance conditions which is recognized as compensation expense over the requisite service period as achievement of the performance objective becomes probable.

The Company issued certain performance stock options (“PSOs”) during the first quarter of 2022, that vest based on the satisfaction of certain service and performance-based conditions. The Company estimates compensation expense based on the grant date fair value of the awards and recognizes the expense on a graded vesting basis over the vesting period of the awards. Compensation expense for these awards is recognized only if the Company has determined that it is probable that the performance condition will be met. The Company reassesses the probability of vesting at each reporting period and adjusts compensation expense based on the probability assessment.

The Company issued certain performance stock units ("PSUs") during the second quarter of 2022. The awards will vest based on the satisfaction of certain service conditions and performance-based conditions. The Company estimates compensation expense based on the grant date fair value of the awards and recognizes the expense on a straight-line basis over the vesting period of the award. Compensation expense for these awards is recognized only if the Company has determined that it is probable that the performance condition will be met. The Company reassesses the probability of vesting at each reporting period and adjusts compensation expense based on the probability assessment.

Correction of immaterial error in previously issued financial statements

The Company has arrangements with Humana, that include a license fee payable by the Company to Humana for the Company’s provision of health care services in certain centers owned or leased by Humana. The license fee is a reimbursement to Humana for its costs of owning or leasing and maintaining the centers, including rental payments, center maintenance or repair expenses, equipment expenses, special assessments, cost of upgrades, taxes, leasehold improvements and other expenses identified by Humana. During the second quarter of 2022, the Company reassessed the nature of its license fee arrangements and determined that the reimbursement for leasehold improvements included in the license fee payments should be included as a lease component and accounted for under ASC 842, Leases ("ASC 842"). As previously

15

disclosed in the Company's 2021 Form 10-K, the Company adopted ASC 842 effective January 1, 2021 under the modified retrospective transition method.

The Company considered the guidance Accounting Standards Codification 250, Accounting Changes and Error Corrections as well as the guidance in SEC Staff Bulletin 99, Materiality and concluded that the error was immaterial to the Company's previously issued interim and annual consolidated financial statements. The Company has corrected the cumulative impact of the error within the Quarterly Report on Form 10-Q for the period ended June 30, 2022 and disclosed the impact in Note 2 therein.

We recorded a decrease to cost of care, excluding depreciation and amortization, within the consolidated statements of operations of $3.6 million and impact of $0.02 to our net loss per share- basic and diluted for the nine-months ended September 30, 2022. There was no impact to the consolidated statement of cash flows or the consolidated statements of equity/(deficit).

Recently Adopted Accounting Pronouncements

In October 2021, the FASB issued Accounting Standard Update ("ASU") 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The new guidance requires contract assets and liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts. Under the current business combinations guidance, such assets and liabilities are recognized by the acquirer at fair value on the acquisition date. The new standard is effective for fiscal years beginning after December 15, 2022. Early adoption is permitted. The standard will not impact acquired contract assets or liabilities from business combinations occurring prior to the effective date of adoption. We elected to adopt this guidance early effective as of the quarter ended September 30, 2022 in connection with the Company’s acquisition of substantially all of the assets of CHW Cares Inc. ("CHW"), which was completed during the quarter. The guidance was not applicable to the CHW acquisition as contract assets and liabilities were not acquired, and as such, the adoption did not have a material effect on our consolidated financial statements or notes to the consolidated financial statements. For more information about the CHW acquisition, see Note 5, "Business Combinations, Goodwill and Intangible Assets."

In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. This update requires annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. This standard is effective for fiscal years beginning after December 15, 2021 and should be applied prospectively or retrospectively. We have adopted ASU 2021-10 as of January 1, 2022 using the prospective method. This adoption did not have a material impact on our consolidated financial statements or notes to the consolidated financial statements.

Recent Accounting Pronouncements Not Yet Adopted

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820) of Equity Securities Subject to Contractual Sale Restrictions. The new guidance clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The guidance is required to be adopted by January 1, 2024, and we do not anticipate this standard update will have a material impact on our consolidated financial statements or notes to the consolidated financial statements.

NOTE 3. REVENUE RECOGNITION

The Company earns revenue from our capitated arrangements with health plan payers and other revenue arrangements. Other revenue is comprised of ancillary fees earned under contracts with certain managed care organizations for the provision of certain care coordination and care management services; license subscription and fees; and fee-for- service revenue. Both our capitated and fee-for-service revenue generally relate to contracts with patients in which our performance obligation is to provide and/or manage healthcare services to the patients. Revenues are recorded during the period our obligations to provide healthcare services are satisfied as noted below within each service type.

Our care coordination services include a single performance obligation to stand ready to provide care coordination services to patients, which constitutes a series of distinct service increments. Payments received are recognized in other revenue ratably over the length of contract terms and are refundable on a pro rata basis to Humana if the Company ceases to provide services at the centers within the length of the term specified in the contracts. Under our care management services, we have a single performance to stand ready to provide care management services, which constitutes a series of distinct service increments.

16

The Company acquired RubiconMD Holdings, Inc. (“RMD”) on October 20, 2021. RMD is a healthcare technology company specializing in an online eConsult platform which enables primary care providers to easily access same-day insights from top specialists in order to provide better care for their patients. RMD generates revenue by providing subscription licenses to its customers to access its eConsult platform, as well as providing integration, training and other ad-hoc services. We have identified the performance obligation to be standing ready to provide access to the eConsult platform. Subscription license revenue is recognized when the performance obligation is met over time by either the straight-line method or when services are performed over the terms of the applicable contract. RMD also provides services to assist customers with initial usage and training of the platform. These services are typically provided for a fixed fee and do not have a variable component. We identified the performance obligation is to provide the other professional services, which is typically achieved over time.

Capitated Revenue and Accounts Receivable

The Company has agreements in place with the payors listed below, and payor sources of capitated revenue for each period presented were as follows:

	Three-Months Ended September 30,				Nine-Months Ended September 30,
	2022		2021		2022		2021
Humana	31	%	35	%	32	%	37	%
Wellcare/Meridian	16	%	15	%	17	%	16	%
UnitedHealth Care	10	%	8	%	9	%	7	%
CMS	8	%	10	%	8	%	7	%
Other	35	%	32	%	34	%	33	%

Medicare Part D comprised 2% of capitated revenues for the three and nine-months ended September 30, 2022 and September 30, 2021. Medicare Part D comprised 3% of medical claims expense for the three-months ended September 30, 2022 and 2% for the nine-months ended September 30, 2022. Medicare Part D comprised 2% of medical claims expense for the three-months ended September 30, 2021 and 3% for the nine-months ended September 30, 2021.

For the nine-months ended September 30, 2022 and 2021, respectively, we estimate that we will receive an additional $44.4 million and $40.1 million for acuity-related adjustments to be received in subsequent periods. Under our capitated revenue arrangements, we receive a fixed fee per patient, per month ("PPPM") for services. In certain contracts, PPPM fees also include adjustments for items such as performance incentives or penalties based on the achievement of certain clinical quality metrics as contracted with payors. There were no material PPPM adjustments related to performance incentives/penalties for quality-related metrics for the three and nine-months ended September 30, 2022 and 2021.

Other Revenue

The composition of other revenue for each period was as follows ($ in millions):

	Three-Months Ended September 30,				Nine-Months Ended September 30,
	2022		2021		2022	2021
Care coordination and care management services	$	1.8	$	9.8	5.2	$	18.4
License subscription and other fees	3.3		—		9.5	—
Fee for service	2.7		2.2		8.4	5.5
Total other revenue	$	7.8	$	12.0	23.1	$	23.9

As of September 30, 2022 and December 31, 2021, the Company’s contract liabilities related to the Humana care coordination payments totaled $37.3 million and $33.9 million, respectively. The short-term portion is recorded in other liabilities and the long-term portion is included in other long-term liabilities in the accompanying consolidated balance sheets. As of September 30, 2022 and December 31, 2021, we recorded $6.7 million and $6.2 million of short-term contract liabilities, respectively, and $30.6 million and $27.7 million of long-term contract liabilities, respectively.

17

NOTE 4. FAIR VALUE MEASUREMENTS AND INVESTMENTS

Fair Value Measurements

In determining the fair value of financial assets and liabilities, the Company utilizes market data or other assumptions that it believes market participants would use in pricing the asset or liability in the principal or most advantageous market and adjusts for non-performance and/or other risks associated with the Company as well as counterparties, as appropriate. Assets and liabilities measured at fair value are classified using the following hierarchy, which is based upon the transparency of inputs to the valuation as of the measurement date:

Level 1 – Valuations based on unadjusted quoted prices which are available in active markets for identical assets or liabilities accessible at the measurement date.

Level 2 – Valuations with inputs other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.

Level 3 – Valuations with unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis ($ in millions):

	Fair Value Measurements as of September 30, 2022 using:						Fair Value Measurements as of December 31, 2021 using:
	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
Marketable debt securities:
Commercial paper	$	61.5	$	—	$	—	$	120.8	$	—	$	—
U.S. Treasury obligations	—		12.8		—		—		26.0		—
Corporate bonds	—		201.2		—		—		412.3		—
Asset-backed securities	—		33.8		—		—		99.2		—
Other	—		29.7		—		—		12.8		—
Total financial assets	$	61.5	$	277.5	$	—	$	120.8	$	550.3	$	—
Liabilities:
Convertible senior notes	$	—	$	710.5	$	—	$	—	$	752.7	$	—
Contingent consideration1	—		—		0.2		—		—		21.8
Total liabilities	$	—	$	710.5	$	0.2	$	—	$	752.7	$	21.8
1 During the quarter-ended June 30, 2022, RMD achieved both earn-out hurdles. As such, the Company no longer measured the fair value of the contingent consideration and instead recorded the maximum earn-out as an amount payable to RMD as of June 30, 2022. See Footnote 5 for further detail.

The Company measures the fair value of corporate bonds, U.S. treasury obligations and asset-backed securities by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. During the three and nine-months ended September 30, 2022, there were no transfers between Levels 1, 2 and 3.

The Company's Convertible Senior Notes are classified within Level 2 of the fair value hierarchy as the valuation inputs are based on quoted prices in an inactive market on the last day in the reporting period.

In September 2022, the Company and certain of its subsidiaries entered into a $300.0 million loan and security agreement (the "Loan Agreement") with Hercules Capital Inc., as administrative and collateral agent and lender (the “Agent”), and Silicon Valley Bank and other lenders from time to time parties thereto (collectively with the Agent in its capacity as a lender, the “Lenders”) with such amount to be funded in five committed tranches (collectively, the "Term Loan"). As of September 30, 2022, the carrying value of the loan is $72.3 million, net of debt issuance costs. The fair value of the Term Loan approximates its carrying value since the interest rate is at market. For more information about the Term Loan, see Note 8, “Long-Term Debt.”

18

Investments

At September 30, 2022, the Company’s marketable debt securities classified as available-for-sale were as follows ($ in millions):

	September 30, 2022						December 31, 2021
	Amortized cost		Net unrealized gains (losses)		Fair value		Amortized cost		Net unrealized gains (losses)		Fair value
Marketable debt securities:
Commercial paper	$	61.7	$	(0.2)	$	61.5	$	120.9	$	(0.1)	$	120.8
U.S. Treasury obligations	12.9		(0.1)		12.8		26.0		—		26.0
Corporate bonds	204.6		(3.4)		201.2		413.4		(1.1)		412.3
Asset-backed securities	34.0		(0.2)		33.8		99.4		(0.2)		99.2
Other	29.9		(0.2)		29.7		12.8		—		12.8
Total marketable debt securities	$	343.1	$	(4.1)	$	339.0	$	672.5	$	(1.4)	$	671.1

These investments in marketable debt securities carry maturity dates of less than five years from the date of purchase. The net realized gains and losses were immaterial during the three and nine-months ended September 30, 2022. We do not intend to sell these investments, and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost basis. We did not record an allowance for credit losses as of September 30, 2022 or December 31, 2021 as no losses were determined to be caused by credit losses.

NOTE 5. BUSINESS COMBINATIONS, GOODWILL AND INTANGIBLE ASSETS

Goodwill, which represents the excess of cost over the fair value of net assets acquired, amounted to $158.0 million and $152.9 million at September 30, 2022 and December 31, 2021, respectively.

Intangible assets with a finite useful life continue to be amortized over their useful lives. Net intangible assets amounted to $9.6 million and $10.8 million at September 30, 2022 and December 31, 2021, respectively. Accumulated amortization related to intangible assets amount to $2.9 million and $1.7 million at September 30, 2022 and December 31, 2021, respectively. The Company recorded amortization expense of $0.4 million and $0.1 million for the three-months ended September 30, 2022 and 2021, respectively. The Company recorded amortization expense of $1.2 million and $0.3 million for the nine-months ended September 30, 2022 and 2021, respectively.

The remaining weighted average amortization period of finite-lived intangible assets is 5.8 years. The remaining estimated future amortization expense by year, as of September 30, 2022, is presented in the following table:

	(in millions)
2022	$	0.5
2023	1.7
2024	1.7
2025	1.7
2026	1.7
Thereafter	2.3
Estimated aggregate future intangible asset amortization	$	9.6

During the nine-months ended September 30, 2022, we made a $0.2 million adjustment to our preliminary allocation of the purchase consideration for the RMD acquisition related to finalized net working capital adjustments. As of September 30, 2022, the purchase price allocation is considered final. During the nine-months ended September 30, 2022, RMD achieved certain internal volumes required to earn the maximum earn-out consideration of $60.0 million. The Company paid out $27.5 million in cash and issued $32.5 million of Oak Street Health common stock during the three-months ended September 30, 2022. Of the total cash paid, $21.7 million had been recorded as a liability at the date of acquisition and presented as cash used in financing activities in the consolidated statement of cash flows with remaining amount reflected as cash used in operating activities- other liabilities. Additionally, the change in fair value of the

19

contingent consideration liability was recorded in other income (expense) on the consolidated statement of operations. For the three and nine-months ended September 30, 2022, the Company recorded $0 million and $38.3 million, respectively, within our other expenses as a result of RMD achieving the maximum earn-out consideration.

On September 23, 2022 OSH acquired substantially all of the assets of CHW for a total purchase price of $6.2 million, including contingent consideration with an estimated fair value of $0.2 million. The estimated fair value of the contingent consideration is recorded within other long-term liabilities. The maximum potential earn-out is $5.5 million dependent on internal metrics. As part of the CHW acquisition, the Company recorded $5.3 million of goodwill. As of September 30, 2022, the purchase price allocation is considered preliminary, and the Company may record certain adjustments during the one-year measurement period following the CHW acquisition.

NOTE 6. LEASES

The components of lease expense for the Company’s operating leases were as follows for the three and nine-months ended September 30, 2022 and September 30, 2021 ($ in millions):

	Three-Months Ended September 30,				Nine-Months Ended September 30,
	2022		2021		2022		2021
Operating lease cost2	$	13.3	$	5.6	$	34.6	$	15.0
Variable lease cost 2	2.1		5.3		7.3		14.0
Total lease cost	$	15.4	$	10.9	$	41.9	$	29.0
2See Note 2 for discussion of the correction of an immaterial prior period error. The correction of the classification of leasehold improvements resulted in a prior period benefit recorded to operating lease costs during the nine-months ended September 30, 2022. Additionally, as a result of the correction, certain variable lease expenses were re-classified as operating lease expenses during the nine-months ended September 30, 2022. These corrections impacted the comparability of variable lease costs year over year.

The Company entered into operating leases that resulted in $22.6 million and $89.2 million of right-of-use assets in exchange for operating lease obligations for the three and nine-months ended September 30, 2022, respectively. The Company entered into operating leases that resulted in $22.7 million and $49.5 million of right-of-use assets in exchange for operating lease obligations for the three and nine-months ended September 30, 2021, respectively.

The weighted-average remaining lease term and discount rate for operating lease liabilities included in the consolidated balance sheets are as follows:

	September 30, 2022		December 31, 2021
Weighted-average remaining lease term (in years)	8.8		9.9
Weighted-average discount rate	4.37	%	4.17	%

The table below presents the future minimum lease payments under the non-cancelable operating leases as of September 30, 2022 ($ in millions):

20

2022	$	10.5
2023	48.5
2024	54.7
2025	52.5
2026	52.1
2027	52.3
Thereafter	196.9
Total lease payments	$	467.5
Less: imputed interest	(101.8)
Total operating lease liabilities	$	365.7
Reported as:
Operating lease liabilities, current (1)	23.9
Operating lease liabilities, noncurrent	341.8
Total operating lease liabilities	$	365.7
(1) Included in other liabilities on the consolidated balance sheet

NOTE 7. LIABILITY FOR UNPAID CLAIMS

Activity within liabilities for unpaid claims was as follows for the nine-months ended ($ in millions):

	September 30,
	2022		2021
Balance, beginning of period	$	556.3	$	262.1
Incurred health care costs:
Current year	1,195.3		785.2
Prior years	—		5.2
Total claims incurred	$	1,195.3	$	790.4
Claims paid:
Current year	(482.9)		(366.5)
Prior years	(485.4)		(246.4)
Total claims paid	$	(968.3)	$	(612.9)
Adjustments to other claims-related liabilities	3.8		2.7
Balance, end of period	$	787.1	$	442.3

We assess the profitability of our managed care capitation arrangements to identify contracts where current operating results or forecasts indicate probable future losses. If anticipated future variable costs exceed anticipated future revenues, a premium deficiency reserve is recognized. No material premium deficiency reserves were recorded as of September 30, 2022 and December 31, 2021.

NOTE 8. LONG-TERM DEBT

Term Loan

On September 30, 2022, the Company and certain of its subsidiaries entered into the Loan Agreement with Hercules Capital, Inc., as administrative and collateral agent and lender, and Silicon Valley Bank and other lenders from time to time parties thereto. The Loan Agreement provides the Company with a Term Loan Facility of up to $300.0 million to be funded in five committed tranches available to be drawn at the Company’s option during the specified time period. Under Tranche A (available from September 30, 2022 ("Closing") until March 31, 2023), the Company was required to draw down $75.0 million upon Closing and may draw up to an additional $25.0 million. Under Tranche B (available from Closing until December 15, 2023), the Company may borrow up to $50.0 million in $25.0 million increments. Under

21

Tranche C (available from January 1, 2024 until June 30, 2024), the Company may borrow up to $50.0 million in $25.0 million increments. Under Tranche D (available from the earlier of (a) the date on which Tranche C is fully drawn and (b) July 1, 2024 until December 15, 2024), the Company may borrow up to $75.0 million in $25.0 million increments. Under Tranche E (available from Closing until June 1, 2025), the Company may borrow up to $25.0 million subject to the approval of the individual lender. If the Company does not elect to draw the entire principal amount available under the Tranche B, C or D during the applicable drawdown period, then any such undrawn portion will be added to the aggregate principal amount available under Tranche E. The obligations under the Term Loan Facility are secured by a perfected security interest in substantially all of the assets of the Company, subject to certain limitations and exceptions. The Term Loan Facility is scheduled to mature on October 1, 2027, subject to a springing maturity date of September 1, 2025 if, prior to June 1, 2025, the Company’s Convertible Senior Notes have not been (i) converted into equity interests of the Company, (ii) amended such that the scheduled maturity date of the Convertible Senior Notes is at least 180 days after the initial maturity date of the tranches of the Term Loans then in effect, or (iii) fully redeemed and extinguished.

The Term Loan interest rate will float and change on the day the prime rate changes from time to time. The Term Loan interest rate is equal to the greater of either 7.95% or the prime rate plus 2.45%. In addition, the principal balance of the Term Loans will bear “payment-in-kind” interest at the rate of 1.00% (“PIK Interest”), which PIK Interest will be added to the outstanding principal balance of the Term Loans and increase the outstanding principal balance of the Term Loans on each payment date. In addition, an end-of-term charge equal to 4.95% of the aggregate original principal amount of the Term Loans, due on the earlier of the maturity date of the Term Loans or the repayment of the Term Loans, is payable by the Company. Interest payments on the loan are due on the first day of each month.

Borrowings under the Term Loan Facility may be voluntarily prepaid in minimum increments of $25.0 million, subject to a prepayment fee equal to (i) 2.00% of the amount prepaid, if the prepayment occurs during the first year following the closing, (ii) 1.00% of the amount prepaid, if the prepayment occurs during the second year following the closing, and (iii) 0.50% of the amount prepaid, if the prepayment occurs during the third year following the closing. There is no prepayment fee, penalty or premium applicable to voluntary prepayments made by the Company on or after the fourth year following the closing.

At September 30, 2022 the outstanding balance of the Term Loan was $72.3 million, net of debt issuance costs.

In addition, beginning on the earlier of (i) the reporting deadline of the Company’s fourth quarter 2023 financial statements under the Loan Agreement and (ii) the date at which more than $100.0 million in aggregate principal (excluding any paid-in-kind interest) is outstanding under the Term Loan Facility, the Company is required to maintain a specified trailing twelve-month platform contribution (as defined in the Loan Agreement), with the applicable platform contribution increasing over time and as the Company’s borrowings under the Term Loan Facility increase. At September 30, 2022, the financial covenant was not yet in effect.

Convertible Senior Notes

On March 16, 2021, the Company issued, at par value, $920.0 million aggregate principal amount of 0% Convertible Senior Notes, including $120.0 million in aggregate principal amount pursuant to the option we granted to the initial purchasers to purchase additional convertible senior notes, which was exercised in full in March 2021. Total proceeds received by the Company from the sale of the Convertible Senior Notes, net of debt issuance and offering costs of $22.1 million, were $897.9 million. The Company used $123.6 million of the net proceeds to pay for the cost of the capped call transactions (see discussion on capped call transactions further below).

The Convertible Senior Notes are governed by an indenture (“Indenture”), dated as of March 16, 2021, between the Company and U.S. Bank National Association, as trustee. Under the Indenture, the Convertible Senior Notes are general senior, unsecured obligations of the Company and will mature on March 15, 2026, unless earlier redeemed, repurchased or converted. The Convertible Senior Notes are equal in right of payment with the Company’s future senior, unsecured indebtedness and structurally subordinated to all indebtedness and liabilities of the Company’s subsidiaries.

Pursuant to the terms of the Indenture, the Convertible Senior Notes are convertible at the option of the holders, or may be called by the Company for redemption, upon the occurrence of certain circumstances. For additional information on the conversion provisions included in the Indenture, please see Long-Term Debt, of the notes to consolidated financial statements included in our 2021 Form 10-Q for the period ended June 30, 2022. Based upon the reported sales price of our common stock during the last 30 consecutive trading days of the third quarter of 2022, the Convertible Senior Notes were not convertible by the holders on September 30, 2022 and will not be convertible until December 15, 2025.

22

Capped Call Transactions

Concurrently with the pricing of the Convertible Senior Notes, the Company entered into convertible note hedge transactions (the “capped call transactions”) with six initial purchasers or their respective affiliates and other financial institutions (the “option counterparties”) to mitigate the impact of potential economic dilution to our common stock upon conversion of the Convertible Senior Notes. The capped calls were purchased for $123.6 million from the net proceeds from the issuance of the Convertible Senior Notes and have an initial strike price of approximately $79.16 per share, which corresponds to the initial conversion price of the Convertible Senior Notes. The capped call transactions cover, subject to customary adjustments, the number of shares of common stock initially underlying the Convertible Senior Notes. The capped call transactions are expected to offset the potential dilution to the Company’s common stock upon any conversion of Convertible Senior Notes, with such reduction and/or offset subject to a cap initially equal to $138.8750 per share.

The capped call transactions will expire on March 12, 2026. The capped call transactions are separate transactions and are not part of the terms of the Convertible Senior Notes.

The capped call transactions cover, subject to anti-dilution adjustments, approximately 11,622,176 shares of the Company’s common stock. The capped call transactions are subject to either adjustment or termination upon the occurrence of specified extraordinary and disruption events affecting the Company.

The Convertible Senior Notes and capped call transactions consisted of the following balances reported in the consolidated balance sheet as of September 30, 2022 and December 31, 2021 ($ in millions):

	September 30, 2022	December 31, 2021
Liability component:
Principal	920.0	920.0
Less: debt issuance costs, net of amortization	(15.3)	(18.6)
Net carrying amount	904.7	901.4
Equity component recorded at issuance:
Capped call transactions	123.6	123.6

The Company recognized $1.1 million and $3.3 million related to the amortization of debt issuance and offering costs in interest expense, net on the consolidated statements of operations related to the Convertible Senior Notes for the three and nine-months ended September 30, 2022, respectively. The Company recognized $1.1 million and $2.4 million related to the amortization of debt issuance and offering costs in interest expense, net on the consolidated statements of operations related to the Convertible Senior Notes for the three and nine-months ended September 30, 2021, respectively. The effective interest rate for all periods was 0.49%.

NOTE 9. STOCK-BASED COMPENSATION

2020 Omnibus Incentive Plan

On August 5, 2020, the Company’s Board of Directors adopted the 2020 Omnibus Incentive Plan (the “2020 Plan,”). Under the 2020 Plan, employees, consultants and directors of the Company and our affiliates that perform services for us are eligible to receive awards. The 2020 Plan provides for the grant of incentive stock options (“ISOs”), non-statutory stock options (“NSOs”), stock appreciation rights, restricted stock awards (“RSAs”), performance awards, other share-based awards (including restricted stock units (“RSUs”)) and other cash-based awards. The maximum number of shares available for issuance under the 2020 Plan may not exceed the sum of (i) 33,473,410 shares and (ii) 21,888,258 shares issued pursuant to restricted shares and the aggregate number of shares that may be issued pursuant to the rights granted under the ESPP may not exceed 2,386,875 shares, subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization (subject to annual increases as approved by the Board of Directors).

Stock Options Activity, excluding PSOs

Stock options granted by the Company generally vest over four years with 25% of the option shares vesting each year. Options generally expire ten years from the date of the grant.

23

The following is a summary of stock option activity, excluding PSOs, as of and for the nine-months ended September 30, 2022 ($ in millions):

	Number of Options	Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Outstanding, December 31, 2021	14,945,566	$	21.89	8.61	$	177.2
Granted	1,829,910	16.92
Exercised	(560,905)	21.00
Cancelled	(442,025)	23.77
Outstanding, September 30, 2022	15,772,546	$	21.31	8.03	$	62.1
Options exercisable as of September 30, 2022	8,630,780	$	21.37	7.85	30.1

The aggregate intrinsic value of options exercised in each of the three-months ended September 30, 2022 and 2021 was $1.6 million, and $2.0 million and $8.2 million in the nine-months ended September 30, 2022 and 2021, respectively. Aggregate intrinsic value represents the difference between the exercise price of the option and the closing price of the Company’s common stock on the date of exercise. The fair value of options granted for the three-months ended September 30, 2022 and 2021 was $0.9 million and $0.4 million, respectively, and $15.7 million and $9.6 million for the nine-months ended September 30, 2022 and 2021, respectively.

Performance Stock Options Activity

In February 2022, the Company granted PSOs to certain of its executives, with 50% of the option shares vesting at the end of year two and the remaining 50% of the option shares vesting at the end of year three, subject in each case to the satisfaction of certain performance-based conditions. The PSOs generally expire ten years from the date of the grant. The fair value of performance stock options granted for the nine-months ended September 30, 2022 was $25.8 million.

The following is a summary of PSO activity as of and for the nine-months ended September 30, 2022 ($ in millions):

	Number of Options	Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Outstanding, December 31, 2021	—	$	—	—	$	—
Granted	3,300,505	15.75
Exercised	—	—
Cancelled	—	—
Outstanding, September 30, 2022	3,300,505	$	15.75	9.4	$	28.9
Options exercisable as of September 30, 2022	—	$	—	—	—

RSU Activity

RSUs granted generally vest ratably over four years. The following is a summary of RSU transactions as of and for the nine-months ended September 30, 2022:

24

	Unvested Shares	Grant Date Fair Value
Unvested, December 31, 2021	476,628	$	47.30
Granted	2,572,673	17.69
Vested	(149,850)	40.39
Canceled and forfeited	(281,823)	21.97
Unvested, September 30, 2022	2,617,628	$	21.59

PSU Activity

The Company granted PSUs to certain of its employees during the second quarter of 2022 with the units vesting in April 2023, subject in each case to the satisfaction of certain performance-based conditions. The following is a summary of PSU activity as of and for the nine-months ended September 30, 2022:

	Unvested Shares	Grant Date Fair Value
Unvested, December 31, 2021	111,184	$	33.73
Granted	455,426	23.66
Vested	—	—
Canceled and forfeited	(5,705)	24.17
Unvested, September 30, 2022	560,905	$	27.88

RSA Activity

The RSAs were granted as part of the pre-IPO conversion. The following is a summary of RSA transactions as of and for the nine-months ended September 30, 2022:

	Unvested Shares	Grant Date Fair Value
Unvested, December 31, 2021	16,090,990	$	14.71
Granted	—	—
Vested	(9,040,014)	15.73
Canceled and forfeited	(280,956)	15.57
Unvested, September 30, 2022	6,770,020	$	13.31

Employee Stock Purchase Plan

On August 5, 2020, the Board of Directors adopted, and the OSH LLC’s and OSH MH LLC’s majority unitholders approved, the 2021 Employee Stock Purchase Plan (the “ESPP”). The ESPP is more fully described in Note 13 to the consolidated financial statements included in our 2021 Form 10-K.

During the nine-months ended September 30, 2022 and 2021, 224,473 shares and 62,575 shares, respectively, were purchased under the ESPP.

Stock-Based Compensation Expense

The following table is a summary of stock-based compensation expense by function ($ in millions):

25

	Three-Months Ended September 30,				Nine-Months Ended September 30,
	2022		2021		2022		2021
Cost of care, excluding depreciation and amortization	$	1.3	$	0.5	$	2.7	$	1.2
Sales and marketing	1.4		0.8		3.8		2.5
Corporate, general and administrative	28.1		37.4		113.5		118.2
Total	30.8		38.7		120.0		121.9

As of September 30, 2022, the Company approximately $98.9 million in unrecognized compensation expense related to all non-vested awards (RSAs, ISOs, PSO, PSUs and RSUs) that will be recognized over the weighted-average period of 1.44 years.

NOTE 10. COMMITMENTS AND CONTINGENCIES

Contingencies

The Company is presently, and from time to time, subject to various claims and lawsuits arising in the normal course of business. In the opinion of management, the ultimate resolution of these matters will not have a material adverse effect on the Company’s financial position or results of operations.

Uncertainties

The healthcare industry is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations include, but are not limited to, matters such as licensure, accreditation, government healthcare program participation requirements, reimbursement for patient services, and Medicare and Medicaid fraud and abuse. Recently, government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by healthcare providers. Violations of these laws and regulations could result in expulsion from government healthcare programs together with imposition of significant fines and penalties, as well as significant repayments for patient services billed.

On November 1, 2021, the Company received a civil investigative demand (“CID”) from the United States Department of Justice. According to the CID, the Department of Justice is investigating whether the Company may have violated the False Claims Act, 31 U.S.C. §§ 3729-3722. The CID requests certain documents and information related to the Company’s relationships with third-party marketing agents and related to the Company’s provision of free transportation to federal health care beneficiaries and requests information and documents related to such matters. We are continuing to cooperate with the Department of Justice in response to the CID. We are currently unable to predict the outcome of this investigation or whether litigation is probable. Regardless of the outcome, this inquiry has the potential to have an adverse impact on us due to any related defense and settlement costs, diversion of management resources and other factors.

On January 10, 2022, Reginald T. Allison, individually and on behalf of all others similarly situated, filed a putative class action lawsuit against the Company, Michael Pykosz, and Timothy Cook in the United States District Court for the Northern District of Illinois (Case No. 1:22-cv-00149).

On March 25, 2022, Central Pennsylvania Teamsters Pension Fund – Defined Benefit Plan, Central Pennsylvania Teamsters Pension Fund – Retirement Income Plan 1987, and Boston Retirement System’s (collectively, the “Northeast Pension Funds”) were appointed as the lead plaintiffs in the case. On May 25, 2022, the Northeast Pension Funds along with an additional named plaintiff, the City of Dearborn Police & Fire Revised Retirement System, filed their consolidated amended and restated complaint (the “Amended Complaint”).

Plaintiffs allege that the Company and certain of its executive officers made false and/or misleading statements about patient acquisition tactics that purportedly violated the False Claims Act and federal Anti-Kickback Statute, and are purportedly the subject of the CID discussed above. The Amended Complaint includes two categories of claims: (1) claims under the Securities Exchange Act of 1934 based on allegedly misleading public statements throughout the class period of August 6, 2020 through November 8, 2021 (the “Exchange Act Claims”), and (2) claims under the Securities Act of 1933 based on allegedly misleading statements in the registration statements and prospectuses accompanying Oak Street Health, Inc.’s initial public offering and secondary public offerings (the “Securities Act Claims”). The Exchange Act claims are asserted against Oak Street Health, Inc., Michael Pykosz, our CEO and Timothy Cook, our CFO, and also against certain stockholders of as “control persons.” The Securities Act Claims are asserted against the same defendants as well as the underwriters of the Company’s public offerings, and the Oak Street Health, Inc. directors who signed the registration statements. The Amended Complaint seeks damages, interest, costs, attorneys’ fees and other unspecified equitable relief.

26

On July 25, 2022, the defendants filed a consolidated motion to dismiss the Amended Complaint. On September 26, 2022, the plaintiffs' opposition to that motion to dismiss was filed, and the defendants reply to that opposition was filed on October 26, 2022. The court will now consider the motion in due course.

In the event that the defendants's motion to dismiss is not granted, the Company intends to continue to vigorously defend this matter. Given the uncertainty of litigation, the preliminary stage of the case, and the legal standards that must be met for success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may result from this action.

Management believes that the Company is in compliance with fraud and abuse laws, as well as other applicable laws and regulations. While no regulatory inquiries have been made, compliance with such laws and regulations is subject to government review and interpretation, as well as regulatory actions unknown at this time.

NOTE 11. VARIABLE INTEREST ENTITIES

The Physician Groups, or affiliated physician practice organizations, were established to employ healthcare providers, contract with managed care payors and to deliver healthcare services to patients in the markets that the Company serves.

The Company evaluated whether it has a variable interest in the Physician Groups, whether the Physician Groups are VIEs and whether the Company has a controlling financial interest in the Physician Groups. The Company concluded that it has variable interests in the Physician Groups on the basis of its Administrative Service Agreement (“ASA”) which provides for reimbursement of costs and a management fee payable to the Company from the Physician Groups in exchange for providing management and administrative services which creates risks and a potential return to the Company. The Physician Group’s equity at risk, as defined by U.S. GAAP, is insufficient to finance its activities without additional support, and, therefore, the Physician Groups are considered VIEs.

The tables below illustrates the VIE assets and liabilities and performance for the Physician Groups as of and for the periods ended ($ in millions):

	September 30, 2022		December 31, 2021
Total assets	$	945.7	$	596.2
Total liabilities	868.2		564.4

	Three-Months Ended September 30,				Nine-Months Ended September 30,
	2022		2021		2022		2021
Total revenues	$	543.3	$	350.5	$	1,575.9	$	644.9
Medical claims expense	426.3		283.0		1,195.4		481.9
Cost of care	55.5		34.5		153.3		67.4
Total operating expenses	$	481.8	$	317.5	$	1,348.7	$	549.3

There are no restrictions on the Physician Groups’ assets or on the settlement of its liabilities. The assets of the Physician Groups can be used to settle obligations of the Company. The Physician Groups are included in the Company’s obligated group; thus, creditors of the Company have recourse to the assets owned by the Physician Groups. There are no liabilities for which creditors of the Physician Groups do not have recourse to the general credit of the Company. There are no restrictions placed on the retained earnings or net income of the Physician Groups with respect to potential dividend payments.

NOTE 12. RELATED PARTIES

Humana

Humana held over 5% of our common stock during the year ended December 31, 2021. Additionally, a Humana representative served on the Board of Directors from 2020 until his retirement, effective September 7, 2021. Humana no longer has a representative on the Board of Directors as of September 7, 2021. Humana is no longer a related party for the year ending December 31, 2022, and as such, the Company has included prior year transaction amounts only on the consolidated balance sheet and consolidated statement of operations.

27

During the year ended December 31, 2021, our related party transactions with Humana included capitated managed care contracts, which resulted in capitated revenue and related receivables. Within the Company’s other revenue, revenues from Humana were included in both fee-for-service revenue and care coordination and care management revenue. The receivable associated with the fee-for-service revenue was recorded in other receivables. The unearned portion of the care coordination payments was recorded as a contract liability in both the current and long-term other liabilities accounts. The Company also incurred medical claims expense related to the Humana payor contracts which are included in medical claims expense. Related unpaid claims were included in the liability for unpaid claims financial statement caption. The Humana Alliance Provision contains an arrangement for a license fee that is payable by the Company to Humana for the Company’s provision of health care services in certain centers owned or leased by Humana. The license fee is a reimbursement to Humana for its costs of owning or leasing and maintaining the centers, including rental payments, center maintenance or repair expenses, equipment expenses, special assessments, cost of upgrades, taxes, leasehold improvements and other expenses identified by Humana. We will continue to have these transaction types with Humana during the year ended December 31, 2022, however, they are no longer considered related party transactions.

NOTE 13. NET LOSS PER SHARE

The following table sets forth the computation of basic and diluted net loss per common share for the three and nine-months ended September 30, 2022 and 2021 ($ in millions).

	Three-Months Ended September 30,				Nine-Months Ended September 30,
	2022		2021		2022		2021
Numerator:
Net loss	$	(130.4)	$	(110.0)	$	(375.3)	$	(274.3)
Less: Net income/(loss) attributable to non-controlling interests	0.3		(0.6)		0.9		(3.5)
Net loss attributable to Oak Street Health, Inc.	(130.7)		(109.4)		(376.2)		(270.8)
Denominator:
Weighted average common shares outstanding - basic and diluted	231,919,421		223,435,698		228,042,160		221,932,624
Net loss per share – basic and diluted	$	(0.56)	$	(0.49)	$	(1.65)	$	(1.22)

The Company’s potentially dilutive securities, which included stock options (including PSOs), unvested RSUs (including PSUs), unvested RSAs, and shares issuable upon conversion of our Convertible Senior Notes, have been excluded from the computation of diluted net loss per share as the effect would reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share was the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated:

	Nine-Months Ended September 30,
	2022	2021
Stock options	19,073,051	14,999,384
RSUs	3,178,533	341,215
RSAs	6,770,020	16,792,134
Convertible Senior Notes	11,622,176	11,622,176
	40,643,780	43,754,909

ITEM 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis is intended to help the reader understand our business, financial condition, results of operations, liquidity and capital resources. This discussion should be read in conjunction with our unaudited consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q and our audited financial statements and the accompanying notes as well as the sections entitled “Risk Factors” and

28

“Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 2021 Form 10-K.

The discussion contains forward-looking statements about the business, operations and financial performance of the Company based on our current expectations that involves risks, uncertainties and assumptions. Actual results could differ materially from those discussed in or implied by forward-looking statements as a result of various factors, including those discussed above in “Forward-Looking Statements,” as well as those discussed under the “Risk Factors” section in our 2021 Form 10-K.

Business Overview

Oak Street Health, Inc. (collectively referred to as “Oak Street Health,” “OSH,” “we,” “us,” “our” or the “Company”) was formed as a Delaware corporation on October 22, 2019 for the purpose of completing a public offering and related restructuring transactions (collectively referred to as the “IPO”) in order to carry on the business of Oak Street Health, LLC (“OSH LLC”) and its affiliates. As the managing member of OSH LLC, Oak Street Health, Inc. operates and controls all of the business affairs of OSH LLC and its affiliates. Our common stock trades on the New York Stock Exchange (“NYSE”) under the ticker symbol “OSH.”

Oak Street Health was designed to provide and manage Medicare-eligible patients’ total healthcare through capitated, value-based arrangements. We created a new care platform because the then-existing primary care infrastructure was not built with the capacity to drive the significant improvements in cost and quality the current health system needs. We decided to focus on the Medicare market due to its size, growth tailwinds and largely clinically cohesive population. We designed our platform to take risk in managing patients’ health below an agreed-upon baseline cost because we believed there was a meaningful opportunity to produce system-wide cost savings by changing where and how patients’ healthcare is delivered. Our platform’s design has included investments in technology and patient-centered, community-based care delivery to create a different and, we believe, better approach to addressing the needs of high-risk Medicare-eligible patients.

As of September 30, 2022, the Company operated 161 centers across 20 states, which provided care for approximately 209,500 patients. We, together with our affiliated physician practice organizations, employ approximately 5,900 team members, including approximately 600 primary care providers. Our operations are organized and reported under one segment.

COVID-19 Update on our Business

On March 11, 2020, the World Health Organization designated COVID-19 as a global pandemic. The rapid spread of COVID-19 around the world and throughout the United States has altered the behavior of businesses and people, with significant negative effects on federal, state and local economies, the duration of which is unknown at this time. Various policies were implemented by federal, state and local governments in response to the COVID-19 pandemic that caused many people to remain at home and forced the closure of or limitations on certain businesses, as well as suspended elective procedures by health care facilities. The on-going COVID-19 global pandemic disproportionately impacts older adults, especially those with chronic illnesses, which describes many of our patients.

The COVID-19 pandemic has impacted both our per-patient capitated revenue and medical claims expense. Throughout the pandemic, our risk scores for existing Oak Street Health patients have been consistent with our historical experience. New patients in 2021 had lower risk scores than what we would expect based on historical experience, due to a lack of availability of care in 2020 as the healthcare system was inaccessible to non-Oak Street Health patients for several months in 2020 because of local COVID-19 restrictions. As we are able to more completely and accurately document both current and new patients’ health conditions, we expect that risk scores will increase to reflect the true severity of these patients’ conditions, which we would further expect to result in increased revenue for our 2022 fiscal year. It is unknown to us at present how significantly, if at all, this new patient risk score dynamic might impact our business during the full 2022 fiscal year.

As we are financially responsible for essentially all of the healthcare costs associated with our at-risk patients whether we provide that care or a third party provides that care, we suspect that the healthcare costs of patients infected with COVID-19 will be greater than had COVID-19 not occurred. It is impossible, however, to know what other healthcare issues these patients may have encountered in their pre-COVID-19 lives and whether the COVID-19 costs are, or will be, greater or lesser than the costs these patients would otherwise incur. Because of the COVID-19 related volatility in medical cost data in 2020 and 2021 and the surge in COVID-19 cases at the end of 2021 and beginning of 2022, we do not believe

29

that these periods can serve as a reliable basis for estimating our future performance and do not know what the impact from COVID-19 will be on medical costs in the future. Given these factors, per-patient medical costs may be greater for the full 2022 fiscal year than the levels we experienced in our recent historical results. We do believe, however, that the impact of on per-patient revenue and medical claims related to COVID-19 that we expect to experience will not have a materially detrimental effect on our long-term financial performance in future periods.

The COVID-19 pandemic had an impact on our results from operations, cash flows and financial position for the nine-months ended September 30, 2022, primarily as a result of an increase in cases in early 2022 due to the Omicron variant. Based upon claims paid to- date, our direct costs related to COVID-19 claims were approximately $89.3 million for the period from March 1, 2020 through September 30, 2022. We estimated that total COVID-19 claims incurred during the nine-months ended September 30, 2022 were approximately $21.2 million, which was comparable to our direct COVID-19 claims of $18.9 million for the nine-months September 30, 2022. We expect to incur additional COVID-19 related costs given the volume of positive cases in our markets. Due to the uncertainty of COVID-19 infection and hospitalization rates, we cannot estimate any incremental COVID-19 related costs we may incur in future periods.

We will continue to closely monitor the COVID-19 pandemic and its continued impact on our patients and prospective patients and our business. The ongoing effects of the pandemic, as well as the extent and significance of any future variants, remain unresolved and could continue for an extended period of time. Even as the COVID-19 pandemic subsides, disruptions caused by the pandemic, including labor shortages, supply chain disruptions, and inflationary pressures, may continue and could, in turn, have a negative impact on the Company. Further, recurring COVID-19 outbreaks, including outbreaks caused by different virus variants, could have the potential to impact the Company and its future results of operations, cash flows and financial position.

The full extent to which the COVID-19 pandemic has and will continue to directly or indirectly impact our business, future results of operations and financial condition will depend on factors that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19 including the impact of new variants of the virus, the actions taken to contain it or treat its impact and the economic impact on our markets. Such factors include, but are not limited to, the scope and duration of stay-at-home practices and business closures and restrictions, rate and effectiveness of vaccinations in the U.S., government-imposed or recommended suspensions of elective procedures, and expenses required for supplies and personal protective equipment. Because of these and other uncertainties, we cannot estimate the length or severity of the impact of the pandemic on our business. Furthermore, because of our business model, the full impact of the COVID-19 pandemic may not be fully reflected in our results of operations and overall financial condition until future periods. We will continue to closely evaluate and monitor the nature and extent of these potential impacts to our business, results of operations and liquidity.

For additional information on the various risks posed by the COVID-19 pandemic, please see the “Risk Factors” section included in our 2021 Form 10-K.

Key Factors Affecting Our Performance

•Adding New Patients in Existing Centers: Our ability to add new patients is a key indicator of the market’s recognition of the attractiveness of the Oak Street Platform, both to our patients and Medicare Advantage ("MA") plan partners, and a key growth driver for the business. As we add patients to our existing centers, we expect these patients to contribute significant incremental economics to Oak Street Health as we leverage our fixed cost base at each center. We grow our patient base through our own internal outreach efforts, which drive most of our new patient growth, as well as assignments from our MA plan partners. We grew our patient base from approximately 131,500 patients as of September 30, 2021 to approximately 209,500 as of September 30, 2022.

•Expand our Center Base within Existing and New Markets: We believe our core market consists of approximately 27 million patients, and we served approximately 209,500 patients as of September 30, 2022. As a result, we believe there is significant opportunity to expand in our existing markets through the acquisition of new patients to existing centers and addition of new centers. For the long term, these strategically developed new sites allow us to access additional neighborhoods while leveraging our established brand and infrastructure in a market. Our existing markets today represent a small fraction of the overall market opportunity. Based upon our experience to date, we believe our care model can scale nationally, and we therefore expect to selectively and strategically expand into new geographies.

30

Additionally, we began participating in the Global and Direct Contracting Model as of April 1, 2021, which we are hopeful will allow us to manage existing fee-for-service (“FFS”) patients on an at-risk basis. The Direct Contracting Model and the Accountable Care Organization Realizing Equity, Access and Community Health ("ACO REACH") model, as its successor, create new opportunities for the Centers for Medicare & Medicaid Services ("CMS") to test an array of financial risk-sharing arrangements in the traditional Medicare fee-for-service population, and it will enable us to assume financial risk for the cost of care for some patients covered by traditional Medicare. Through the Direct Contracting model, CMS aims to transform risk-sharing arrangements in Medicare FFS, empower and engage beneficiaries (or patients or members) in their own care delivery, broaden participation in CMS Innovation Center models, reduce provider burden and shift providers from FFS to value-based payments in primary care. The stated goals of the ACO REACH model are to advance health equity to bring benefits of accountable care to underserved communities, promote provider leadership and governance, and protect beneficiaries and the model with more participant vetting, monitoring and greater transparency. There can be no assurances, however, that these or any other payment models that align with our strategy and investments will be continued or changed in ways that could be disadvantageous to our business.

•Contract with Payors: Our economic model relies on our capitated arrangements with payors and CMS, which manage and market MA plans across the United States. In our short history, we have been able to establish strategic value-based relationships with over 30 different payors, including each of the top 5 national payors by number of MA patients. These existing contracts and relationships and our payors’ understanding of the value of our model reduces the risk of entering into new markets as we typically have payor contracts before entering a new market. Maintaining, supporting, and growing these relationships, particularly as we enter new geographies, is critical to our long-term success.

•Effectively Manage the Cost of Care for Our Patients: The capitated nature of our contracts with payors requires us to prudently manage the medical expense of our patients. Our care model focuses on leveraging the primary care setting as a means of avoiding costly downstream healthcare costs, such as acute hospital admissions. Our patients, however, retain the freedom to seek care at emergency rooms or hospitals; we do not restrict their access to care beyond the limits of their MA plan, although we have developed many capabilities to manage and control the associated costs of this care. Therefore, we are liable for potentially large medical claims should we not effectively manage our patients’ health. On October 20, 2021, we acquired RubiconMD Holdings, Inc. ("RMD"), a leading technology platform in New York providing access to specialist expertise. The acquisition enables Oak Street Health to integrate virtual specialty care into its existing care model, which is expected to significantly streamline the referral process and better manage costs, enhance patient experience and provide comprehensive care far beyond traditional primary care.

•Center-Level Contribution Margin: We endeavor to expand our number of centers and number of patients at each center over time. Due to the significant fixed costs associated with operating and managing our centers and the increases we experience in patient contribution on a per-patient basis the longer a patient is part of the Oak Street Platform, we generate significantly better center-level contribution margins (defined as (i) patient revenue, excluding Medicare Part D revenue minus (ii) the sum of (a) medical claims expense, excluding Medicare Part D related expenses, and (b) cost of care, excluding depreciation and amortization) as the patient base within our centers increases and matures and our costs decrease as a percent of revenue. As a result, the value of a center to our business increases over time.

•Seasonality to our Business: Our operational and financial results, including at-risk patient growth, per-patient revenue, and medical costs, will experience some variability depending upon the time of year in which they are measured. We typically experience the largest portion of our at-risk patient growth during

31

the first quarter, when plan enrollment selections made during the prior Annual Enrollment Period (“AEP”) from October 15th through December 7th of the prior year take effect. Our per-patient revenue will generally decline over the course of the year. As the year progresses, our per-patient revenue declines as new patients join us typically with less complete or accurate documentation (and therefore lower risk-adjustment scores) and our attrition skews towards our higher-risk (and therefore greater revenue) patients. Finally, medical costs will vary seasonally depending on a number of factors, including the weather which can be a driver of certain illnesses, such as the influenza virus. We would therefore expect to see higher levels of per-patient medical costs in the first and fourth quarters. Medical costs also depend upon the number of business days in a period as periods with fewer business days will have lower medical costs all else equal.

•Investments in Growth: We expect to continue to focus on long-term growth through investments in our centers, care model and sales and marketing. In addition, we expect our corporate, general and administrative expenses to increase in absolute dollars for the foreseeable future to support our growth and because of the additional costs of being a public company.

Executive Summary

The following table presents key financial statistics for the three and nine-months ended September 30, 2022 and 2021:

	Three-Months Ended September 30,				Nine-Months Ended September 30,
(dollars in millions)	2022		2021		2022		2021
Centers	161		110		161		110
Total patients	209,500		131,500		209,500		131,500
At-risk	145,000		100,500		145,000		100,500
Fee-for-service	64,500		31,000		64,500		31,000
Total revenues	$	545.7	$	388.7	$	1,583.2	$	1,038.5
Loss from operations1	$	(130.2)	$	(109.4)	$	(333.9)	$	(272.5)
Net loss1	$	(130.4)	$	(110.0)	$	(375.3)	$	(274.3)
Platform contribution (Non-GAAP)2	$	6.0	$	3.1	$	79.9	$	45.2
Patient contribution (Non-GAAP)2	$	110.5	$	66.9	$	361.7	$	223.7
Adjusted EBITDA (Non-GAAP)2	$	(88.3)	$	(64.4)	$	(183.7)	$	(135.3)

_______________________________________

1Includes stock-based compensation expense as shown in the table in the Results of Operations section below.

2See “Non-GAAP Reconciliations” below for reconciliations to the most directly comparable financial measures calculated in accordance with GAAP and related disclosures.

Centers

We define our centers as those primary care centers open for business and attending to patients at the end of a particular period. Our centers are leased or licensed by Oak Street Health MSO, LLC or an affiliated entity and, pursuant to the terms of certain contractual relationships between Oak Street Health MSO, LLC and our affiliated medical practices, made available for use by the medical practices in the provision of primary care services.

Total Patients

Total patients includes both at-risk MA and Direct Contracting patients (those patients for whom we are financially responsible for their total healthcare costs) as well as fee-for-service Medicare patients (those patients for whom our affiliated medical groups submit claims to the federal government for direct reimbursement under the Medicare program or to MA plans with which we do not have value-based arrangements). We define our total at-risk patients as at-risk patients who have selected one of our affiliated medical groups as their provider of primary care medical services as of the end of a particular period or have been aligned under the Direct Contracting program. We define our total fee-for-service Medicare patients as fee-for-service Medicare patients who come to one of our centers for medical care at least once per year. A fee-

32

for-service patient continues to be included in our patient count until the earlier to occur of (a) more than one year since the patient’s last visit, (b) the patient communicates a desire to stop receiving care from us or (c) the patient passes away.

Non-GAAP Financial Measures

We utilize certain financial measures that are not calculated based on GAAP. Certain of these financial measures are considered “non-GAAP” financial measures within the meaning of Item 10 of Regulation S-K promulgated by the SEC. We believe that non-GAAP financial measures provide an additional way of viewing aspects of our operations that, when viewed with the GAAP results, provide a more complete understanding of our results of operations and the factors and trends affecting our business. These non-GAAP financial measures are also used by our management to evaluate financial results and to plan and forecast future periods. However, non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Non-GAAP financial measures used by us may differ from the non-GAAP financial measures used by other companies, including our competitors.

To supplement our consolidated financial statements presented on a GAAP basis, we disclose the following non-GAAP financial measures: patient contribution, platform contribution and adjusted EBITDA as these are performance measures that our management uses to assess our operating performance. Because patient contribution, platform contribution and adjusted EBITDA facilitate internal comparisons of our historical operating performance on a more consistent basis, we use these measures for business planning purposes and in evaluating acquisition opportunities.

Patient and platform contributions are reconciled to gross profit as the most directly comparable GAAP measure as set forth in the below tables under “Non-GAAP Reconciliations.” Gross profit is defined as total revenues less medical claims expense. Adjusted EBITDA is reconciled to net loss as the most directly comparable GAAP measure as set forth in the below table under “Non-GAAP Reconciliations.”

Our definitions of patient contribution, platform contribution and adjusted EBITDA may differ from the definition used by other companies and therefore comparability may be limited. In addition, other companies may not publish this or similar metrics. Thus, our non-GAAP financial measures should be considered in addition to, not as a substitute for, or in isolation from, measures prepared in accordance with GAAP, such as net loss and loss from operations.

We provide investors and other users of our financial information with reconciliations of patient contribution, platform contribution and adjusted EBITDA to loss from operations and net loss, respectively. We encourage investors and others to review our financial information in its entirety, not to rely on any single financial measure and to view patient contribution, platform contribution and adjusted EBITDA in conjunction with loss from operations and net loss, respectively.

Patient Contribution

We define patient contribution as capitated revenue less medical claims expense. Patient contribution is intended to isolate the profitability of the Company's capitation arrangements with our health plan payors and/or CMS for which the Company provides and/or manages healthcare services for its at-risk patients. We expect that patient contribution will grow year-over-year in absolute dollars as our at-risk patient base continues to grow. We would also expect that our patient contribution per-patient-per-month economics on our at-risk patients will continue to improve the longer our patients are part of the Oak Street Platform as we better understand their health conditions and the patients better engage with our care model. We would expect, however, that our aggregate patient contribution per-patient-per-month economics on our at-risk patients may decrease at an aggregate level to the extent our patient growth skews our mix of patients towards patients newer to the Oak Street Platform.

We would also expect to experience seasonality in patient contribution per-patient-per-month with the first quarter generally generating the greatest patient contribution per-patient-per-month, decreasing for the rest of the year. This seasonality is primarily driven by our adding new patients to the Oak Street Platform throughout the year, who generally have lower per-patient capitated revenue compared to our existing patient base.

Platform Contribution

We define platform contribution as total revenues less the sum of medical claims expense and cost of care, excluding depreciation and amortization and stock-based compensation. We believe this metric best reflects the economics or overall profit margin of our care model and related centers as it includes all medical claims expense associated with our patients’ care as well as the costs we incur to care for our patients via the Oak Street Platform. As a center matures, we

33

expect the platform contribution from that center to increase both in terms of absolute dollars as well as a percent of capitated revenue. This increase will be driven by improving patient contribution economics over time as well as our ability to generate operating leverage on the costs of our centers. Our aggregate platform contribution may not increase despite improving economics at our existing centers should we open new centers at a pace that skews our mix of centers towards newer centers. We would expect to experience seasonality in platform contribution due to seasonality in our patient contribution.

Adjusted EBITDA

We define adjusted EBITDA as net loss excluding interest expense and other income (expense), income taxes, fair value adjustments related to assets and liabilities recorded in purchase accounting such as earn-out liabilities and intangibles and related to impairment of equity investments, depreciation and amortization, transaction/offering costs, one-time in nature litigation costs and stock-based compensation. We include adjusted EBITDA in this Quarterly Report on Form 10-Q because it is an important measure upon which our management assesses and believes investors should assess our operating performance. We also consider adjusted EBITDA to be an important measure because it helps illustrate underlying trends in our business and our historical operating performance on a more consistent basis.

Results of Operations

The following tables set forth our results of operations for the periods presented and as a percentage of our total revenues for those periods.

	Three-Months Ended September 30,						Nine-Months Ended September 30,
(dollars in millions)	2022		2021		% Change		2022		2021		% Change
Revenues:
Capitated revenue	$	537.9	$	376.7	43	%	$	1,560.1	$	1,014.6	54	%
Other revenue	$	7.8	$	12.0	(35)	%	$	23.1	$	23.9	(3)	%
Total revenues	$	545.7	$	388.7	40	%	$	1,583.2	$	1,038.5	52	%
Operating expenses:
Medical claims expense	$	427.4	$	309.8	38	%	$	1,198.4	$	790.9	52	%
Cost of care, excluding depreciation and amortization (1)	$	113.6	$	76.3	49	%	$	307.6	$	203.6	51	%
Sales and marketing (2)	$	44.1	$	30.5	45	%	$	120.5	$	80.5	50	%
Corporate, general and administrative (3)	$	81.7	$	77.0	6	%	$	265.3	$	224.3	18	%
Depreciation and amortization	$	9.1	$	4.5	102	%	$	25.3	$	11.7	116	%
Total operating expenses	$	675.9	$	498.1	36	%	$	1,917.1	$	1,311.0	46	%
Loss from operations	$	(130.2)	$	(109.4)	19	%	$	(333.9)	$	(272.5)	23	%
Other income/(expense):
Interest expense, net	—		(0.6)		100	%	(1.1)		(1.8)		(38)	%
Other	(0.2)		—		100	%	(40.3)		—		100	%
Total other expense	(0.2)		(0.6)		(67)	%	(41.4)		(1.8)		2200	%
Net loss	(130.4)		(110.0)		19	%	(375.3)		(274.3)		37	%
Net income/(loss) attributable to non-controlling interests	0.3		(0.6)		(150)	%	0.9		(3.5)		(127)	%
Net loss attributable to the Company	(130.7)		(109.4)		19	%	(376.2)		(270.8)		39	%
(1) Includes stock-based compensation, as follows:	1.3		0.5		160	%	2.7		1.2		125	%
(2) Includes stock-based compensation, as follows:	1.4		0.8		75	%	3.8		2.5		52	%
(3) Includes stock-based compensation, as follows:	28.1		37.4		(25)	%	113.5		118.2		(4)	%

34

	Three-Months Ended September 30,				Nine-Months Ended September 30,
	2022		2021		2022		2021
Revenues:
Capitated revenue	99	%	97	%	99	%	98	%
Other revenue	1	%	3	%	1	%	2	%
Total revenues	100	%	100	%	100	%	100	%
Operating expenses:
Medical claims expense	78	%	80	%	76	%	76	%
Cost of care, excluding depreciation and amortization	21	%	20	%	19	%	20	%
Sales and marketing	8	%	8	%	8	%	8	%
Corporate, general and administrative	15	%	20	%	17	%	22	%
Depreciation and amortization	2	%	1	%	2	%	1	%
Total operating expenses	124	%	128	%	121	%	126	%
Loss from operations	(24)	%	(28)	%	(21)	%	(26)	%
Other income/(expense):
Interest expense, net	—	%	—	%	—	%	—	%
Other	—	%	—	%	(3)	%	—	%
Total other expense	—	%	—	%	(3)	%	—	%
Net loss	(24)	%	(28)	%	(24)	%	24	%
Net income/(loss) attributable to non-controlling interests	0	%	—	%	—	%	—	%
Net loss attributable to the Company	(24)	%	(28)	%	(24)	%	(26)	%

Total Revenues

	Three-Months Ended September 30,				Change				Nine-Months Ended September 30,				Change
(dollars in millions)	2022		2021		$		%		2022		2021		$		%
Revenues:
Capitated revenue	$	537.9	$	376.7	$	161.2	43	%	$	1,560.1	$	1,014.6	$	545.5	54	%
Other revenue	$	7.8	$	12.0	(4.2)		(35)	%	$	23.1	$	23.9	(0.8)		(3)	%
Total revenues	$	545.7	$	388.7	$	157.0	40	%	$	1,583.2	$	1,038.5	$	544.7	52	%

Capitated revenue was $537.9 million for the three-months ended September 30, 2022, an increase of $161.2 million, or 43%, compared to $376.7 million for the three-months ended September 30, 2021. This increase was driven primarily by a 44% increase in total patients under capitated arrangements, slightly offset by a decrease of approximately 1% in the capitated revenue rate. For the three-months ended September 30, 2022, we recorded a reduction in capitated revenue of $5.9 million related to prior periods primarily due to the retrospective trend adjustments made by CMS under the Direct Contracting program and Direct contracting patient retroactivity. During the three-months ended September 30, 2021, we recorded $15.4 million of incremental capitated revenue related to prior periods due to patient retroactivity and increases in our acuity adjustments. When excluding the prior period revenue for the three-months ended September 30, 2022 and 2021, the year over year capitated revenue rate per patient increased by approximately 4%.

Capitated revenue was $1,560.1 million for the nine-months ended September 30, 2022, an increase of $545.5 million, or 54%, compared to $1,014.6 million for the nine-months ended September 30, 2021. This increase was driven primarily by a 44% increase in total patients under capitated arrangements (including Direct Contracting, which started as of April 2021) and an increase of approximately 7% in capitated revenue rate. Immaterial prior period capitated revenue was included in balance for the nine-months ended September 30, 2022. For the nine-months ended September 30, 2021, incremental capitated revenue of $20.2 million was recorded related to prior periods related to patient retroactivity and increases in our acuity adjustments. When excluding the prior period revenue for the nine-months ended September 30, 2021, the year over year capitated revenue rate per patient increased by approximately 9%.

35

Other revenue was $7.8 million for the three-months ended September 30, 2022, a decrease of $4.2 million, or 35%, compared to $12.0 million for the three-months ended September 30, 2021. Other revenue was $23.1 million for the nine-months ended September 30, 2022, a decrease of $0.8 million, or 3%, compared to $23.9 million for the nine-months ended September 30, 2021. The decreases are primarily related to incremental revenues recorded during the three-months ended September 30, 2021 related to prior periods due to the ACO shared savings program.

Operating Expenses

	Three-Months Ended September 30,				Change				Nine-Months Ended September 30,				Change
(dollars in millions)	2022		2021		$		%		2022		2021		$		%
Medical claims expense	$	427.4	$	309.8	$	117.6	38	%	$	1,198.4	$	790.9	$	407.5	52	%
Cost of care, excluding depreciation and amortization	$	113.6	$	76.3	37.3		49	%	$	307.6	$	203.6	104.0		51	%
Sales and marketing	$	44.1	$	30.5	13.6		45	%	$	120.5	$	80.5	40.0		50	%
Corporate, general and administrative	$	81.7	$	77.0	4.7		6	%	$	265.3	$	224.3	41.0		18	%
Depreciation and amortization	$	9.1	$	4.5	4.6		102	%	$	25.3	$	11.7	13.6		116	%
Total operating expenses	$	675.9	$	498.1	$	177.8	36	%	$	1,917.1	$	1,311.0	$	606.0	46	%

Medical claims expense was $427.4 million or 78% of total revenues for the three-months ended September 30, 2022, an increase of $117.6 million, or 38%, compared to $309.8 million or 80% of total revenues for the three-months ended September 30, 2021. This increase was driven primarily by a 44% increase in total patients under capitated arrangements, slightly offset by an 4% decrease in cost per patient. For the three-months ended September 30, 2022, we recorded a reduction to medical claims expense of $12.8 million related to prior periods due to 2022 costs developing more favorably versus our estimates and Direct contracting patient retroactivity. During the three-months ended September 30, 2021, we recorded incremental medical claims expenses of $9.4 million as a result of an increase in prior period incurred claims. When excluding these prior period costs for the three-months ended September 30, 2022 and 2021, respectively, the year over year medical claims expense per patient increased by 2%.

Medical claims expense was $1,198.4 million or 76% of total revenues for the nine-months ended September 30, 2022, an increase of $407.5 million, or 52%, compared to $790.9 million or 76% of total revenues for the nine-months ended September 30, 2021. This increase was driven primarily by a 44% increase in total patients under capitated arrangements (including those under Direct Contracting which started as of April 2021) and a 5% increase in cost per patient.

Cost of care, excluding depreciation and amortization was $113.6 million or 21% of total revenues for the three-months ended September 30, 2022, an increase of $37.3 million or 49%, compared to $76.3 million or 20% of total revenues for the three-months ended September 30, 2021. The increase was primarily driven by increases in salaries and benefits of $24.7 million; occupancy costs of $5.4 million; and medical supplies and patient transportation costs of $5.7 million, due to growth in both the number of centers we operate and the number of team members supporting our larger patient base.

Cost of care, excluding depreciation and amortization was $307.6 million or 19% of total revenues for the nine-months ended September 30, 2022, an increase of $104.0 million or 51%, compared to $203.6 million or 20% of total revenues for the nine-months ended September 30, 2021. The increase was primarily driven by increases in salaries and benefits of $67.0 million; occupancy costs of $16.3 million; and patient transportation costs of $16.2 million, due to growth in both the number of centers we operate and the number of team members supporting our larger patient base.

Sales and marketing expense was $44.1 million or 8% of total revenues for the three-months ended September 30, 2022, an increase of $13.6 million or 45%, compared to $30.5 million or 8% of total revenues for the three-months ended September 30, 2021. The increase was driven by net headcount growth of $10.0 million and greater advertising spend of $3.3 million to drive new patients to our clinics.

36

Sales and marketing expense was $120.5 million or 8% of total revenues for the nine-months ended September 30, 2022, an increase of $40.0 million, or 50%, compared to $80.5 million or 8% of total revenues for the nine-months ended September 30, 2021. The increase was driven by net headcount growth of $31.2 million and greater advertising spend of $7.0 million to drive new patients to our clinics.

Corporate, general and administrative expense was $81.7 million or 15% of total revenues for the three-months ended September 30, 2022, an increase of $4.7 million, or 6%, compared to $77.0 million or 20% of total revenues for the three-months ended September 30, 2021. The increase was primarily driven by greater salaries and benefits, including stock-based compensation expense, of $2.2 million, an increase in travel and entertainment expenses of $1.0 million and an increase in technology costs of $1.1 million. These increased costs can be primarily attributed to increased headcount to support our growth.

Corporate, general and administrative expense was $265.3 million or 17% of total revenues for the nine-months ended September 30, 2022, an increase of $41.0 million, or 18%, compared to $224.3 million or 22% of total revenues for the nine-months ended September 30, 2021. The increase was primarily driven by greater salaries and benefits, including stock-based compensation expense, of $30.1 million, an increase in legal and professional fees of $2.1 million, an increase in travel and entertainment expenses of $2.3 million and an increase in technology costs of $4.4 million. These increased costs can be primarily attributed to increased headcount to support our growth.

Depreciation and amortization expense was $9.1 million or 2% of total revenues for the three-months ended September 30, 2022, an increase of $4.6 million, or 102%, compared to $4.5 million or 1% of total revenues for the three-months ended September 30, 2021. Depreciation and amortization expense was $25.3 million or 2% of total revenues for the nine-months ended September 30, 2022, an increase of $13.6 million, or 116%, compared to $11.7 million or 1% of total revenues for the nine-months ended September 30, 2021. The increases were primarily due to capital expenditures purchased to support the continued growth of our business.

Other (Expense) Income

	Three-Months Ended September 30,				Change				Nine-Months Ended September 30,				Change
(dollars in millions)	2022		2021		$		%		2022		2021		$		%
Other income (expense):
Interest expense, net	$	—	$	(0.6)	$	0.6	(100)	%	$	(1.1)	$	(1.8)	$	0.7	39	%
Other	$	(0.2)	$	—	(0.2)		100	%	$	(40.3)	$	—	(40.3)		100	%
Total other expense	$	(0.2)	$	(0.6)	$	0.4	(67)	%	$	(41.4)	$	(1.8)	(39.6)		2200	%

Other expense was $40.3 million for the nine-months ended September 30, 2022, an increase of $40.3 million, or 100%, compared to $0.0 million for the nine-months ended September 30, 2021. The increase was primarily due to a fair value adjustment to the contingent consideration or earn-out related to the acquisition of RMD in October 2021. During the nine-months ended September 30, 2022, RMD achieved internal metrics that resulted in the maximum earn-out amount, and we increased the balance of the earn-out liability to reflect the actual payout amount of $60.0 million. The earn-out was paid out via cash and common stock during the quarter ended September 30, 2022.

Non-GAAP Reconciliations

The following table provides a reconciliation of gross profit, the most closely comparable GAAP financial measure, to platform contribution. Gross profit is defined as total revenues less medical claims expense.

	Three-Months Ended September 30,				Nine-Months Ended September 30,
(dollars in millions)	2022		2021		2022		2021
Gross profit	$	118.3	$	78.9	$	384.8	$	247.6
Cost of care, excluding depreciation and amortization	(113.6)		(76.3)		(307.6)		(203.6)
Stock-based compensation	1.3		0.5		2.7		1.2
Platform contribution	$	6.0	$	3.1	$	79.9	$	45.2

37

The following table provides a reconciliation of gross profit, the most closely comparable GAAP financial measure, to patient contribution. Gross profit is defined as total revenues less medical claims expense.

	Three-Months Ended September 30,				Nine-Months Ended September 30,
(dollars in millions)	2022		2021		2022		2021
Gross profit	$	118.3	$	78.9	$	384.8	$	247.6
Other revenue	(7.8)		(12.0)		(23.1)		(23.9)
Patient contribution	$	110.5	$	66.9	$	361.7	$	223.7

The following table provides a reconciliation of net loss, the most closely comparable GAAP financial measure, to adjusted EBITDA:

	Three-Months Ended September 30,				Nine-Months Ended September 30,
(dollars in millions)	2022		2021		2022		2021
Net loss	$	(130.4)	$	(110.0)	$	(375.3)	$	(274.3)
Interest expense, net	—		0.6		1.1		1.8
Fair value adjustments	—		—		40.1		—
Depreciation and amortization	9.1		4.5		25.3		11.7
Stock-based compensation	30.8		38.7		120.0		121.9
Litigation costs1	0.7		—		3.0		—
Transaction/offering related costs	1.3		1.8		1.9		3.6
Other income/expense	0.2		$	—	$	0.2	$	—
Adjusted EBITDA	$	(88.3)	$	(64.4)	$	(183.7)	$	(135.3)

Liquidity and Capital Resources

Overview

The Company’s long-term capital policy is to: maintain a strong balance sheet and financial flexibility; reinvest in its care model; and invest in strategic opportunities that reinforce its care model and meet return requirements. To date, we have financed our operations through private placements of our equity securities, payments received from various payors, the issuance of Convertible Senior Notes, our IPO and additional borrowings under our Term Loan Facility. We believe that our access to capital markets will provide adequate resources to fund our short-term and long-term operating and financing needs. As of September 30, 2022, we had cash, restricted cash and cash equivalents of $223.0 million. Our cash and cash equivalents primarily consist of highly liquid investments in money market funds and cash. Since our inception and through September 30, 2022, we have generated significant operating losses from our operations as reflected in our accumulated deficit and negative cash flows from operations.

We expect to continue to incur operating losses and generate negative cash flows from operations for the foreseeable future due to the investments we intend to continue to make in expanding our operations and sales and marketing and due to additional general and administrative costs we expect to incur in connection with operating as a public company. As a result, we may require additional capital resources to execute strategic initiatives to grow our business.

We believe that the proceeds from the Term Loan Facility in September 2022 and convertible debt offering in 2021 are sufficient to satisfy our anticipated cash requirements, which consist of capital expenditures, working capital, and potential acquisition and strategic transactions, for the next twelve months even with the uncertainty arising from the COVID-19 pandemic. Under the Loan Agreement, we have drawn down $72.3 million, net of debt issuance costs, and have the ability to draw down up to $300 million over the life of the loan pursuant to separate tranches that are available at specified time periods. See Note 8, "Long-Term Debt." Our assessment of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties.

1 Litigation costs included in the calculation of Adjusted EBITDA include only those costs which are considered one-time in nature and outside of the ordinary course of business based on the following considerations which we assess regularly: (i) the frequency of similar cases that have been brought to date, or are expected to be brought within two years, (ii) the complexity of the case, (iii) the nature of the remedy(ies) sought, including the size of any monetary damages sought, (iv) the counterparty involved, and (v) our overall litigation strategy, such as litigation costs related to the DOJ matter and class-action lawsuit (refer to Note 10 in the Form 10-Q herein).

38

Our actual results and our future capital requirements could vary because of, many factors, including our growth rate, the timing and extent of spending to open new centers and expand into new markets and the expansion of outreach activities.

We may in the future enter into arrangements to acquire or invest in complementary businesses, services and technologies, including intellectual property rights. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. We may be required to seek additional equity or debt financing. In the event that additional financing is required from outside sources, we may not be able to raise it on terms acceptable to us or at all. If we are unable to raise additional capital when desired, or if we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, results of operations and financial condition would be adversely affected.

Term Loan

On September 30, 2022, the Company and certain of its subsidiaries entered into the Loan Agreement with Hercules Capital, Inc., as administrative and collateral agent and lender, and Silicon Valley Bank and other lenders from time to time parties thereto. The Loan Agreement provides the Company with a Term Loan Facility of up to $300.0 million to be funded in five committed tranches available to be drawn during the specified time period at the Company's option. Under Tranche A (available from September 30, 2022 ("Closing") until March 31, 2023), the Company was required to draw down $75.0 million upon closing and may draw up to an additional $25.0 million. Under Tranche B (available from Closing until December 15, 2023), the Company may borrow up to $50.0 million in $25.0 million increments. Under Tranche C (available from January 1, 2024 until June 30, 2024), the Company may borrow up to $50.0 million in $25.0 million increments. Under Tranche D (available from the earlier of (a) the date on which Tranche C is fully drawn down and (b) July 1, 2024 until December 15, 2024), the Company may borrow up to $75.0 million in $25.0 million increments. Under Tranche E (available from Closing until June 1, 2025), the Company may borrow up to $25.0 million subject to the approval of the individual lender. If the Company does not elect to draw the entire principal amount available under the Tranche B, C or D during the applicable drawdown period, then any such undrawn portion will be added to the aggregate principal amount available under Tranche E. The Term Loan Facility is scheduled to mature on October 1, 2027, subject to a springing maturity date of September 1, 2025 if, prior to June 1, 2025, the Company’s Convertible Senior Notes have not been (i) converted into equity interests of the Company, (ii) amended such that the scheduled maturity date of the Convertible Senior Notes is at least 180 days after the initial maturity date of the tranches of the Term Loans then in effect, or (iii) fully redeemed and extinguished.

As required under the Loan Agreement, at the Closing, the Company borrowed $75.0 million under Tranche A of the Term Loan Facility. The Company intends to use the proceeds from the initial borrowing of the Term Loan for related fees and expenses in connection with the Loan Agreement and for working capital and general corporate purposes. The Loan Agreement contains customary affirmative and negative covenants. In addition, beginning on the earlier of (i) the reporting deadline of the Company’s fourth quarter 2023 financial statements under the Loan Agreement and (ii) the date at which more than $100.0 million in aggregate principal (excluding any paid-in-kind interest) is outstanding under the Term Loan Facility, the Company is required to maintain a specified trailing twelve-month platform contribution, with the applicable platform contribution increasing over time and as the Company’s borrowings under the Term Loan Facility increase. At September 30, 2022, the financial covenant is not yet in effect. Refer to Note 8, "Long-Term Debt," of the notes to consolidated financial statements included in this Quarterly Report on Form 10-Q.

Convertible Senior Notes, Capped Call Transactions and Marketable Debt Securities

In March 2021, we issued $920.0 million aggregate principal amount of Convertible Senior Notes. Concurrently with the pricing of the Convertible Senior Notes, we entered into capped call transactions to mitigate the impact of potential economic dilution to our common stock upon conversion of the Convertible Senior Notes. The Convertible Senior Notes are governed by an Indenture, are general senior, unsecured obligations of the Company and will mature on March 15, 2026, unless earlier redeemed, repurchased or converted. Refer to Note 8, "Long-Term Debt," of the notes to consolidated financial statements included in this Quarterly Report on Form 10-Q.

Total proceeds realized from the sale of the Convertible Senior Notes, net of debt issuance and offering costs of $22.1 million, were $897.9 million. We used approximately $123.6 million of the net proceeds to pay the cost of the capped call transactions. We intend to use the remainder of the net proceeds for general corporate purposes, which may include working capital, capital expenditures, and potential acquisitions and strategic transactions.

The Indenture contains customary covenants related to timely filings and reporting, and customary events of default. As of September 30, 2022, we were in compliance with all covenants under the Indenture.

39

Changes in Cash Flows

The following table presents a summary of our consolidated cash flows from operating, investing and financing activities for the periods indicated.

	Nine-Months Ended September 30,
(dollars in millions)	2022		2021		$ Change		% Change
Net cash used in operating activities	$	(213.3)	$	(125.9)	$	(87.4)	69	%
Net cash provided by (used in) investing activities	251.2		(815.9)		1,067.1		(131)	%
Net cash provided by financing activities	64.7		780.4		(715.7)		(92)	%
Net change in cash	$	102.6	$	(161.4)	$	264.0	(164)	%

Operating Activities

For the nine-months ended September 30, 2022, net cash used in operating activities was $(213.3) million, an increase of $(87.4) million in cash outflows compared to net cash used in operating activities of $(125.9) million for the nine-months ended September 30, 2021. The principal contributors to the year-over-year change in the operating cash flows were as follows:

•A net change of $(27.2) million in net loss and non-cash charges and credits, primarily due to an increase in net loss for the business, as noted above under “Results of Operations” offset by the fair value adjustment to RMD contingent consideration (see Note 5 to our consolidated financial statements included in this Quarterly Form on Form 10-Q) and other non-cash charges.

•An increase of $(60.2) million in cash outflows related to operating assets and liabilities primarily resulting from:

◦Changes in accounts receivable due to the timing of collections and the growth in the number of at-risk patients;

◦Changes in liability for unpaid claims due to the growth in the number of at-risk patients; and,

◦Changes in accounts payable, accrued compensation and benefits and other liabilities mainly due to the timing of payments to our vendors.

Investing Activities

For the nine-months ended September 30, 2022, net cash provided by investing activities was $251.2 million, an increase of $1,067.1 million in cash inflows compared to net cash used in investing activities of $(815.9) million for the nine-months ended September 30, 2021 primarily due to the net cash inflows of $1,098.3 million from sales, maturities and purchases of marketable debt securities, offset by continued increased investments in our centers and purchases of property and equipment of approximately $(27.0) million.

Financing Activities

Cash provided by financing activities for the nine-months ended September 30, 2022 was $64.7 million, primarily related to the proceeds received of $72.3 million from the Company's borrowings under its Term Loan Facility executed September 30, 2022. Cash provided by financing activities for the nine-months ended September 30, 2021 of $780.4 million was primarily due to $897.9 million in proceeds from the issuance of the Convertible Senior Notes, partially offset by cash outflows of $123.6 million related to the capped call transactions completed in March 2021.

40

Contractual Obligations and Commitments

As of September 30, 2022, our contractual obligations are summarized in the table below.

(dollars in millions)	Total		Less than 1 Year		1-3 Years		3-5 Years		More than 5 Years
Convertible senior notes	$	920.0	$	—	$	—	$	920.0	$	—
Term loan	75.0		—		—		—		75.0
Operating lease obligations	467.5		45.9		107.3		104.5		209.8
Contingent consideration	0.2		—		0.2		—		—
Total	$	1,462.7	$	45.9	$	107.5	$	1,024.5	$	284.8

Convertible Senior Notes- The Company holds borrowings under our Convertible Senior Notes, which have a 0% interest rate. The Convertible Senior Notes are governed by an indenture (“Indenture”), dated as of March 16, 2021, between the Company and U.S. Bank National Association, as the trustee. Under the Indenture, the Convertible Senior Notes are general senior, unsecured obligations of the Company and will mature on March 15, 2026, unless earlier redeemed, repurchased or converted.

Term loan- On September 30, 2022, the Company entered into a the Loan Agreement, which provides the Company with the Term Loan Facility. Under the Term Loan Facility, the Company may borrow up to $300.0 million in five committed tranches. At September 30, 2022 the outstanding balance under the Term Loan was $72.3 million, which includes debt issuance costs. The Term Loan Facility is scheduled to mature on October 1, 2027.

Operating lease obligations- The Company leases offices, operating facilities, vehicles and information technology ("IT") equipment, which are accounted for as operating leases. These leases have remaining lease terms of up to 30 years, inclusive of renewal or termination options that the Company is reasonably certain to exercise. Also included in the operating lease obligations are license fees paid as a reimbursement to Humana for its costs of owning or leasing and maintaining the centers, including reimbursements for rental payments and leasehold improvements.

Contingent consideration- As part of the CHW acquisition, the Company is obligated to pay contingent consideration of up to a maximum earn-out of $5.5 million during the fiscal year 2024 should the acquired business achieve certain internal metrics in the year following the acquisition. We have recorded the fair value of this contingent consideration at $0.2 million.

Off-Balance Sheet Obligations

As of September 30, 2022, we did not have any significant off-balance sheet arrangements.

Critical Accounting Policies and Estimates

Our condensed consolidated financial statements and accompanying notes have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the amounts reported amounts of assets, liabilities, revenue and expenses, and related disclosures. We base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. The future effects of the COVID-19 pandemic on our results of operations, cash flows and financial position are unclear, however, we believe we have made reasonable estimates and assumptions in preparing the financial statements. Actual results may differ from these estimates. To the extent that there are material differences between these estimates and our actual results, our future financial statements will be affected.

For a description of our critical accounting policies, see “Critical Accounting Policies” in our 2021 Form 10-K. There have been no significant changes in our critical accounting estimate policies or methodologies to our condensed consolidated financial statements.

Recently Adopted Accounting Pronouncements

For a description of recently issued accounting pronouncements, see Note 2, Summary of Significant Accounting Policies, to our consolidated financial statements included in this Quarterly Report on Form 10-Q.

41

ITEM 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

For information regarding our exposure to certain market risks, see “Quantitative and Qualitative Disclosures about Market Risk,” in Part II, Item 7A of our 2021 Form 10-K. There have been no material changes in our market risk exposures for the nine-months ended September 30, 2022, as compared to those discussed in our 2021 Form 10-K.

ITEM 4.    CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that these disclosure controls and procedures were effective as of September 30, 2022.

Changes to our Internal Controls over Financial Reporting

There were no material changes in our internal control over financial reporting during the nine-months ended September 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

42

PART II.    OTHER INFORMATION

ITEM 1.    LEGAL PROCEEDINGS

See Note 10, "Commitments and Contingencies," to the consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.

ITEM 1A.    RISK FACTORS

There have been no material changes to the risk factors disclosed under Part I, Item 1A “Risk Factors” in our 2021 Form 10-K.

ITEM 2.    UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Recent Unregistered Sales of Equity Securities

None.

ITEM 3.    DEFAULT UPON SENIOR SECURITIES

None.

ITEM 4.    MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5.    OTHER INFORMATION

None.

ITEM 6.    EXHIBITS

Exhibit No.	Description
3.1	Amended and Restated Certificate of Incorporation of Oak Street Health, Inc. dated August 10, 2020 (incorporated by reference to Exhibit 3.1 to the Company's Form 8-K filed on August 11, 2020).
3.2	Amended and Restated Bylaws of Oak Street Health, Inc. dated August 10, 2020 (incorporated by reference to Exhibit 3.2 to the Company's Form 8-K filed on August 11, 2020).
10.1	Security and Loan Agreement, dated as of September 30, 2022, by and among the Company and certain of its subsidiaries named thereto, as borrowers, Hercules Capital, Inc. as agent and lender, Silicon Valley Bank and the several banks and other financial institutions or entities from time to time parties thereto as lenders (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed on October 3, 2022).
31.1	Certification of the Chief Executive Officer pursuant to Exchange Act Rules Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.
31.2	Certification of the Chief Financial Officer pursuant to Exchange Act Rules Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.
32.1*	Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, filed herewith.
32.2*	Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, filed herewith.
101.INS	Inline XBRL Instance Document
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted in Inline XBRL)

________________

43

*The certifications furnished in Exhibit 32.1 and Exhibit 32.2 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference.

**    Schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC.

44

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Oak Street Health, Inc. (Registrant)
Date: November 7, 2022	By:	/s/Timothy Cook
		Timothy Cook
		Chief Financial Officer (Principal Financial Officer)

45

EX-31.1

Exhibit 31.1

Certification Pursuant to Section 302 of Sarbanes-Oxley Act of 2002

I, Michael Pykosz, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Oak Street Health, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 7, 2022
	/s/ Michael Pykosz
	Michael Pykosz
	Chief Executive Officer

EX-31.2

Exhibit 31.2

Certification Pursuant to Section 302 of Sarbanes-Oxley Act of 2002

I, Timothy Cook, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Oak Street Health, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 7, 2022
	/s/ Timothy Cook
	Timothy Cook
	Chief Financial Officer

EX-32.1

Exhibit 32.1

Certification of the Chief Executive Officer

Pursuant to Rule 18 U.S.C. Section 1350

In connection with the Quarterly Report on Form 10-Q of Oak Street Health, Inc. (the “Company”) for the period ended September 30, 2022, as filed with the U.S. Securities and Exchange Commission (the “Report”), I, Michael Pykosz, Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 7, 2022
	/s/ Michael Pykosz
	Michael Pykosz
	Chief Executive Officer

EX-32.2

Exhibit 32.2

Certification of the Chief Financial Officer

Pursuant to Rule 18 U.S.C. Section 1350

In connection with the Quarterly Report on Form 10-Q of Oak Street Health, Inc. (the “Company”) for the period ended September 30, 2022 as filed with the U.S. Securities and Exchange Commission (the “Report”), I, Timothy Cook, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 7, 2022
	/s/ Timothy Cook
	Timothy Cook
	Chief Financial Officer

XML

Cover Page - shares	9 Months Ended
	Sep. 30, 2022	Nov. 02, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-39427
Entity Registrant Name	Oak Street Health, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	84-3446686
Entity Address, Address Line One	30 W. Monroe Street
Entity Address, Address Line Two	Suite 1200
Entity Address, City or Town	Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60603
City Area Code	844
Local Phone Number	871-5650
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	OSH
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		242,915,915
Entity Central Index Key	0001564406
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Amendment Flag	false

XML

CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 204,300,000	$ 104,700,000
Restricted cash	18,700,000	15,700,000
Other receivables, net (Humana comprised $0.2 as of December 31, 2021)	2,100,000	3,100,000
Capitated accounts receivable (Humana comprised $105.0 as of December 31, 2021)	833,900,000	559,400,000
Marketable debt securities	339,000,000.0	671,100,000
Prepaid expenses and other current assets	18,100,000	14,000,000.0
Total current assets	1,416,100,000	1,368,000,000
Property, plant and equipment, net	196,100,000	144,800,000
Goodwill	158,000,000.0	152,900,000
Intangible assets, net	9,600,000	10,800,000
Operating right-of-use assets (Humana comprised $70.9 as of December 31, 2021)	313,100,000	157,700,000
Other long-term assets	7,600,000	6,900,000
Total assets	2,100,500,000	1,841,100,000
Current liabilities:
Accounts payable	25,900,000	22,100,000
Accrued compensation and benefits	47,100,000	41,700,000
Liability for unpaid claims (Humana comprised $99.1 as of December 31, 2021)	787,100,000	556,300,000
Other liabilities (Humana comprised $19.3 as of December 31, 2021)	46,400,000	44,000,000.0
Total current liabilities	906,500,000	664,100,000
Long-term debt	977,000,000.0	901,400,000
Long-term operating lease liabilities (Humana comprised $66.0 as of December 31, 2021)	341,800,000	164,200,000
Other long-term liabilities (Humana comprised $43.1 as of December 31, 2021)	30,800,000	55,400,000
Total liabilities	2,256,100,000	1,785,100,000
Commitments and contingencies (See Note 10)
STOCKHOLDERS' EQUITY/(DEFICIT)
Preferred stock, par value $0.001; 50,000,000 shares authorized as of September 30, 2022 and December 31, 2021; no shares issued and outstanding as of September 30, 2022 and December 31, 2021	0	0
Common stock, par value $0.001; 500,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 242,950,926 and 240,937,465 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively	200,000	200,000
Additional paid-in capital (Humana comprised $50.0 as of December 31, 2021)	1,185,000,000	1,017,900,000
Accumulated other comprehensive loss	(4,100,000)	(1,400,000)
Accumulated deficit	(1,341,500,000)	(965,300,000)
Total stockholders' equity/(deficit) allocated to Oak Street Health, Inc.	(160,400,000)	51,400,000
Non-controlling interests	4,800,000	4,600,000
Total stockholders' equity/(deficit)	(155,600,000)	56,000,000.0
Total liabilities and stockholders' equity/(deficit)	$ 2,100,500,000	$ 1,841,100,000

XML

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Other receivables, net	$ 2.1	$ 3.1
Operating right-of-use assets	313.1	157.7
Liability for unpaid claims	787.1	556.3
Other Liabilities, Current	46.4	44.0
Operating Lease, Liability, Noncurrent	341.8	164.2
Other Liabilities, Noncurrent	$ 30.8	$ 55.4
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock authorized (in shares)	50,000,000	50,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	500,000,000	500,000,000
Common stock, shares issued (in shares)	242,950,926	240,937,465
Common stock, shares outstanding (in shares)	242,950,926	240,937,465
Additional paid-in capital	$ 1,185.0	$ 1,017.9
Humana
Other receivables, net		0.2
Capitated accounts receivable, related parties		105.0
Operating right-of-use assets		70.9
Liability for unpaid claims		99.1
Other Liabilities, Current		19.3
Operating Lease, Liability, Noncurrent		66.0
Other Liabilities, Noncurrent		43.1
Additional paid-in capital		$ 50.0

XML

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Total revenues	$ 545.7	$ 388.7	$ 1,583.2	$ 1,038.5
Operating expenses:
Medical claims expense (Humana comprised $99.1 for the three-months ended September 30, 2021 and $277.7 for the nine-months ended September 30, 2021)	427.4	309.8	1,198.4	790.9
Cost of care, excluding depreciation and amortization (Humana comprised $2.8 for the three-months ended September 30, 2021 and $7.1 for the nine-months ended September 30, 2021)	113.6	76.3	307.6	203.6
Sales and marketing	44.1	30.5	120.5	80.5
Corporate, general and administrative	81.7	77.0	265.3	224.3
Depreciation and amortization	9.1	4.5	25.3	11.7
Total operating expenses	675.9	498.1	1,917.1	1,311.0
Loss from operations	(130.2)	(109.4)	(333.9)	(272.5)
Other (expense):
Interest expense, net	0.0	(0.6)	(1.1)	(1.8)
Other	(0.2)	0.0	(40.3)	0.0
Total other (expense)	(0.2)	(0.6)	(41.4)	(1.8)
Net loss	(130.4)	(110.0)	(375.3)	(274.3)
Net income/(loss) attributable to non-controlling interests	0.3	(0.6)	0.9	(3.5)
Net loss attributable to Oak Street Health, Inc.	$ (130.7)	$ (109.4)	$ (376.2)	$ (270.8)
Weighted average common shares outstanding - basic (in shares)	231,919,421	223,435,698	228,042,160	221,932,624
Weighted average common shares outstanding - diluted (in shares)	231,919,421	223,435,698	228,042,160	221,932,624
Net loss per share – diluted (in dollars per share)	$ (0.56)	$ (0.49)	$ (1.65)	$ (1.22)
Net loss per share – basic (in dollars per share)	$ (0.56)	$ (0.49)	$ (1.65)	$ (1.22)
Capitated Revenue
Total revenues	$ 537.9	$ 376.7	$ 1,560.1	$ 1,014.6
Other Revenue
Total revenues	$ 7.8	$ 12.0	$ 23.1	$ 23.9

XML

CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Total revenues	$ 388.7	$ 1,038.5
Medical claims expense	309.8	790.9
Cost of care	76.3	203.6
Humana
Medical claims expense	99.1	277.7
Cost of care	2.8	7.1
Capitated Revenue
Total revenues	376.7	1,014.6
Capitated Revenue | Humana
Total revenues	130.7	379.2
Other Revenue
Total revenues	12.0	23.9
Other Revenue | Humana
Total revenues	$ 2.8	$ 4.5

XML

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Comprehensive Income [Abstract]
Net loss	$ (130.4)	$ (110.0)	$ (375.3)	$ (274.3)
Other comprehensive loss:
Net unrealized gain/(loss) on marketable debt securities, net of tax	0.7	0.1	(2.7)	(0.2)
Comprehensive loss	(129.7)	(109.9)	(378.0)	(274.5)
Less: Comprehensive income/(loss) attributable to non-controlling interests	0.3	(0.6)	0.9	(3.5)
Comprehensive loss attributable to Oak Street Health, Inc.	$ (130.0)	$ (109.3)	$ (378.9)	$ (271.0)

XML

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY/(DEFICIT) - USD ($) $ in Millions	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Non-controlling Interest
Beginning balance (in shares) at Dec. 31, 2020		240,756,714
Beginning balance at Dec. 31, 2020	$ 423.2	$ 0.2	$ 971.8	$ (555.8)	$ 0.0	$ 7.0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Purchase of capped calls	(123.6)		(123.6)
Issuance of common stock upon vesting of restricted stock units, (in shares)		55,781
Issuance of common stock upon exercise of options (in shares)		222,203
Issuance of common stock upon exercise of options	4.5		4.5
Shares withheld related to net settlement of stock based awards (in shares)		(1,412)
Stock issued during period shares employee stock purchase plans (in shares)		62,575
Issuance of common stock under the employee purchase plan	3.0		3.0
Forfeitures (in shares)		(175,905)
Forfeitures	(0.9)		(0.9)
Stock-based compensation expense	122.8		122.8
Payments to non-controlling interests	0.1					0.1
Payments to non-controlling interests	(1.5)					(1.5)
Net unrealized gain (loss) on marketable debt securities	(0.2)				(0.2)
Net loss	(274.3)			(270.8)		(3.5)
Ending balance (in shares) at Sep. 30, 2021		240,919,956
Ending balance at Sep. 30, 2021	153.1	$ 0.2	977.6	(826.6)	(0.2)	2.1
Beginning balance (in shares) at Jun. 30, 2021		240,785,554
Beginning balance at Jun. 30, 2021	220.8	$ 0.2	935.0	(717.2)	(0.3)	3.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon vesting of restricted stock units, (in shares)		33,542
Issuance of common stock upon exercise of options (in shares)		47,389
Issuance of common stock upon exercise of options	0.9		0.9
Shares withheld related to net settlement of stock based awards (in shares)		(782)
Stock issued during period shares employee stock purchase plans (in shares)		62,575
Issuance of common stock under the employee purchase plan	3.0		3.0
Forfeitures (in shares)		(8,322)
Forfeitures	(0.1)		(0.1)
Stock-based compensation expense	38.8		38.8
Payments to non-controlling interests	(0.4)					(0.4)
Net unrealized gain (loss) on marketable debt securities	0.1				0.1
Net loss	(110.0)			(109.4)		(0.6)
Ending balance (in shares) at Sep. 30, 2021		240,919,956
Ending balance at Sep. 30, 2021	153.1	$ 0.2	977.6	(826.6)	(0.2)	2.1
Beginning balance (in shares) at Dec. 31, 2021		240,937,465
Beginning balance at Dec. 31, 2021	$ 56.0	$ 0.2	1,017.9	(965.3)	(1.4)	4.6
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon vesting of restricted stock units, (in shares)		149,850
Issuance of common stock upon exercise of options (in shares)	560,905	662,034
Issuance of common stock upon exercise of options	$ 13.4		13.4
Shares withheld related to net settlement of stock based awards (in shares)		(15,995)
Shares withheld related to net settlement of stock based awards	(0.2)		(0.2)
Stock issued during period shares employee stock purchase plans (in shares)		224,473
Issuance of common stock under the employee purchase plan	4.1		4.1
Issuance of common stock under RMD earnout (in shares)		1,225,122
Issuance of common stock pursuant to RubiconMD Holdings, Inc. earn-out	$ 32.5		32.5
Forfeitures (in shares)	(442,025)	(232,023)
Forfeitures	$ (4.3)		(4.3)
Stock-based compensation expense	124.3		124.3
Payments to non-controlling interests	(1.3)					(1.3)
Purchase of joint venture minority interest	(2.1)		(2.7)			0.6
Net unrealized gain (loss) on marketable debt securities	(2.7)				(2.7)
Net loss	(375.3)			(376.2)		0.9
Ending balance (in shares) at Sep. 30, 2022		242,950,926
Ending balance at Sep. 30, 2022	(155.6)	$ 0.2	1,185.0	(1,341.5)	(4.1)	4.8
Beginning balance (in shares) at Jun. 30, 2022		241,084,244
Beginning balance at Jun. 30, 2022	(101.9)	$ 0.2	1,108.5	(1,210.8)	(4.8)	5.0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon vesting of restricted stock units, (in shares)		70,849
Issuance of common stock upon exercise of options (in shares)		543,082
Issuance of common stock upon exercise of options	11.1		11.1
Shares withheld related to net settlement of stock based awards (in shares)		(9,478)
Shares withheld related to net settlement of stock based awards	(0.2)		(0.2)
Stock issued during period shares employee stock purchase plans (in shares)		161,189
Issuance of common stock under the employee purchase plan	2.3		2.3
Issuance of common stock under RMD earnout (in shares)		1,225,122
Issuance of common stock pursuant to RubiconMD Holdings, Inc. earn-out	32.5		32.5
Forfeitures (in shares)		(124,082)
Forfeitures	(2.9)		(2.9)
Stock-based compensation expense	33.7		33.7
Payments to non-controlling interests	(0.5)					(0.5)
Net unrealized gain (loss) on marketable debt securities	0.7				0.7
Net loss	(130.4)			(130.7)		0.3
Ending balance (in shares) at Sep. 30, 2022		242,950,926
Ending balance at Sep. 30, 2022	$ (155.6)	$ 0.2	$ 1,185.0	$ (1,341.5)	$ (4.1)	$ 4.8

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (375.3)	$ (274.3)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of discount on debt and related issuance costs	3.3	2.4
Accretion of discounts and amortization of premiums on short-term marketable securities, net	4.9	2.4
Fair value adjustment to contingent consideration	38.3	0.0
Depreciation and amortization	25.3	11.7
Non-cash operating lease costs	31.6	11.2
Stock-based compensation, net of forfeitures	120.0	121.9
Change in operating assets and liabilities, net of impact of acquisitions:
Accounts receivables	(273.4)	(208.0)
Other assets	(5.3)	(10.5)
Accounts payable and accrued compensation and benefits	7.4	23.1
Liability for unpaid claims	230.9	180.2
Operating lease liabilities	(15.6)	(9.9)
Other liabilities	(5.4)	23.9
Net cash used in operating activities	(213.3)	(125.9)
Cash flows from investing activities:
Proceeds from sales and maturities of marketable debt securities	716.6	43.7
Purchases of marketable debt securities	(392.2)	(817.6)
Purchase of business, net of cash acquired	(5.6)	(1.4)
Purchases of property and equipment	(67.6)	(40.6)
Net cash provided by (used by) investing activities	251.2	(815.9)
Cash flows from financing activities:
Proceeds from borrowings on term loan, net	72.3	0.0
Proceeds from borrowings on Convertible Senior Notes, net	0.0	897.9
Purchase of capped calls	0.0	(123.6)
Capital contributions from non-controlling interests	0.0	0.1
Settlement of contingent earnout liability	(21.7)	0.0
Capital distributions to non-controlling interests	(1.3)	(1.5)
Purchase of joint venture minority interest	(2.1)	0.0
Proceeds from exercise of options	13.4	4.5
Proceeds from issuance of common stock under the employee purchase plan	4.1	3.0
Net cash provided by financing activities	64.7	780.4
Net change in cash, cash equivalents and restricted cash	102.6	(161.4)
Cash, cash equivalents and restricted cash, beginning of period	120.4	419.7
Cash, cash equivalents and restricted cash, end of period	223.0	258.3
Supplemental disclosures
Additions to construction in process funded through accounts payable	$ 7.0	$ 4.7

XML

ORGANIZATION AND NATURE OF BUSINESS

9 Months Ended

Sep. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

ORGANIZATION AND NATURE OF BUSINESS

ORGANIZATION AND NATURE OF BUSINESS

Description of Business

Oak Street Health, Inc. (collectively with its consolidated subsidiaries is referred to as “Oak Street Health,” “OSH,” “we,” “us,” “our” or the “Company”) was formed as a Delaware corporation on October 22, 2019 for the purpose of completing a public offering and related reorganization transactions (collectively referred to as the “IPO”) in order to carry on the business of Oak Street Health, LLC (“OSH LLC”) and its affiliates. On August 10, 2020, the Company completed its IPO. As the managing member of OSH LLC, Oak Street Health, Inc. operates and controls all of the business affairs of OSH LLC and its affiliates.

The Company operates primary care centers serving Medicare beneficiaries. The Company, through its centers and management services organization, combines an innovative care model with superior patient experience. The Company invests resources into primary care to prevent unnecessary acute events and manage chronic illnesses. The Company engages Medicare eligible patients through the use of an innovative community outreach approach. Once patients are engaged, the Company integrates population health analytics, social support services and primary care into the care model to drive improved outcomes. The Company contracts with health plans to generate medical costs savings and realize a return on its investment in primary care. As of September 30, 2022, the Company operated 161 centers.

Basis of Presentation and Consolidation

The accompanying unaudited interim consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such regulations that would substantially duplicate the disclosures contained in the Company's annual audited consolidated financial statements. These financial statements have been prepared on a basis consistent with the accounting principles applied for the fiscal year ended December 31, 2021 in the Company’s 2021 Form 10-K filed with the SEC. In the opinion of management, all adjustments (consisting of all normal and recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and nine-months ended September 30, 2022, including the impact of COVID-19, are not necessarily indicative of the results that may be expected any other interim period for or for the year ending December 31, 2022.

The consolidated financial statements of the Company include the financial statements of all wholly owned subsidiaries and majority-owned or controlled companies, which include the variable interest entities (“VIE”) in which OSH has an interest and is the primary beneficiary. See Note 11, “Variable Interest Entities.” For those consolidated subsidiaries where our ownership is less than 100%, the portion of the net income or loss allocable to the non-controlling interests is reported as “Net loss (gain) attributable to non-controlling interests” in the consolidated statements of operations. Intercompany balances and transactions have been eliminated in consolidation.

In addition, Oak Street Health is the majority interest owner in two joint ventures: OSH-PCJ Joliet, LLC ("PCJ JV") and OSH-RI, LLC ("RI JV"), which are consolidated in the Company’s financial statements. In January 2022, the Company paid a former joint venture partner, Evangelical Services Corporation, $2.1 million to acquire its 49.9% ownership interest in OSH-ESC Joint Venture, LLC. As such, OSH owned 100% of this entity as of March 31, 2022, and the joint venture was effectively dissolved. During the quarters ended June and September 30, 2022, distributions were made from OSH-PCJ Joliet, LLC to Oak Street Health MSO, LLC, a subsidiary of the Company that holds 50.1% ownership interest in PCJ JV, and Primary Care Physicians of Joliet, an unaffiliated third party that holds 49.9% ownership interest in PCJ JV. Distributions made during the quarter ended June 30, 2022 totaled $0.8 million to each owner and in the quarter ended September 30, 2022 distributions totaled $0.5 million to each owner.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates on the information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of COVID-19. The areas

where significant estimates are used in the accompanying financial statements include revenue recognition, the liability for unpaid claims, stock-based compensation, valuation and related impairment recognition of long-lived assets, including intangibles and goodwill and the valuation of stock options. Actual results could differ from those estimates.

COVID-19

Even as the COVID-19 pandemic subsides, disruptions caused by the pandemic, including labor shortages and inflationary pressures, may continue and could, in turn, have a negative impact on the Company. Further, recurring COVID-19 outbreaks, including outbreaks caused by different virus variants, could have the potential to impact the Company and its future results of operations, cash flows and financial position.

On March 27, 2020, the United States President signed into law the Coronavirus Aid, Relief and Economic Securities Act (“CARES Act”) which provides economic assistance to a wide array of industries, including healthcare. This legislation did not have a material impact on our financial statements as of and for the nine-months ended September 30, 2022. Refer to our 2021 Form 10-K for details on the prior year impact of the legislation.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company described its significant accounting policies in Note 2 of the notes to consolidated financial statements for the year ended December 31, 2021 included in its 2021 Form 10-K. During the nine-months ended September 30, 2022, there were no significant changes to those accounting policies, other than those noted below and those policies impacted by the new accounting pronouncements adopted during the period and further described below.

Stock-based compensation expense

The Company accounts for stock-based compensation as an expense in the statements of operations based on the awards' fair values at their respective grant dates. The Company estimates the fair value of options with service conditions granted using the Black-Scholes option pricing model. Stock options that include service and performance conditions are valued at their grant date using the Black-Scholes model and estimates regarding the probability of achieving the performance metrics. The Black-Scholes option pricing model requires inputs based on certain assumptions, including (a) the fair value per share of the Company's common stock, (b) the expected stock price volatility, (c) the expected term of the award, (d) the risk-free interest rate and (e) expected dividends.

The fair value of stock-based awards is recognized as compensation expense, net of actual forfeitures, over the requisite service period, which is generally the vesting period, with the exception of the fair value of stock-based payments for awards that include service and performance conditions which is recognized as compensation expense over the requisite service period as achievement of the performance objective becomes probable.

The Company issued certain performance stock options (“PSOs”) during the first quarter of 2022, that vest based on the satisfaction of certain service and performance-based conditions. The Company estimates compensation expense based on the grant date fair value of the awards and recognizes the expense on a graded vesting basis over the vesting period of the awards. Compensation expense for these awards is recognized only if the Company has determined that it is probable that the performance condition will be met. The Company reassesses the probability of vesting at each reporting period and adjusts compensation expense based on the probability assessment.

The Company issued certain performance stock units ("PSUs") during the second quarter of 2022. The awards will vest based on the satisfaction of certain service conditions and performance-based conditions. The Company estimates compensation expense based on the grant date fair value of the awards and recognizes the expense on a straight-line basis over the vesting period of the award. Compensation expense for these awards is recognized only if the Company has determined that it is probable that the performance condition will be met. The Company reassesses the probability of vesting at each reporting period and adjusts compensation expense based on the probability assessment.

Correction of immaterial error in previously issued financial statements

The Company has arrangements with Humana, that include a license fee payable by the Company to Humana for the Company’s provision of health care services in certain centers owned or leased by Humana. The license fee is a reimbursement to Humana for its costs of owning or leasing and maintaining the centers, including rental payments, center maintenance or repair expenses, equipment expenses, special assessments, cost of upgrades, taxes, leasehold improvements and other expenses identified by Humana. During the second quarter of 2022, the Company reassessed the nature of its license fee arrangements and determined that the reimbursement for leasehold improvements included in the license fee payments should be included as a lease component and accounted for under ASC 842, Leases ("ASC 842"). As previously

disclosed in the Company's 2021 Form 10-K, the Company adopted ASC 842 effective January 1, 2021 under the modified retrospective transition method.

The Company considered the guidance Accounting Standards Codification 250, Accounting Changes and Error Corrections as well as the guidance in SEC Staff Bulletin 99, Materiality and concluded that the error was immaterial to the Company's previously issued interim and annual consolidated financial statements. The Company has corrected the cumulative impact of the error within the Quarterly Report on Form 10-Q for the period ended June 30, 2022 and disclosed the impact in Note 2 therein.

We recorded a decrease to cost of care, excluding depreciation and amortization, within the consolidated statements of operations of $3.6 million and impact of $0.02 to our net loss per share- basic and diluted for the nine-months ended September 30, 2022. There was no impact to the consolidated statement of cash flows or the consolidated statements of equity/(deficit).

Recently Adopted Accounting Pronouncements

In October 2021, the FASB issued Accounting Standard Update ("ASU") 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The new guidance requires contract assets and liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts. Under the current business combinations guidance, such assets and liabilities are recognized by the acquirer at fair value on the acquisition date. The new standard is effective for fiscal years beginning after December 15, 2022. Early adoption is permitted. The standard will not impact acquired contract assets or liabilities from business combinations occurring prior to the effective date of adoption. We elected to adopt this guidance early effective as of the quarter ended September 30, 2022 in connection with the Company’s acquisition of substantially all of the assets of CHW Cares Inc. ("CHW"), which was completed during the quarter. The guidance was not applicable to the CHW acquisition as contract assets and liabilities were not acquired, and as such, the adoption did not have a material effect on our consolidated financial statements or notes to the consolidated financial statements. For more information about the CHW acquisition, see Note 5, "Business Combinations, Goodwill and Intangible Assets."

In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. This update requires annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. This standard is effective for fiscal years beginning after December 15, 2021 and should be applied prospectively or retrospectively. We have adopted ASU 2021-10 as of January 1, 2022 using the prospective method. This adoption did not have a material impact on our consolidated financial statements or notes to the consolidated financial statements.

Recent Accounting Pronouncements Not Yet Adopted

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820) of Equity Securities Subject to Contractual Sale Restrictions. The new guidance clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The guidance is required to be adopted by January 1, 2024, and we do not anticipate this standard update will have a material impact on our consolidated financial statements or notes to the consolidated financial statements.

XML

REVENUE RECOGNITION

9 Months Ended

Sep. 30, 2022

Revenue from Contract with Customer [Abstract]

REVENUE RECOGNITION

REVENUE RECOGNITION

The Company earns revenue from our capitated arrangements with health plan payers and other revenue arrangements. Other revenue is comprised of ancillary fees earned under contracts with certain managed care organizations for the provision of certain care coordination and care management services; license subscription and fees; and fee-for- service revenue. Both our capitated and fee-for-service revenue generally relate to contracts with patients in which our performance obligation is to provide and/or manage healthcare services to the patients. Revenues are recorded during the period our obligations to provide healthcare services are satisfied as noted below within each service type.

Our care coordination services include a single performance obligation to stand ready to provide care coordination services to patients, which constitutes a series of distinct service increments. Payments received are recognized in other revenue ratably over the length of contract terms and are refundable on a pro rata basis to Humana if the Company ceases to provide services at the centers within the length of the term specified in the contracts. Under our care management services, we have a single performance to stand ready to provide care management services, which constitutes a series of distinct service increments.

The Company acquired RubiconMD Holdings, Inc. (“RMD”) on October 20, 2021. RMD is a healthcare technology company specializing in an online eConsult platform which enables primary care providers to easily access same-day insights from top specialists in order to provide better care for their patients. RMD generates revenue by providing subscription licenses to its customers to access its eConsult platform, as well as providing integration, training and other ad-hoc services. We have identified the performance obligation to be standing ready to provide access to the eConsult platform. Subscription license revenue is recognized when the performance obligation is met over time by either the straight-line method or when services are performed over the terms of the applicable contract. RMD also provides services to assist customers with initial usage and training of the platform. These services are typically provided for a fixed fee and do not have a variable component. We identified the performance obligation is to provide the other professional services, which is typically achieved over time.

Capitated Revenue and Accounts Receivable

The Company has agreements in place with the payors listed below, and payor sources of capitated revenue for each period presented were as follows:

	Three-Months Ended September 30,				Nine-Months Ended September 30,
	2022		2021		2022		2021
Humana	31	%	35	%	32	%	37	%
Wellcare/Meridian	16	%	15	%	17	%	16	%
UnitedHealth Care	10	%	8	%	9	%	7	%
CMS	8	%	10	%	8	%	7	%
Other	35	%	32	%	34	%	33	%

Medicare Part D comprised 2% of capitated revenues for the three and nine-months ended September 30, 2022 and September 30, 2021. Medicare Part D comprised 3% of medical claims expense for the three-months ended September 30, 2022 and 2% for the nine-months ended September 30, 2022. Medicare Part D comprised 2% of medical claims expense for the three-months ended September 30, 2021 and 3% for the nine-months ended September 30, 2021.

For the nine-months ended September 30, 2022 and 2021, respectively, we estimate that we will receive an additional $44.4 million and $40.1 million for acuity-related adjustments to be received in subsequent periods. Under our capitated revenue arrangements, we receive a fixed fee per patient, per month ("PPPM") for services. In certain contracts, PPPM fees also include adjustments for items such as performance incentives or penalties based on the achievement of certain clinical quality metrics as contracted with payors. There were no material PPPM adjustments related to performance incentives/penalties for quality-related metrics for the three and nine-months ended September 30, 2022 and 2021.

Other Revenue

The composition of other revenue for each period was as follows ($ in millions):

	Three-Months Ended September 30,				Nine-Months Ended September 30,
	2022		2021		2022	2021
Care coordination and care management services	$	1.8	$	9.8	5.2	$	18.4
License subscription and other fees	3.3		—		9.5	—
Fee for service	2.7		2.2		8.4	5.5
Total other revenue	$	7.8	$	12.0	23.1	$	23.9

As of September 30, 2022 and December 31, 2021, the Company’s contract liabilities related to the Humana care coordination payments totaled $37.3 million and $33.9 million, respectively. The short-term portion is recorded in other liabilities and the long-term portion is included in other long-term liabilities in the accompanying consolidated balance sheets. As of September 30, 2022 and December 31, 2021, we recorded $6.7 million and $6.2 million of short-term contract liabilities, respectively, and $30.6 million and $27.7 million of long-term contract liabilities, respectively.

XML

FAIR VALUE MEASUREMENTS AND INVESTMENTS

9 Months Ended

Sep. 30, 2022

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS AND INVESTMENTS

FAIR VALUE MEASUREMENTS AND INVESTMENTS

Fair Value Measurements

In determining the fair value of financial assets and liabilities, the Company utilizes market data or other assumptions that it believes market participants would use in pricing the asset or liability in the principal or most advantageous market and adjusts for non-performance and/or other risks associated with the Company as well as counterparties, as appropriate. Assets and liabilities measured at fair value are classified using the following hierarchy, which is based upon the transparency of inputs to the valuation as of the measurement date:

Level 1 – Valuations based on unadjusted quoted prices which are available in active markets for identical assets or liabilities accessible at the measurement date.

Level 2 – Valuations with inputs other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.

Level 3 – Valuations with unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis ($ in millions):

	Fair Value Measurements as of September 30, 2022 using:						Fair Value Measurements as of December 31, 2021 using:
	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
Marketable debt securities:
Commercial paper	$	61.5	$	—	$	—	$	120.8	$	—	$	—
U.S. Treasury obligations	—		12.8		—		—		26.0		—
Corporate bonds	—		201.2		—		—		412.3		—
Asset-backed securities	—		33.8		—		—		99.2		—
Other	—		29.7		—		—		12.8		—
Total financial assets	$	61.5	$	277.5	$	—	$	120.8	$	550.3	$	—
Liabilities:
Convertible senior notes	$	—	$	710.5	$	—	$	—	$	752.7	$	—
Contingent consideration1	—		—		0.2		—		—		21.8
Total liabilities	$	—	$	710.5	$	0.2	$	—	$	752.7	$	21.8
1 During the quarter-ended June 30, 2022, RMD achieved both earn-out hurdles. As such, the Company no longer measured the fair value of the contingent consideration and instead recorded the maximum earn-out as an amount payable to RMD as of June 30, 2022. See Footnote 5 for further detail.

The Company measures the fair value of corporate bonds, U.S. treasury obligations and asset-backed securities by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. During the three and nine-months ended September 30, 2022, there were no transfers between Levels 1, 2 and 3.

The Company's Convertible Senior Notes are classified within Level 2 of the fair value hierarchy as the valuation inputs are based on quoted prices in an inactive market on the last day in the reporting period.

In September 2022, the Company and certain of its subsidiaries entered into a $300.0 million loan and security agreement (the "Loan Agreement") with Hercules Capital Inc., as administrative and collateral agent and lender (the “Agent”), and Silicon Valley Bank and other lenders from time to time parties thereto (collectively with the Agent in its capacity as a lender, the “Lenders”) with such amount to be funded in five committed tranches (collectively, the "Term Loan"). As of September 30, 2022, the carrying value of the loan is $72.3 million, net of debt issuance costs. The fair value of the Term Loan approximates its carrying value since the interest rate is at market. For more information about the Term Loan, see Note 8, “Long-Term Debt.”

Investments

At September 30, 2022, the Company’s marketable debt securities classified as available-for-sale were as follows ($ in millions):

	September 30, 2022						December 31, 2021
	Amortized cost		Net unrealized gains (losses)		Fair value		Amortized cost		Net unrealized gains (losses)		Fair value
Marketable debt securities:
Commercial paper	$	61.7	$	(0.2)	$	61.5	$	120.9	$	(0.1)	$	120.8
U.S. Treasury obligations	12.9		(0.1)		12.8		26.0		—		26.0
Corporate bonds	204.6		(3.4)		201.2		413.4		(1.1)		412.3
Asset-backed securities	34.0		(0.2)		33.8		99.4		(0.2)		99.2
Other	29.9		(0.2)		29.7		12.8		—		12.8
Total marketable debt securities	$	343.1	$	(4.1)	$	339.0	$	672.5	$	(1.4)	$	671.1

These investments in marketable debt securities carry maturity dates of less than five years from the date of purchase. The net realized gains and losses were immaterial during the three and nine-months ended September 30, 2022. We do not intend to sell these investments, and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost basis. We did not record an allowance for credit losses as of September 30, 2022 or December 31, 2021 as no losses were determined to be caused by credit losses.

XML

BUSINESS COMBINATIONS, GOODWILL AND INTANGIBLE ASSETS

9 Months Ended

Sep. 30, 2022

Business Combination And Goodwill And Intangible Assets Disclosure [Abstract]

BUSINESS COMBINATIONS, GOODWILL AND INTANGIBLE ASSETS

BUSINESS COMBINATIONS, GOODWILL AND INTANGIBLE ASSETS

Goodwill, which represents the excess of cost over the fair value of net assets acquired, amounted to $158.0 million and $152.9 million at September 30, 2022 and December 31, 2021, respectively.

Intangible assets with a finite useful life continue to be amortized over their useful lives. Net intangible assets amounted to $9.6 million and $10.8 million at September 30, 2022 and December 31, 2021, respectively. Accumulated amortization related to intangible assets amount to $2.9 million and $1.7 million at September 30, 2022 and December 31, 2021, respectively. The Company recorded amortization expense of $0.4 million and $0.1 million for the three-months ended September 30, 2022 and 2021, respectively. The Company recorded amortization expense of $1.2 million and $0.3 million for the nine-months ended September 30, 2022 and 2021, respectively.

The remaining weighted average amortization period of finite-lived intangible assets is 5.8 years. The remaining estimated future amortization expense by year, as of September 30, 2022, is presented in the following table:

	(in millions)
2022	$	0.5
2023	1.7
2024	1.7
2025	1.7
2026	1.7
Thereafter	2.3
Estimated aggregate future intangible asset amortization	$	9.6

During the nine-months ended September 30, 2022, we made a $0.2 million adjustment to our preliminary allocation of the purchase consideration for the RMD acquisition related to finalized net working capital adjustments. As of September 30, 2022, the purchase price allocation is considered final. During the nine-months ended September 30, 2022, RMD achieved certain internal volumes required to earn the maximum earn-out consideration of $60.0 million. The Company paid out $27.5 million in cash and issued $32.5 million of Oak Street Health common stock during the three-months ended September 30, 2022. Of the total cash paid, $21.7 million had been recorded as a liability at the date of acquisition and presented as cash used in financing activities in the consolidated statement of cash flows with remaining amount reflected as cash used in operating activities- other liabilities. Additionally, the change in fair value of the

contingent consideration liability was recorded in other income (expense) on the consolidated statement of operations. For the three and nine-months ended September 30, 2022, the Company recorded $0 million and $38.3 million, respectively, within our other expenses as a result of RMD achieving the maximum earn-out consideration.

On September 23, 2022 OSH acquired substantially all of the assets of CHW for a total purchase price of $6.2 million, including contingent consideration with an estimated fair value of $0.2 million. The estimated fair value of the contingent consideration is recorded within other long-term liabilities. The maximum potential earn-out is $5.5 million dependent on internal metrics. As part of the CHW acquisition, the Company recorded $5.3 million of goodwill. As of September 30, 2022, the purchase price allocation is considered preliminary, and the Company may record certain adjustments during the one-year measurement period following the CHW acquisition.

XML

LEASES

9 Months Ended

Sep. 30, 2022

Leases [Abstract]

LEASES

LEASES

The components of lease expense for the Company’s operating leases were as follows for the three and nine-months ended September 30, 2022 and September 30, 2021 ($ in millions):

	Three-Months Ended September 30,				Nine-Months Ended September 30,
	2022		2021		2022		2021
Operating lease cost2	$	13.3	$	5.6	$	34.6	$	15.0
Variable lease cost 2	2.1		5.3		7.3		14.0
Total lease cost	$	15.4	$	10.9	$	41.9	$	29.0
2See Note 2 for discussion of the correction of an immaterial prior period error. The correction of the classification of leasehold improvements resulted in a prior period benefit recorded to operating lease costs during the nine-months ended September 30, 2022. Additionally, as a result of the correction, certain variable lease expenses were re-classified as operating lease expenses during the nine-months ended September 30, 2022. These corrections impacted the comparability of variable lease costs year over year.

The Company entered into operating leases that resulted in $22.6 million and $89.2 million of right-of-use assets in exchange for operating lease obligations for the three and nine-months ended September 30, 2022, respectively. The Company entered into operating leases that resulted in $22.7 million and $49.5 million of right-of-use assets in exchange for operating lease obligations for the three and nine-months ended September 30, 2021, respectively.

The weighted-average remaining lease term and discount rate for operating lease liabilities included in the consolidated balance sheets are as follows:

	September 30, 2022		December 31, 2021
Weighted-average remaining lease term (in years)	8.8		9.9
Weighted-average discount rate	4.37	%	4.17	%

The table below presents the future minimum lease payments under the non-cancelable operating leases as of September 30, 2022 ($ in millions):

2022	$	10.5
2023	48.5
2024	54.7
2025	52.5
2026	52.1
2027	52.3
Thereafter	196.9
Total lease payments	$	467.5
Less: imputed interest	(101.8)
Total operating lease liabilities	$	365.7
Reported as:
Operating lease liabilities, current (1)	23.9
Operating lease liabilities, noncurrent	341.8
Total operating lease liabilities	$	365.7
(1) Included in other liabilities on the consolidated balance sheet

XML

LIABILITY FOR UNPAID CLAIMS

9 Months Ended

Sep. 30, 2022

Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]

LIABILITY FOR UNPAID CLAIMS

LIABILITY FOR UNPAID CLAIMS

Activity within liabilities for unpaid claims was as follows for the nine-months ended ($ in millions):

	September 30,
	2022		2021
Balance, beginning of period	$	556.3	$	262.1
Incurred health care costs:
Current year	1,195.3		785.2
Prior years	—		5.2
Total claims incurred	$	1,195.3	$	790.4
Claims paid:
Current year	(482.9)		(366.5)
Prior years	(485.4)		(246.4)
Total claims paid	$	(968.3)	$	(612.9)
Adjustments to other claims-related liabilities	3.8		2.7
Balance, end of period	$	787.1	$	442.3

We assess the profitability of our managed care capitation arrangements to identify contracts where current operating results or forecasts indicate probable future losses. If anticipated future variable costs exceed anticipated future revenues, a premium deficiency reserve is recognized. No material premium deficiency reserves were recorded as of September 30, 2022 and December 31, 2021.

XML

LONG-TERM DEBT

9 Months Ended

Sep. 30, 2022

Debt Disclosure [Abstract]

LONG-TERM DEBT

LONG-TERM DEBT

Term Loan

On September 30, 2022, the Company and certain of its subsidiaries entered into the Loan Agreement with Hercules Capital, Inc., as administrative and collateral agent and lender, and Silicon Valley Bank and other lenders from time to time parties thereto. The Loan Agreement provides the Company with a Term Loan Facility of up to $300.0 million to be funded in five committed tranches available to be drawn at the Company’s option during the specified time period. Under Tranche A (available from September 30, 2022 ("Closing") until March 31, 2023), the Company was required to draw down $75.0 million upon Closing and may draw up to an additional $25.0 million. Under Tranche B (available from Closing until December 15, 2023), the Company may borrow up to $50.0 million in $25.0 million increments. Under

Tranche C (available from January 1, 2024 until June 30, 2024), the Company may borrow up to $50.0 million in $25.0 million increments. Under Tranche D (available from the earlier of (a) the date on which Tranche C is fully drawn and (b) July 1, 2024 until December 15, 2024), the Company may borrow up to $75.0 million in $25.0 million increments. Under Tranche E (available from Closing until June 1, 2025), the Company may borrow up to $25.0 million subject to the approval of the individual lender. If the Company does not elect to draw the entire principal amount available under the Tranche B, C or D during the applicable drawdown period, then any such undrawn portion will be added to the aggregate principal amount available under Tranche E. The obligations under the Term Loan Facility are secured by a perfected security interest in substantially all of the assets of the Company, subject to certain limitations and exceptions. The Term Loan Facility is scheduled to mature on October 1, 2027, subject to a springing maturity date of September 1, 2025 if, prior to June 1, 2025, the Company’s Convertible Senior Notes have not been (i) converted into equity interests of the Company, (ii) amended such that the scheduled maturity date of the Convertible Senior Notes is at least 180 days after the initial maturity date of the tranches of the Term Loans then in effect, or (iii) fully redeemed and extinguished.

The Term Loan interest rate will float and change on the day the prime rate changes from time to time. The Term Loan interest rate is equal to the greater of either 7.95% or the prime rate plus 2.45%. In addition, the principal balance of the Term Loans will bear “payment-in-kind” interest at the rate of 1.00% (“PIK Interest”), which PIK Interest will be added to the outstanding principal balance of the Term Loans and increase the outstanding principal balance of the Term Loans on each payment date. In addition, an end-of-term charge equal to 4.95% of the aggregate original principal amount of the Term Loans, due on the earlier of the maturity date of the Term Loans or the repayment of the Term Loans, is payable by the Company. Interest payments on the loan are due on the first day of each month.

Borrowings under the Term Loan Facility may be voluntarily prepaid in minimum increments of $25.0 million, subject to a prepayment fee equal to (i) 2.00% of the amount prepaid, if the prepayment occurs during the first year following the closing, (ii) 1.00% of the amount prepaid, if the prepayment occurs during the second year following the closing, and (iii) 0.50% of the amount prepaid, if the prepayment occurs during the third year following the closing. There is no prepayment fee, penalty or premium applicable to voluntary prepayments made by the Company on or after the fourth year following the closing.

At September 30, 2022 the outstanding balance of the Term Loan was $72.3 million, net of debt issuance costs.

In addition, beginning on the earlier of (i) the reporting deadline of the Company’s fourth quarter 2023 financial statements under the Loan Agreement and (ii) the date at which more than $100.0 million in aggregate principal (excluding any paid-in-kind interest) is outstanding under the Term Loan Facility, the Company is required to maintain a specified trailing twelve-month platform contribution (as defined in the Loan Agreement), with the applicable platform contribution increasing over time and as the Company’s borrowings under the Term Loan Facility increase. At September 30, 2022, the financial covenant was not yet in effect.

Convertible Senior Notes

On March 16, 2021, the Company issued, at par value, $920.0 million aggregate principal amount of 0% Convertible Senior Notes, including $120.0 million in aggregate principal amount pursuant to the option we granted to the initial purchasers to purchase additional convertible senior notes, which was exercised in full in March 2021. Total proceeds received by the Company from the sale of the Convertible Senior Notes, net of debt issuance and offering costs of $22.1 million, were $897.9 million. The Company used $123.6 million of the net proceeds to pay for the cost of the capped call transactions (see discussion on capped call transactions further below).

The Convertible Senior Notes are governed by an indenture (“Indenture”), dated as of March 16, 2021, between the Company and U.S. Bank National Association, as trustee. Under the Indenture, the Convertible Senior Notes are general senior, unsecured obligations of the Company and will mature on March 15, 2026, unless earlier redeemed, repurchased or converted. The Convertible Senior Notes are equal in right of payment with the Company’s future senior, unsecured indebtedness and structurally subordinated to all indebtedness and liabilities of the Company’s subsidiaries.

Pursuant to the terms of the Indenture, the Convertible Senior Notes are convertible at the option of the holders, or may be called by the Company for redemption, upon the occurrence of certain circumstances. For additional information on the conversion provisions included in the Indenture, please see Long-Term Debt, of the notes to consolidated financial statements included in our 2021 Form 10-Q for the period ended June 30, 2022. Based upon the reported sales price of our common stock during the last 30 consecutive trading days of the third quarter of 2022, the Convertible Senior Notes were not convertible by the holders on September 30, 2022 and will not be convertible until December 15, 2025.

Capped Call Transactions

Concurrently with the pricing of the Convertible Senior Notes, the Company entered into convertible note hedge transactions (the “capped call transactions”) with six initial purchasers or their respective affiliates and other financial institutions (the “option counterparties”) to mitigate the impact of potential economic dilution to our common stock upon conversion of the Convertible Senior Notes. The capped calls were purchased for $123.6 million from the net proceeds from the issuance of the Convertible Senior Notes and have an initial strike price of approximately $79.16 per share, which corresponds to the initial conversion price of the Convertible Senior Notes. The capped call transactions cover, subject to customary adjustments, the number of shares of common stock initially underlying the Convertible Senior Notes. The capped call transactions are expected to offset the potential dilution to the Company’s common stock upon any conversion of Convertible Senior Notes, with such reduction and/or offset subject to a cap initially equal to $138.8750 per share.

The capped call transactions will expire on March 12, 2026. The capped call transactions are separate transactions and are not part of the terms of the Convertible Senior Notes.

The capped call transactions cover, subject to anti-dilution adjustments, approximately 11,622,176 shares of the Company’s common stock. The capped call transactions are subject to either adjustment or termination upon the occurrence of specified extraordinary and disruption events affecting the Company.

The Convertible Senior Notes and capped call transactions consisted of the following balances reported in the consolidated balance sheet as of September 30, 2022 and December 31, 2021 ($ in millions):

	September 30, 2022	December 31, 2021
Liability component:
Principal	920.0	920.0
Less: debt issuance costs, net of amortization	(15.3)	(18.6)
Net carrying amount	904.7	901.4
Equity component recorded at issuance:
Capped call transactions	123.6	123.6

The Company recognized $1.1 million and $3.3 million related to the amortization of debt issuance and offering costs in interest expense, net on the consolidated statements of operations related to the Convertible Senior Notes for the three and nine-months ended September 30, 2022, respectively. The Company recognized $1.1 million and $2.4 million related to the amortization of debt issuance and offering costs in interest expense, net on the consolidated statements of operations related to the Convertible Senior Notes for the three and nine-months ended September 30, 2021, respectively. The effective interest rate for all periods was 0.49%.

XML

STOCK-BASED COMPENSATION

9 Months Ended

Sep. 30, 2022

Share-Based Payment Arrangement [Abstract]

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION

2020 Omnibus Incentive Plan

On August 5, 2020, the Company’s Board of Directors adopted the 2020 Omnibus Incentive Plan (the “2020 Plan,”). Under the 2020 Plan, employees, consultants and directors of the Company and our affiliates that perform services for us are eligible to receive awards. The 2020 Plan provides for the grant of incentive stock options (“ISOs”), non-statutory stock options (“NSOs”), stock appreciation rights, restricted stock awards (“RSAs”), performance awards, other share-based awards (including restricted stock units (“RSUs”)) and other cash-based awards. The maximum number of shares available for issuance under the 2020 Plan may not exceed the sum of (i) 33,473,410 shares and (ii) 21,888,258 shares issued pursuant to restricted shares and the aggregate number of shares that may be issued pursuant to the rights granted under the ESPP may not exceed 2,386,875 shares, subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization (subject to annual increases as approved by the Board of Directors).

Stock Options Activity, excluding PSOs

Stock options granted by the Company generally vest over four years with 25% of the option shares vesting each year. Options generally expire ten years from the date of the grant.

The following is a summary of stock option activity, excluding PSOs, as of and for the nine-months ended September 30, 2022 ($ in millions):

	Number of Options	Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Outstanding, December 31, 2021	14,945,566	$	21.89	8.61	$	177.2
Granted	1,829,910	16.92
Exercised	(560,905)	21.00
Cancelled	(442,025)	23.77
Outstanding, September 30, 2022	15,772,546	$	21.31	8.03	$	62.1
Options exercisable as of September 30, 2022	8,630,780	$	21.37	7.85	30.1

The aggregate intrinsic value of options exercised in each of the three-months ended September 30, 2022 and 2021 was $1.6 million, and $2.0 million and $8.2 million in the nine-months ended September 30, 2022 and 2021, respectively. Aggregate intrinsic value represents the difference between the exercise price of the option and the closing price of the Company’s common stock on the date of exercise. The fair value of options granted for the three-months ended September 30, 2022 and 2021 was $0.9 million and $0.4 million, respectively, and $15.7 million and $9.6 million for the nine-months ended September 30, 2022 and 2021, respectively.

Performance Stock Options Activity

In February 2022, the Company granted PSOs to certain of its executives, with 50% of the option shares vesting at the end of year two and the remaining 50% of the option shares vesting at the end of year three, subject in each case to the satisfaction of certain performance-based conditions. The PSOs generally expire ten years from the date of the grant. The fair value of performance stock options granted for the nine-months ended September 30, 2022 was $25.8 million.

The following is a summary of PSO activity as of and for the nine-months ended September 30, 2022 ($ in millions):

	Number of Options	Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Outstanding, December 31, 2021	—	$	—	—	$	—
Granted	3,300,505	15.75
Exercised	—	—
Cancelled	—	—
Outstanding, September 30, 2022	3,300,505	$	15.75	9.4	$	28.9
Options exercisable as of September 30, 2022	—	$	—	—	—

RSU Activity

RSUs granted generally vest ratably over four years. The following is a summary of RSU transactions as of and for the nine-months ended September 30, 2022:

	Unvested Shares	Grant Date Fair Value
Unvested, December 31, 2021	476,628	$	47.30
Granted	2,572,673	17.69
Vested	(149,850)	40.39
Canceled and forfeited	(281,823)	21.97
Unvested, September 30, 2022	2,617,628	$	21.59

PSU Activity

The Company granted PSUs to certain of its employees during the second quarter of 2022 with the units vesting in April 2023, subject in each case to the satisfaction of certain performance-based conditions. The following is a summary of PSU activity as of and for the nine-months ended September 30, 2022:

	Unvested Shares	Grant Date Fair Value
Unvested, December 31, 2021	111,184	$	33.73
Granted	455,426	23.66
Vested	—	—
Canceled and forfeited	(5,705)	24.17
Unvested, September 30, 2022	560,905	$	27.88

RSA Activity

The RSAs were granted as part of the pre-IPO conversion. The following is a summary of RSA transactions as of and for the nine-months ended September 30, 2022:

	Unvested Shares	Grant Date Fair Value
Unvested, December 31, 2021	16,090,990	$	14.71
Granted	—	—
Vested	(9,040,014)	15.73
Canceled and forfeited	(280,956)	15.57
Unvested, September 30, 2022	6,770,020	$	13.31

Employee Stock Purchase Plan

On August 5, 2020, the Board of Directors adopted, and the OSH LLC’s and OSH MH LLC’s majority unitholders approved, the 2021 Employee Stock Purchase Plan (the “ESPP”). The ESPP is more fully described in Note 13 to the consolidated financial statements included in our 2021 Form 10-K.

During the nine-months ended September 30, 2022 and 2021, 224,473 shares and 62,575 shares, respectively, were purchased under the ESPP.

Stock-Based Compensation Expense

The following table is a summary of stock-based compensation expense by function ($ in millions):

	Three-Months Ended September 30,				Nine-Months Ended September 30,
	2022		2021		2022		2021
Cost of care, excluding depreciation and amortization	$	1.3	$	0.5	$	2.7	$	1.2
Sales and marketing	1.4		0.8		3.8		2.5
Corporate, general and administrative	28.1		37.4		113.5		118.2
Total	30.8		38.7		120.0		121.9

As of September 30, 2022, the Company approximately $98.9 million in unrecognized compensation expense related to all non-vested awards (RSAs, ISOs, PSO, PSUs and RSUs) that will be recognized over the weighted-average period of 1.44 years.

XML

COMMITMENTS AND CONTINGENCIES

9 Months Ended

Sep. 30, 2022

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES

Contingencies

The Company is presently, and from time to time, subject to various claims and lawsuits arising in the normal course of business. In the opinion of management, the ultimate resolution of these matters will not have a material adverse effect on the Company’s financial position or results of operations.

Uncertainties

The healthcare industry is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations include, but are not limited to, matters such as licensure, accreditation, government healthcare program participation requirements, reimbursement for patient services, and Medicare and Medicaid fraud and abuse. Recently, government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by healthcare providers. Violations of these laws and regulations could result in expulsion from government healthcare programs together with imposition of significant fines and penalties, as well as significant repayments for patient services billed.

On November 1, 2021, the Company received a civil investigative demand (“CID”) from the United States Department of Justice. According to the CID, the Department of Justice is investigating whether the Company may have violated the False Claims Act, 31 U.S.C. §§ 3729-3722. The CID requests certain documents and information related to the Company’s relationships with third-party marketing agents and related to the Company’s provision of free transportation to federal health care beneficiaries and requests information and documents related to such matters. We are continuing to cooperate with the Department of Justice in response to the CID. We are currently unable to predict the outcome of this investigation or whether litigation is probable. Regardless of the outcome, this inquiry has the potential to have an adverse impact on us due to any related defense and settlement costs, diversion of management resources and other factors.

On January 10, 2022, Reginald T. Allison, individually and on behalf of all others similarly situated, filed a putative class action lawsuit against the Company, Michael Pykosz, and Timothy Cook in the United States District Court for the Northern District of Illinois (Case No. 1:22-cv-00149).

On March 25, 2022, Central Pennsylvania Teamsters Pension Fund – Defined Benefit Plan, Central Pennsylvania Teamsters Pension Fund – Retirement Income Plan 1987, and Boston Retirement System’s (collectively, the “Northeast Pension Funds”) were appointed as the lead plaintiffs in the case. On May 25, 2022, the Northeast Pension Funds along with an additional named plaintiff, the City of Dearborn Police & Fire Revised Retirement System, filed their consolidated amended and restated complaint (the “Amended Complaint”).

Plaintiffs allege that the Company and certain of its executive officers made false and/or misleading statements about patient acquisition tactics that purportedly violated the False Claims Act and federal Anti-Kickback Statute, and are purportedly the subject of the CID discussed above. The Amended Complaint includes two categories of claims: (1) claims under the Securities Exchange Act of 1934 based on allegedly misleading public statements throughout the class period of August 6, 2020 through November 8, 2021 (the “Exchange Act Claims”), and (2) claims under the Securities Act of 1933 based on allegedly misleading statements in the registration statements and prospectuses accompanying Oak Street Health, Inc.’s initial public offering and secondary public offerings (the “Securities Act Claims”). The Exchange Act claims are asserted against Oak Street Health, Inc., Michael Pykosz, our CEO and Timothy Cook, our CFO, and also against certain stockholders of as “control persons.” The Securities Act Claims are asserted against the same defendants as well as the underwriters of the Company’s public offerings, and the Oak Street Health, Inc. directors who signed the registration statements. The Amended Complaint seeks damages, interest, costs, attorneys’ fees and other unspecified equitable relief.

On July 25, 2022, the defendants filed a consolidated motion to dismiss the Amended Complaint. On September 26, 2022, the plaintiffs' opposition to that motion to dismiss was filed, and the defendants reply to that opposition was filed on October 26, 2022. The court will now consider the motion in due course.

In the event that the defendants's motion to dismiss is not granted, the Company intends to continue to vigorously defend this matter. Given the uncertainty of litigation, the preliminary stage of the case, and the legal standards that must be met for success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may result from this action.

Management believes that the Company is in compliance with fraud and abuse laws, as well as other applicable laws and regulations. While no regulatory inquiries have been made, compliance with such laws and regulations is subject to government review and interpretation, as well as regulatory actions unknown at this time.

XML

VARIABLE INTEREST ENTITIES

9 Months Ended

Sep. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

VARIABLE INTEREST ENTITIES

VARIABLE INTEREST ENTITIES

The Physician Groups, or affiliated physician practice organizations, were established to employ healthcare providers, contract with managed care payors and to deliver healthcare services to patients in the markets that the Company serves.

The Company evaluated whether it has a variable interest in the Physician Groups, whether the Physician Groups are VIEs and whether the Company has a controlling financial interest in the Physician Groups. The Company concluded that it has variable interests in the Physician Groups on the basis of its Administrative Service Agreement (“ASA”) which provides for reimbursement of costs and a management fee payable to the Company from the Physician Groups in exchange for providing management and administrative services which creates risks and a potential return to the Company. The Physician Group’s equity at risk, as defined by U.S. GAAP, is insufficient to finance its activities without additional support, and, therefore, the Physician Groups are considered VIEs.

The tables below illustrates the VIE assets and liabilities and performance for the Physician Groups as of and for the periods ended ($ in millions):

	September 30, 2022		December 31, 2021
Total assets	$	945.7	$	596.2
Total liabilities	868.2		564.4

	Three-Months Ended September 30,				Nine-Months Ended September 30,
	2022		2021		2022		2021
Total revenues	$	543.3	$	350.5	$	1,575.9	$	644.9
Medical claims expense	426.3		283.0		1,195.4		481.9
Cost of care	55.5		34.5		153.3		67.4
Total operating expenses	$	481.8	$	317.5	$	1,348.7	$	549.3

There are no restrictions on the Physician Groups’ assets or on the settlement of its liabilities. The assets of the Physician Groups can be used to settle obligations of the Company. The Physician Groups are included in the Company’s obligated group; thus, creditors of the Company have recourse to the assets owned by the Physician Groups. There are no liabilities for which creditors of the Physician Groups do not have recourse to the general credit of the Company. There are no restrictions placed on the retained earnings or net income of the Physician Groups with respect to potential dividend payments.

XML

RELATED PARTIES

9 Months Ended

Sep. 30, 2022

Related Party Transactions [Abstract]

RELATED PARTIES

RELATED PARTIES

Humana

Humana held over 5% of our common stock during the year ended December 31, 2021. Additionally, a Humana representative served on the Board of Directors from 2020 until his retirement, effective September 7, 2021. Humana no longer has a representative on the Board of Directors as of September 7, 2021. Humana is no longer a related party for the year ending December 31, 2022, and as such, the Company has included prior year transaction amounts only on the consolidated balance sheet and consolidated statement of operations.

During the year ended December 31, 2021, our related party transactions with Humana included capitated managed care contracts, which resulted in capitated revenue and related receivables. Within the Company’s other revenue, revenues from Humana were included in both fee-for-service revenue and care coordination and care management revenue. The receivable associated with the fee-for-service revenue was recorded in other receivables. The unearned portion of the care coordination payments was recorded as a contract liability in both the current and long-term other liabilities accounts. The Company also incurred medical claims expense related to the Humana payor contracts which are included in medical claims expense. Related unpaid claims were included in the liability for unpaid claims financial statement caption. The Humana Alliance Provision contains an arrangement for a license fee that is payable by the Company to Humana for the Company’s provision of health care services in certain centers owned or leased by Humana. The license fee is a reimbursement to Humana for its costs of owning or leasing and maintaining the centers, including rental payments, center maintenance or repair expenses, equipment expenses, special assessments, cost of upgrades, taxes, leasehold improvements and other expenses identified by Humana. We will continue to have these transaction types with Humana during the year ended December 31, 2022, however, they are no longer considered related party transactions.

XML

NET LOSS PER SHARE

9 Months Ended

Sep. 30, 2022

Earnings Per Share [Abstract]

NET LOSS PER SHARE

NET LOSS PER SHARE

The following table sets forth the computation of basic and diluted net loss per common share for the three and nine-months ended September 30, 2022 and 2021 ($ in millions).

	Three-Months Ended September 30,				Nine-Months Ended September 30,
	2022		2021		2022		2021
Numerator:
Net loss	$	(130.4)	$	(110.0)	$	(375.3)	$	(274.3)
Less: Net income/(loss) attributable to non-controlling interests	0.3		(0.6)		0.9		(3.5)
Net loss attributable to Oak Street Health, Inc.	(130.7)		(109.4)		(376.2)		(270.8)
Denominator:
Weighted average common shares outstanding - basic and diluted	231,919,421		223,435,698		228,042,160		221,932,624
Net loss per share – basic and diluted	$	(0.56)	$	(0.49)	$	(1.65)	$	(1.22)

The Company’s potentially dilutive securities, which included stock options (including PSOs), unvested RSUs (including PSUs), unvested RSAs, and shares issuable upon conversion of our Convertible Senior Notes, have been excluded from the computation of diluted net loss per share as the effect would reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share was the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated:

	Nine-Months Ended September 30,
	2022	2021
Stock options	19,073,051	14,999,384
RSUs	3,178,533	341,215
RSAs	6,770,020	16,792,134
Convertible Senior Notes	11,622,176	11,622,176
	40,643,780	43,754,909

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Policies)

9 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

Basis of Presentation

The accompanying unaudited interim consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such regulations that would substantially duplicate the disclosures contained in the Company's annual audited consolidated financial statements. These financial statements have been prepared on a basis consistent with the accounting principles applied for the fiscal year ended December 31, 2021 in the Company’s 2021 Form 10-K filed with the SEC. In the opinion of management, all adjustments (consisting of all normal and recurring adjustments) considered necessary for a fair presentation have been included.

Consolidation

The consolidated financial statements of the Company include the financial statements of all wholly owned subsidiaries and majority-owned or controlled companies, which include the variable interest entities (“VIE”) in which OSH has an interest and is the primary beneficiary. See Note 11, “Variable Interest Entities.” For those consolidated subsidiaries where our ownership is less than 100%, the portion of the net income or loss allocable to the non-controlling interests is reported as “Net loss (gain) attributable to non-controlling interests” in the consolidated statements of operations. Intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates on the information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of COVID-19. The areas where significant estimates are used in the accompanying financial statements include revenue recognition, the liability for unpaid claims, stock-based compensation, valuation and related impairment recognition of long-lived assets, including intangibles and goodwill and the valuation of stock options. Actual results could differ from those estimates.

Stock-based compensation expense

The Company accounts for stock-based compensation as an expense in the statements of operations based on the awards' fair values at their respective grant dates. The Company estimates the fair value of options with service conditions granted using the Black-Scholes option pricing model. Stock options that include service and performance conditions are valued at their grant date using the Black-Scholes model and estimates regarding the probability of achieving the performance metrics. The Black-Scholes option pricing model requires inputs based on certain assumptions, including (a) the fair value per share of the Company's common stock, (b) the expected stock price volatility, (c) the expected term of the award, (d) the risk-free interest rate and (e) expected dividends.

The fair value of stock-based awards is recognized as compensation expense, net of actual forfeitures, over the requisite service period, which is generally the vesting period, with the exception of the fair value of stock-based payments for awards that include service and performance conditions which is recognized as compensation expense over the requisite service period as achievement of the performance objective becomes probable.

The Company issued certain performance stock options (“PSOs”) during the first quarter of 2022, that vest based on the satisfaction of certain service and performance-based conditions. The Company estimates compensation expense based on the grant date fair value of the awards and recognizes the expense on a graded vesting basis over the vesting period of the awards. Compensation expense for these awards is recognized only if the Company has determined that it is probable that the performance condition will be met. The Company reassesses the probability of vesting at each reporting period and adjusts compensation expense based on the probability assessment.

The Company issued certain performance stock units ("PSUs") during the second quarter of 2022. The awards will vest based on the satisfaction of certain service conditions and performance-based conditions. The Company estimates compensation expense based on the grant date fair value of the awards and recognizes the expense on a straight-line basis over the vesting period of the award. Compensation expense for these awards is recognized only if the Company has determined that it is probable that the performance condition will be met. The Company reassesses the probability of vesting at each reporting period and adjusts compensation expense based on the probability assessment.

Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted

Recently Adopted Accounting Pronouncements

In October 2021, the FASB issued Accounting Standard Update ("ASU") 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The new guidance requires contract assets and liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts. Under the current business combinations guidance, such assets and liabilities are recognized by the acquirer at fair value on the acquisition date. The new standard is effective for fiscal years beginning after December 15, 2022. Early adoption is permitted. The standard will not impact acquired contract assets or liabilities from business combinations occurring prior to the effective date of adoption. We elected to adopt this guidance early effective as of the quarter ended September 30, 2022 in connection with the Company’s acquisition of substantially all of the assets of CHW Cares Inc. ("CHW"), which was completed during the quarter. The guidance was not applicable to the CHW acquisition as contract assets and liabilities were not acquired, and as such, the adoption did not have a material effect on our consolidated financial statements or notes to the consolidated financial statements. For more information about the CHW acquisition, see Note 5, "Business Combinations, Goodwill and Intangible Assets."

In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. This update requires annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. This standard is effective for fiscal years beginning after December 15, 2021 and should be applied prospectively or retrospectively. We have adopted ASU 2021-10 as of January 1, 2022 using the prospective method. This adoption did not have a material impact on our consolidated financial statements or notes to the consolidated financial statements.

Recent Accounting Pronouncements Not Yet Adopted

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820) of Equity Securities Subject to Contractual Sale Restrictions. The new guidance clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The guidance is required to be adopted by January 1, 2024, and we do not anticipate this standard update will have a material impact on our consolidated financial statements or notes to the consolidated financial statements.

XML

REVENUE RECOGNITION (Tables)

9 Months Ended

Sep. 30, 2022

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

The Company has agreements in place with the payors listed below, and payor sources of capitated revenue for each period presented were as follows:

	Three-Months Ended September 30,				Nine-Months Ended September 30,
	2022		2021		2022		2021
Humana	31	%	35	%	32	%	37	%
Wellcare/Meridian	16	%	15	%	17	%	16	%
UnitedHealth Care	10	%	8	%	9	%	7	%
CMS	8	%	10	%	8	%	7	%
Other	35	%	32	%	34	%	33	%

The composition of other revenue for each period was as follows ($ in millions):

	Three-Months Ended September 30,				Nine-Months Ended September 30,
	2022		2021		2022	2021
Care coordination and care management services	$	1.8	$	9.8	5.2	$	18.4
License subscription and other fees	3.3		—		9.5	—
Fee for service	2.7		2.2		8.4	5.5
Total other revenue	$	7.8	$	12.0	23.1	$	23.9

XML

FAIR VALUE MEASUREMENTS AND INVESTMENTS (Tables)

9 Months Ended

Sep. 30, 2022

Fair Value Disclosures [Abstract]

Schedule of Financial Assets Measured at Fair Value on a Recurring Basis

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis ($ in millions):

	Fair Value Measurements as of September 30, 2022 using:						Fair Value Measurements as of December 31, 2021 using:
	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
Marketable debt securities:
Commercial paper	$	61.5	$	—	$	—	$	120.8	$	—	$	—
U.S. Treasury obligations	—		12.8		—		—		26.0		—
Corporate bonds	—		201.2		—		—		412.3		—
Asset-backed securities	—		33.8		—		—		99.2		—
Other	—		29.7		—		—		12.8		—
Total financial assets	$	61.5	$	277.5	$	—	$	120.8	$	550.3	$	—
Liabilities:
Convertible senior notes	$	—	$	710.5	$	—	$	—	$	752.7	$	—
Contingent consideration1	—		—		0.2		—		—		21.8
Total liabilities	$	—	$	710.5	$	0.2	$	—	$	752.7	$	21.8
1 During the quarter-ended June 30, 2022, RMD achieved both earn-out hurdles. As such, the Company no longer measured the fair value of the contingent consideration and instead recorded the maximum earn-out as an amount payable to RMD as of June 30, 2022. See Footnote 5 for further detail.

Schedule of Marketable Debt Securities Classified as Available-for-sale

At September 30, 2022, the Company’s marketable debt securities classified as available-for-sale were as follows ($ in millions):

	September 30, 2022						December 31, 2021
	Amortized cost		Net unrealized gains (losses)		Fair value		Amortized cost		Net unrealized gains (losses)		Fair value
Marketable debt securities:
Commercial paper	$	61.7	$	(0.2)	$	61.5	$	120.9	$	(0.1)	$	120.8
U.S. Treasury obligations	12.9		(0.1)		12.8		26.0		—		26.0
Corporate bonds	204.6		(3.4)		201.2		413.4		(1.1)		412.3
Asset-backed securities	34.0		(0.2)		33.8		99.4		(0.2)		99.2
Other	29.9		(0.2)		29.7		12.8		—		12.8
Total marketable debt securities	$	343.1	$	(4.1)	$	339.0	$	672.5	$	(1.4)	$	671.1

XML

BUSINESS COMBINATIONS, GOODWILL AND INTANGIBLE ASSETS (Tables)

9 Months Ended

Sep. 30, 2022

Business Combination And Goodwill And Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets

The remaining estimated future amortization expense by year, as of September 30, 2022, is presented in the following table:

	(in millions)
2022	$	0.5
2023	1.7
2024	1.7
2025	1.7
2026	1.7
Thereafter	2.3
Estimated aggregate future intangible asset amortization	$	9.6

XML

LEASES (Tables)

9 Months Ended

Sep. 30, 2022

Leases [Abstract]

Schedule of Components of Lease Expense

The components of lease expense for the Company’s operating leases were as follows for the three and nine-months ended September 30, 2022 and September 30, 2021 ($ in millions):

	Three-Months Ended September 30,				Nine-Months Ended September 30,
	2022		2021		2022		2021
Operating lease cost2	$	13.3	$	5.6	$	34.6	$	15.0
Variable lease cost 2	2.1		5.3		7.3		14.0
Total lease cost	$	15.4	$	10.9	$	41.9	$	29.0
2See Note 2 for discussion of the correction of an immaterial prior period error. The correction of the classification of leasehold improvements resulted in a prior period benefit recorded to operating lease costs during the nine-months ended September 30, 2022. Additionally, as a result of the correction, certain variable lease expenses were re-classified as operating lease expenses during the nine-months ended September 30, 2022. These corrections impacted the comparability of variable lease costs year over year.

The weighted-average remaining lease term and discount rate for operating lease liabilities included in the consolidated balance sheets are as follows:

	September 30, 2022		December 31, 2021
Weighted-average remaining lease term (in years)	8.8		9.9
Weighted-average discount rate	4.37	%	4.17	%

Lessee, Operating Lease, Liability, Maturity

The table below presents the future minimum lease payments under the non-cancelable operating leases as of September 30, 2022 ($ in millions):

2022	$	10.5
2023	48.5
2024	54.7
2025	52.5
2026	52.1
2027	52.3
Thereafter	196.9
Total lease payments	$	467.5
Less: imputed interest	(101.8)
Total operating lease liabilities	$	365.7
Reported as:
Operating lease liabilities, current (1)	23.9
Operating lease liabilities, noncurrent	341.8
Total operating lease liabilities	$	365.7
(1) Included in other liabilities on the consolidated balance sheet

XML

LIABILITY FOR UNPAID CLAIMS (Tables)

9 Months Ended

Sep. 30, 2022

Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]

Summary of Liability for Unpaid Claims and Claims Adjustment Expense

Activity within liabilities for unpaid claims was as follows for the nine-months ended ($ in millions):

	September 30,
	2022		2021
Balance, beginning of period	$	556.3	$	262.1
Incurred health care costs:
Current year	1,195.3		785.2
Prior years	—		5.2
Total claims incurred	$	1,195.3	$	790.4
Claims paid:
Current year	(482.9)		(366.5)
Prior years	(485.4)		(246.4)
Total claims paid	$	(968.3)	$	(612.9)
Adjustments to other claims-related liabilities	3.8		2.7
Balance, end of period	$	787.1	$	442.3

XML

LONG-TERM DEBT (Tables)

9 Months Ended

Sep. 30, 2022

Debt Disclosure [Abstract]

Summary of Long-term Debt Instruments

The Convertible Senior Notes and capped call transactions consisted of the following balances reported in the consolidated balance sheet as of September 30, 2022 and December 31, 2021 ($ in millions):

	September 30, 2022	December 31, 2021
Liability component:
Principal	920.0	920.0
Less: debt issuance costs, net of amortization	(15.3)	(18.6)
Net carrying amount	904.7	901.4
Equity component recorded at issuance:
Capped call transactions	123.6	123.6

XML

STOCK-BASED COMPENSATION (Tables)

9 Months Ended

Sep. 30, 2022

Share-Based Payment Arrangement [Abstract]

Summary of Stock Option Activity

The following is a summary of stock option activity, excluding PSOs, as of and for the nine-months ended September 30, 2022 ($ in millions):

	Number of Options	Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Outstanding, December 31, 2021	14,945,566	$	21.89	8.61	$	177.2
Granted	1,829,910	16.92
Exercised	(560,905)	21.00
Cancelled	(442,025)	23.77
Outstanding, September 30, 2022	15,772,546	$	21.31	8.03	$	62.1
Options exercisable as of September 30, 2022	8,630,780	$	21.37	7.85	30.1

Share-based Payment Arrangement, Performance Shares, Activity

The following is a summary of PSO activity as of and for the nine-months ended September 30, 2022 ($ in millions):

	Number of Options	Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Outstanding, December 31, 2021	—	$	—	—	$	—
Granted	3,300,505	15.75
Exercised	—	—
Cancelled	—	—
Outstanding, September 30, 2022	3,300,505	$	15.75	9.4	$	28.9
Options exercisable as of September 30, 2022	—	$	—	—	—

Summary of Restricted Stock Awards (RSA) Activity

The following is a summary of RSU transactions as of and for the nine-months ended September 30, 2022:

	Unvested Shares	Grant Date Fair Value
Unvested, December 31, 2021	476,628	$	47.30
Granted	2,572,673	17.69
Vested	(149,850)	40.39
Canceled and forfeited	(281,823)	21.97
Unvested, September 30, 2022	2,617,628	$	21.59

The RSAs were granted as part of the pre-IPO conversion. The following is a summary of RSA transactions as of and for the nine-months ended September 30, 2022:

	Unvested Shares	Grant Date Fair Value
Unvested, December 31, 2021	16,090,990	$	14.71
Granted	—	—
Vested	(9,040,014)	15.73
Canceled and forfeited	(280,956)	15.57
Unvested, September 30, 2022	6,770,020	$	13.31

Schedule of Nonvested Performance-based Units Activity

The following is a summary of PSU activity as of and for the nine-months ended September 30, 2022:

	Unvested Shares	Grant Date Fair Value
Unvested, December 31, 2021	111,184	$	33.73
Granted	455,426	23.66
Vested	—	—
Canceled and forfeited	(5,705)	24.17
Unvested, September 30, 2022	560,905	$	27.88

Share-based Payment Arrangement, Expensed and Capitalized, Amount

The following table is a summary of stock-based compensation expense by function ($ in millions):

	Three-Months Ended September 30,				Nine-Months Ended September 30,
	2022		2021		2022		2021
Cost of care, excluding depreciation and amortization	$	1.3	$	0.5	$	2.7	$	1.2
Sales and marketing	1.4		0.8		3.8		2.5
Corporate, general and administrative	28.1		37.4		113.5		118.2
Total	30.8		38.7		120.0		121.9

XML

VARIABLE INTEREST ENTITIES (Tables)

9 Months Ended

Sep. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of VIE Assets and Liabilities and Performance for the Physician Groups

The tables below illustrates the VIE assets and liabilities and performance for the Physician Groups as of and for the periods ended ($ in millions):

	September 30, 2022		December 31, 2021
Total assets	$	945.7	$	596.2
Total liabilities	868.2		564.4

	Three-Months Ended September 30,				Nine-Months Ended September 30,
	2022		2021		2022		2021
Total revenues	$	543.3	$	350.5	$	1,575.9	$	644.9
Medical claims expense	426.3		283.0		1,195.4		481.9
Cost of care	55.5		34.5		153.3		67.4
Total operating expenses	$	481.8	$	317.5	$	1,348.7	$	549.3

XML

NET LOSS PER SHARE (Tables)

9 Months Ended

Sep. 30, 2022

Earnings Per Share [Abstract]

Summary of Basic and Diluted Net Loss Per Common Unit

The following table sets forth the computation of basic and diluted net loss per common share for the three and nine-months ended September 30, 2022 and 2021 ($ in millions).

	Three-Months Ended September 30,				Nine-Months Ended September 30,
	2022		2021		2022		2021
Numerator:
Net loss	$	(130.4)	$	(110.0)	$	(375.3)	$	(274.3)
Less: Net income/(loss) attributable to non-controlling interests	0.3		(0.6)		0.9		(3.5)
Net loss attributable to Oak Street Health, Inc.	(130.7)		(109.4)		(376.2)		(270.8)
Denominator:
Weighted average common shares outstanding - basic and diluted	231,919,421		223,435,698		228,042,160		221,932,624
Net loss per share – basic and diluted	$	(0.56)	$	(0.49)	$	(1.65)	$	(1.22)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated:

	Nine-Months Ended September 30,
	2022	2021
Stock options	19,073,051	14,999,384
RSUs	3,178,533	341,215
RSAs	6,770,020	16,792,134
Convertible Senior Notes	11,622,176	11,622,176
	40,643,780	43,754,909

XML

ORGANIZATION AND NATURE OF BUSINESS (Details) $ in Millions	1 Months Ended	3 Months Ended
	Jan. 31, 2022 USD ($)	Sep. 30, 2022 USD ($) center jointVenture	Jun. 30, 2022 USD ($)	Mar. 31, 2022
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Number of centers operated | center		161
Number of majority interest joint ventures | jointVenture		2
OSH-ESC Joint Venture, LLC
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Payments to acquire business, gross	$ 2.1
Percentage of interests acquired	49.90%
Ownership percentage				100.00%
Primary Care Physicians of Joliet
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Distribution from limited partnership		$ 0.5	$ 0.8
Primary Care Physicians of Joliet | OSH-PCJ Joliet, LLC (PCJ JV)
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Limited liability company, ownership interest				49.90%
Oak Street Health MSO, LLC
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Distribution from limited partnership		$ 0.5	$ 0.8
Oak Street Health MSO, LLC | OSH-PCJ Joliet, LLC (PCJ JV)
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Limited liability company, ownership interest				50.10%

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Significant Accounting Policies [Line Items]
Decrease in cost of care	$ (113.6)	$ (76.3)	$ (307.6)	$ (203.6)
Net loss per share – basic (in dollars per share)	$ (0.56)	$ (0.49)	$ (1.65)	$ (1.22)
Net loss per share – diluted (in dollars per share)	$ (0.56)	$ (0.49)	$ (1.65)	$ (1.22)
Revision of Prior Period, Adjustment | Lease Liability Correction
Significant Accounting Policies [Line Items]
Decrease in cost of care			$ 3.6
Net loss per share – basic (in dollars per share)			$ 0.02
Net loss per share – diluted (in dollars per share)			$ 0.02

XML

REVENUE RECOGNITION - Summary of Sources of Capitated Revenue (Details) - Capitated Revenue - Capitated Revenue - Customer Concentration Risk	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Humana
Disaggregation Of Revenue [Line Items]
Concentration risk percentage	31.00%	35.00%	32.00%	37.00%
Wellcare/Meridian
Disaggregation Of Revenue [Line Items]
Concentration risk percentage	16.00%	15.00%	17.00%	16.00%
UnitedHealth Care
Disaggregation Of Revenue [Line Items]
Concentration risk percentage	10.00%	8.00%	9.00%	7.00%
CMS
Disaggregation Of Revenue [Line Items]
Concentration risk percentage	8.00%	10.00%	8.00%	7.00%
Other
Disaggregation Of Revenue [Line Items]
Concentration risk percentage	35.00%	32.00%	34.00%	33.00%

XML

REVENUE RECOGNITION - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Disaggregation Of Revenue [Line Items]
Acuity-related adjustments receivable	$ 44,400,000	$ 40,100,000	$ 44,400,000	$ 40,100,000
Contract liabilities	37,300,000		37,300,000		$ 33,900,000
Short-term contract liability	6,700,000		6,700,000		6,200,000
Long-term contract liability	$ 30,600,000		$ 30,600,000		$ 27,700,000
Capitated Revenue | Customer Concentration Risk | Medicare Part D
Disaggregation Of Revenue [Line Items]
Concentration risk percentage	2.00%	2.00%	2.00%	2.00%
Medical Claims Expense Benchmark | Customer Concentration Risk | Medicare Part D
Disaggregation Of Revenue [Line Items]
Concentration risk percentage	3.00%	2.00%	2.00%	3.00%

XML

REVENUE RECOGNITION - Summary of Composition of Revenues (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation Of Revenue [Line Items]
Revenue	$ 545.7	$ 388.7	$ 1,583.2	$ 1,038.5
Other Revenue
Disaggregation Of Revenue [Line Items]
Revenue	7.8	12.0	23.1	23.9
Fee-For-Service
Disaggregation Of Revenue [Line Items]
Revenue	2.7	2.2	8.4	5.5
Care Coordination And Care Management
Disaggregation Of Revenue [Line Items]
Revenue	1.8	9.8	5.2	18.4
License Subscription And Other Fees
Disaggregation Of Revenue [Line Items]
Revenue	$ 3.3	$ 0.0	$ 9.5	$ 0.0

XML

FAIR VALUE MEASUREMENTS AND INVESTMENTS - Schedule of Financial Assets Measured at Fair Value on a Recurring Basis (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
ASSETS
Marketable debt securities	$ 339,000,000.0	$ 671,100,000
Commercial paper
ASSETS
Marketable debt securities	61,500,000	120,800,000
U.S. Treasury obligations
ASSETS
Marketable debt securities	12,800,000	26,000,000.0
Corporate bonds
ASSETS
Marketable debt securities	201,200,000	412,300,000
Asset-backed securities
ASSETS
Marketable debt securities	33,800,000	99,200,000
Other
ASSETS
Marketable debt securities	29,700,000	12,800,000
Fair Value Measurements, Recurring Basis | Level 1
ASSETS
Total financial assets	61,500,000	120,800,000
Liabilities:
Convertible senior notes	0	0
Contingent consideration	0	0
Total liabilities	0	0
Fair Value Measurements, Recurring Basis | Level 1 | Commercial paper
ASSETS
Marketable debt securities	61,500,000	120,800,000
Fair Value Measurements, Recurring Basis | Level 1 | U.S. Treasury obligations
ASSETS
Marketable debt securities	0	0
Fair Value Measurements, Recurring Basis | Level 1 | Corporate bonds
ASSETS
Marketable debt securities	0	0
Fair Value Measurements, Recurring Basis | Level 1 | Asset-backed securities
ASSETS
Marketable debt securities	0	0
Fair Value Measurements, Recurring Basis | Level 1 | Other
ASSETS
Marketable debt securities	0	0
Fair Value Measurements, Recurring Basis | Level 2
ASSETS
Total financial assets	277,500,000	550,300,000
Liabilities:
Convertible senior notes	710,500,000	752,700,000
Contingent consideration	0	0
Total liabilities	710,500,000	752,700,000
Fair Value Measurements, Recurring Basis | Level 2 | Commercial paper
ASSETS
Marketable debt securities	0	0
Fair Value Measurements, Recurring Basis | Level 2 | U.S. Treasury obligations
ASSETS
Marketable debt securities	12,800,000	26,000,000.0
Fair Value Measurements, Recurring Basis | Level 2 | Corporate bonds
ASSETS
Marketable debt securities	201,200,000	412,300,000
Fair Value Measurements, Recurring Basis | Level 2 | Asset-backed securities
ASSETS
Marketable debt securities	33,800,000	99,200,000
Fair Value Measurements, Recurring Basis | Level 2 | Other
ASSETS
Marketable debt securities	29,700,000	12,800,000
Fair Value Measurements, Recurring Basis | Level 3
ASSETS
Total financial assets	0	0
Liabilities:
Convertible senior notes	0	0
Contingent consideration	200,000	21,800,000
Total liabilities	200,000	21,800,000
Fair Value Measurements, Recurring Basis | Level 3 | Commercial paper
ASSETS
Marketable debt securities	0	0
Fair Value Measurements, Recurring Basis | Level 3 | U.S. Treasury obligations
ASSETS
Marketable debt securities	0	0
Fair Value Measurements, Recurring Basis | Level 3 | Corporate bonds
ASSETS
Marketable debt securities	0	0
Fair Value Measurements, Recurring Basis | Level 3 | Asset-backed securities
ASSETS
Marketable debt securities	0	0
Fair Value Measurements, Recurring Basis | Level 3 | Other
ASSETS
Marketable debt securities	$ 0	$ 0

XML

FAIR VALUE MEASUREMENTS AND INVESTMENTS - Schedule of Marketable Debt Securities Classified as Available-for-sale (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]
Amortized cost	$ 343.1	$ 672.5
Net unrealized gains (losses)	(4.1)	(1.4)
Fair value	339.0	671.1
Commercial paper
Debt Securities, Available-for-sale [Line Items]
Amortized cost	61.7	120.9
Net unrealized gains (losses)	(0.2)	(0.1)
Fair value	61.5	120.8
U.S. Treasury obligations
Debt Securities, Available-for-sale [Line Items]
Amortized cost	12.9	26.0
Net unrealized gains (losses)	(0.1)	0.0
Fair value	12.8	26.0
Corporate bonds
Debt Securities, Available-for-sale [Line Items]
Amortized cost	204.6	413.4
Net unrealized gains (losses)	(3.4)	(1.1)
Fair value	201.2	412.3
Asset-backed securities
Debt Securities, Available-for-sale [Line Items]
Amortized cost	34.0	99.4
Net unrealized gains (losses)	(0.2)	(0.2)
Fair value	33.8	99.2
Other
Debt Securities, Available-for-sale [Line Items]
Amortized cost	29.9	12.8
Net unrealized gains (losses)	(0.2)	0.0
Fair value	$ 29.7	$ 12.8

XML

FAIR VALUE MEASUREMENTS AND INVESTMENTS - Additional Information (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Debt securities, available-for-sale, term	5 years
Debt securities, available-for-sale, allowance for credit loss	$ 0	$ 0
Line of Credit | Term Loan | Secured Debt
Debt Instrument [Line Items]
Debt instrument face value	300,000,000
Net carrying amount	$ 72,300,000

XML

BUSINESS COMBINATIONS, GOODWILL AND INTANGIBLE ASSETS -Summary of remaining weighted average amortization period of finite-lived intangible assets (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Business Combination And Goodwill And Intangible Assets Disclosure [Abstract]
2022	$ 500,000
2023	1,700,000
2024	1,700,000
2025	1,700,000
2026	1,700,000
Thereafter	2,300,000
Other long-term assets	$ 9,600,000	$ 10,800,000

XML

BUSINESS COMBINATIONS, GOODWILL AND INTANGIBLE ASSETS - Additional Information (Detail) - USD ($)		3 Months Ended		9 Months Ended
	Sep. 23, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Business Combination And Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill		$ 158,000,000.0		$ 158,000,000.0		$ 152,900,000
Net intangible assets		9,600,000		9,600,000		10,800,000
Accumulated amortization		2,900,000		2,900,000		1,700,000
Amortization of intangible assets		400,000	$ 100,000	$ 1,200,000	$ 300,000
Weighted average useful life of finite-lived intangible assets acquired				5 years 9 months 18 days
Business Acquisition [Line Items]
Settlement of contingent earnout liability				$ 21,700,000	0
Fair value adjustment to contingent consideration				38,300,000	$ 0
Goodwill		158,000,000.0		158,000,000.0		$ 152,900,000
RMD
Business Acquisition [Line Items]
Purchase accounting adjustments				200,000
Current contingent liability		60,000,000.0		60,000,000.0
Payments for previous acquisition		27,500,000
Equity interests issuable		32,500,000
Fair value adjustment to contingent consideration		$ 0		$ 38,300,000
CHW Cares Inc.
Business Combination And Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	$ 5,300,000
Business Acquisition [Line Items]
Total purchase price	6,200,000
Estimated fair value of contingent consideration	200,000
Maximum potential earn-out	5,500,000
Goodwill	$ 5,300,000

XML

LEASES - Summary of Components of Lease Expense (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Leases [Abstract]
Operating lease cost	$ 13.3	$ 5.6	$ 34.6	$ 15.0
Variable lease cost	2.1	5.3	7.3	14.0
Total lease cost	$ 15.4	$ 10.9	$ 41.9	$ 29.0

XML

LEASES - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Leases [Abstract]
Operating lease right-of-use asset	$ 22.6	$ 22.7	$ 89.2	$ 49.5

XML

LEASES - Summary of Weighted Average Remaining Lease Term and Discount Rate (Details)	Sep. 30, 2022	Dec. 31, 2021
Leases [Abstract]
Weighted-average remaining lease term (in years)	8 years 9 months 18 days	9 years 10 months 24 days
Weighted-average discount rate	4.37%	4.17%

XML

LEASES - Summary of Future Minimum Lease Payments (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Leases [Abstract]
2022	$ 10.5
2023	48.5
2024	54.7
2025	52.5
2026	52.1
2027	52.3
Thereafter	196.9
Total lease payments	467.5
Less: imputed interest	(101.8)
Total operating lease liabilities	365.7
Reported as:
Operating lease liabilities, current	23.9
Operating Lease, Liability, Noncurrent	341.8	$ 164.2
Total operating lease liabilities	$ 365.7
Operating lease, liability, current, statement of financial position	Other liabilities (Humana comprised $19.3 as of December 31, 2021)

XML

LIABILITY FOR UNPAID CLAIMS (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Balance, beginning of period	$ 556.3	$ 262.1
Incurred health care costs:
Current year	1,195.3	785.2
Prior years	0.0	5.2
Total claims incurred	1,195.3	790.4
Claims paid:
Current year	(482.9)	(366.5)
Prior years	(485.4)	(246.4)
Total claims paid	(968.3)	(612.9)
Adjustments to other claims-related liabilities	3.8	2.7
Balance, end of period	$ 787.1	$ 442.3

XML

LONG-TERM DEBT - Additional Information (Detail)			3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($)	Mar. 16, 2021 USD ($) center $ / shares shares	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Mar. 31, 2021 USD ($)
Prepayment Penalty Fee, Year One | Secured Debt
Debt Instrument [Line Items]
Prepayment fee	2.00%		2.00%		2.00%
Prepayment Penalty Fee, Year Two | Secured Debt
Debt Instrument [Line Items]
Prepayment fee	1.00%		1.00%		1.00%
Prepayment Penalty Fee, Year Three | Secured Debt
Debt Instrument [Line Items]
Prepayment fee	0.50%		0.50%		0.50%
Prepayment Penalty Fee, Year Four And After Year Four | Secured Debt
Debt Instrument [Line Items]
Prepayment fee	0.00%		0.00%		0.00%
Capped Call Transactions
Debt Instrument [Line Items]
Payments for capped calls		$ 123,600,000
Capped call strike price (in dollars per share) | $ / shares		$ 79.16
Conversion price cap (in dollars per share) | $ / shares		$ 138.8750
Number of shares covered by capped calls (in shares) | shares		11,622,176
Convertible Debt
Debt Instrument [Line Items]
Proceeds from long term debt issuance		$ 897,900,000
Net carrying amount	$ 904,700,000		$ 904,700,000		$ 904,700,000		$ 901,400,000
Debt instrument face value		$ 920,000,000						$ 120,000,000
Long term debt variable interest rate percentage		0.00%
Debt issuance cost		$ 22,100,000
Amortization of debt issuance costs			$ 1,100,000	$ 1,100,000	$ 3,300,000	$ 2,400,000
Effective interest rate	0.49%		0.49%	0.49%	0.49%	0.49%
Consecutive trading days | center		30
Line of Credit | Term Loan | Secured Debt
Debt Instrument [Line Items]
Stated interest rate	795.00%		795.00%		795.00%
Debt instrument, PIK interest percentage	1.00%		1.00%		1.00%
End of term fee	4.95%		4.95%		4.95%
Net carrying amount	$ 72,300,000		$ 72,300,000		$ 72,300,000
Debt instrument face value	300,000,000		300,000,000		300,000,000
Voluntary prepaid minimum increment amount	25,000,000
Debt instrument, covenant, outstanding threshold	$ 100,000,000		100,000,000		100,000,000
Line of Credit | Term Loan | Prime Rate | Secured Debt
Debt Instrument [Line Items]
Debt instrument variable interest rate spread	245.00%
Line of Credit | Term Loan, Tranche A
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 25,000,000		25,000,000		25,000,000
Line of Credit | Term Loan, Tranche A | Secured Debt
Debt Instrument [Line Items]
Proceeds from long term debt issuance	75,000,000
Line of Credit | Term Loan, Tranche B
Debt Instrument [Line Items]
Maximum borrowing capacity	50,000,000		50,000,000		50,000,000
Incremental borrowing value	25,000,000		25,000,000		25,000,000
Line of Credit | Term Loan, Tranche C | Secured Debt
Debt Instrument [Line Items]
Maximum borrowing capacity	50,000,000		50,000,000		50,000,000
Incremental borrowing value	25,000,000		25,000,000		25,000,000
Line of Credit | Term Loan, Tranche D | Secured Debt
Debt Instrument [Line Items]
Maximum borrowing capacity	75,000,000		75,000,000		75,000,000
Incremental borrowing value	25,000,000		25,000,000		25,000,000
Line of Credit | Term Loan, Tranche E | Secured Debt
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 25,000,000		$ 25,000,000		$ 25,000,000

XML

LONG-TERM DEBT - Summary of Long-term Debt Instruments (Detail) - Convertible Debt - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Liability component:
Principal	$ 920.0	$ 920.0
Less: debt issuance costs, net of amortization	(15.3)	(18.6)
Net carrying amount	904.7	901.4
Equity component recorded at issuance:
Capped call transactions	$ 123.6	$ 123.6

XML

STOCK-BASED COMPENSATION - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		9 Months Ended
	Feb. 28, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Aug. 05, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based payment award, number of shares available for issuance (in shares)						33,473,410
Aggregate intrinsic value of options exercised		$ 1.6	$ 1.6	$ 2.0	$ 8.2
Fair value of grants in period		0.9	$ 0.4	15.7	$ 9.6
Unrecognized compensation expense		$ 98.9		$ 98.9
Unrecognized compensation expense, period of recognition				1 year 5 months 8 days
RSAs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based payment award, number of shares available for issuance (in shares)						21,888,258
Employee Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based payment award, number of shares available for issuance (in shares)						2,386,875
Stock options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period				4 years
Share-based payment award, expiration period				10 years
Stock options | Tranche Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage				25.00%
Stock options | Tranche Three
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage				25.00%
Stock options | Tranche Four
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage				25.00%
Performance Shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based payment award, expiration period	10 years
Fair value of grants in period	$ 25.8
Performance Shares | Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period	2 years
Vesting percentage	50.00%
Performance Shares | Tranche Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period	3 years
Vesting percentage	50.00%
RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period				4 years

XML

STOCK-BASED COMPENSATION - Summary of Stock Option Activity (Detail) $ / shares in Units, $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares
Number of Options
Outstanding at beginning of period (in shares) | shares	14,945,566
Granted (in shares) | shares	1,829,910
Exercised (in shares) | shares	(560,905)
Cancelled (in shares) | shares	(442,025)
Outstanding at end of period (in shares) | shares	15,772,546	14,945,566
Options exercisable (in shares) | shares	8,630,780
Weighted-Average Exercise Price
Outstanding at beginning of period (in dollars per share) | $ / shares	$ 21.89
Granted (in dollars per share) | $ / shares	16.92
Exercised (in dollars per share) | $ / shares	21.00
Cancelled (in dollars per share) | $ / shares	23.77
Outstanding at end of period (in dollars per share) | $ / shares	21.31	$ 21.89
Options exercisable (in dollars per share) | $ / shares	$ 21.37
Weighted-Average Remaining Contractual Term (Years)
Outstanding balance	8 years 10 days	8 years 7 months 9 days
Options exercisable	7 years 10 months 6 days
Aggregate Intrinsic Value
Options outstanding | $	$ 62.1	$ 177.2
Options exercisable | $	$ 30.1

XML

STOCK-BASED COMPENSATION - Summary of Performance Share Activity (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares
Number of Options
Outstanding at beginning of period (in shares) | shares	14,945,566
Granted (in shares) | shares	1,829,910
Exercised (in shares) | shares	(560,905)
Cancelled (in shares) | shares	(442,025)
Outstanding at end of period (in shares) | shares	15,772,546	14,945,566
Weighted-Average Exercise Price
Outstanding at beginning of period (in dollars per share) | $ / shares	$ 21.89
Granted (in dollars per share) | $ / shares	16.92
Exercised (in dollars per share) | $ / shares	21.00
Cancelled (in dollars per share) | $ / shares	23.77
Outstanding at end of period (in dollars per share) | $ / shares	$ 21.31	$ 21.89
Weighted-Average Remaining Contractual Term (Years)
Outstanding balance	8 years 10 days	8 years 7 months 9 days
Options exercisable	7 years 10 months 6 days
Aggregate Intrinsic Value
Options outstanding | $	$ 62,100,000	$ 177,200,000
Options exercisable | $	$ 30,100,000
Performance Stock Options
Number of Options
Outstanding at beginning of period (in shares) | shares	0
Granted (in shares) | shares	3,300,505
Exercised (in shares) | shares	0
Cancelled (in shares) | shares	0
Outstanding at end of period (in shares) | shares	3,300,505	0
Options exercisable (in shares) | shares	0
Weighted-Average Exercise Price
Outstanding at beginning of period (in dollars per share) | $ / shares	$ 0
Granted (in dollars per share) | $ / shares	15.75
Exercised (in dollars per share) | $ / shares	0
Cancelled (in dollars per share) | $ / shares	0
Outstanding at end of period (in dollars per share) | $ / shares	15.75	$ 0
Options exercisable (in dollars per share) | $ / shares	$ 0
Weighted-Average Remaining Contractual Term (Years)
Outstanding balance	9 years 4 months 24 days	0 years
Options exercisable	0 years
Aggregate Intrinsic Value
Options outstanding | $	$ 28,900,000	$ 0
Options exercisable | $	$ 0

XML

STOCK-BASED COMPENSATION - Summary of RSU Activity (Details) - RSUs	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Unvested Shares
Beginning balance (in shares) | shares	476,628
Granted (in shares) | shares	2,572,673
Vested (in shares) | shares	(149,850)
Canceled and forfeited (in shares) | shares	(281,823)
Ending balance (in shares) | shares	2,617,628
Grant Date Fair Value
Beginning balance (in dollars per share) | $ / shares	$ 47.30
Granted (in dollars per share) | $ / shares	17.69
Vested (in dollars per share) | $ / shares	40.39
Canceled and forfeited (in dollars per share) | $ / shares	21.97
Ending balance (in dollars per share) | $ / shares	$ 21.59

XML

STOCK-BASED COMPENSATION - Summary of PSU Activity (Details) - Performance Share Unit (PSU)	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Unvested Shares
Beginning balance (in shares) | shares	111,184
Granted (in shares) | shares	455,426
Vested (in shares) | shares	0
Canceled and forfeited (in shares) | shares	(5,705)
Ending balance (in shares) | shares	560,905
Grant Date Fair Value
Beginning balance (in dollars per share) | $ / shares	$ 33.73
Granted (in dollars per share) | $ / shares	23.66
Vested (in dollars per share) | $ / shares	0
Canceled and forfeited (in dollars per share) | $ / shares	24.17
Ending balance (in dollars per share) | $ / shares	$ 27.88

XML

STOCK-BASED COMPENSATION - Summary of Restricted Stock Awards (RSA) (Detail) - RSAs	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Number of Options
Beginning balance (in shares) | shares	16,090,990
Granted (in shares) | shares	0
Vested (in shares) | shares	(9,040,014)
Canceled and forfeited (in shares) | shares	(280,956)
Ending balance (in shares) | shares	6,770,020
Grant Date Fair Value
Beginning balance (in dollars per share) | $ / shares	$ 14.71
Granted (in dollars per share) | $ / shares	0
Vested (in dollars per share) | $ / shares	15.73
Canceled and forfeited (in dollars per share) | $ / shares	15.57
Ending balance (in dollars per share) | $ / shares	$ 13.31

XML

STOCK-BASED COMPENSATION - Summary of Stock-based Compensation Expense by Function (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 30,800,000	$ 38,700,000	$ 120,000,000.0	$ 121,900,000
Cost of care, excluding depreciation and amortization
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	1,300,000	500,000	2,700,000	1,200,000
Sales and marketing
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	1,400,000	800,000	3,800,000	2,500,000
Corporate, general and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 28,100,000	$ 37,400,000	$ 113,500,000	$ 118,200,000

XML

VARIABLE INTEREST ENTITIES (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Variable Interest Entity [Line Items]
Total assets	$ 2,100.5		$ 2,100.5		$ 1,841.1
Total liabilities	2,256.1		2,256.1		1,785.1
Total revenues	545.7	$ 388.7	1,583.2	$ 1,038.5
Medical claims expense	427.4	309.8	1,198.4	790.9
Cost of care	113.6	76.3	307.6	203.6
Total operating expenses	675.9	498.1	1,917.1	1,311.0
Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]
Total assets	945.7		945.7		596.2
Total liabilities	868.2		868.2		$ 564.4
Total revenues	543.3	350.5	1,575.9	644.9
Medical claims expense	426.3	283.0	1,195.4	481.9
Cost of care	55.5	34.5	153.3	67.4
Total operating expenses	$ 481.8	$ 317.5	$ 1,348.7	$ 549.3

XML

RELATED PARTIES (Details)	12 Months Ended
	Dec. 31, 2021
Humana
Related Party Transaction [Line Items]
Percentage Of Common Stock Hold By Related Parties	5.00%

XML

NET LOSS PER SHARE - Summary of Basic and Diluted Net Loss Per Common Share (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Numerator:
Net loss	$ (130.4)	$ (110.0)	$ (375.3)	$ (274.3)
Less: Net loss attributable to non-controlling interests	0.3	(0.6)	0.9	(3.5)
Net loss attributable to Oak Street Health, Inc.	$ (130.7)	$ (109.4)	$ (376.2)	$ (270.8)
Denominator:
Weighted average common shares outstanding - basic (in shares)	231,919,421	223,435,698	228,042,160	221,932,624
Weighted average common shares outstanding - diluted (in shares)	231,919,421	223,435,698	228,042,160	221,932,624
Net loss per share – basic (in dollars per share)	$ (0.56)	$ (0.49)	$ (1.65)	$ (1.22)
Net loss per share – diluted (in dollars per share)	$ (0.56)	$ (0.49)	$ (1.65)	$ (1.22)

XML

NET LOSS PER SHARE - Summary of Potential Common Shares Outstanding from the Computation of Diluted Net Loss Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Computation of diluted net loss per share	40,643,780	43,754,909
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Computation of diluted net loss per share	19,073,051	14,999,384
RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Computation of diluted net loss per share	3,178,533	341,215
RSAs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Computation of diluted net loss per share	6,770,020	16,792,134
Convertible Senior Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Computation of diluted net loss per share	11,622,176	11,622,176